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Summary
The main aims of this thesis were to examine the role of the Visual System 
Homeobox gene 1 (VSX1) in keratoconus and development using molecular biology 
techniques and biophysics. The opportunity existed to examine a Vsxl knockout mouse using 
X-ray diffraction to see whether the structure of the cornea was altered due to the removal of 
this gene. Upon examination with X-ray diffraction further experiments were devised in 
order to clarify possible interactions of other genes that may play a part in keratoconus 
pathogenesis. The interfibrillar and intermolecular collagen spacings and the average 
collagen fibril diameters between Vsxl knockout mice and background matched littermate 
controls were compared. There were no statistical differences found in all cases. This is a 
similar finding to human keratoconic corneas when compared with normal controls. It was 
found that the Vsxl knockout mouse had significant alterations to the preferential alignment 
of collagen fibrils and altered comeal collagen mass distribution. This also is similar to 
human keratoconic corneas, strengthening the proposition that the Vsxl knockout mouse is a 
model system for keratoconus. Additionally, significantly altered expression levels of the 
genes HSF1, Hsp47 and Aqp5 were found along with no expression of Col8a2.
It was believed that the initial fault that allows keratoconus to develop occurs during 
development, so to explore this normal mouse development was explored using X-ray 
diffraction to map the collagen fibrils of the cornea as it develops in postnatal stages. This 
would provide a good baseline for future experiments. In addition to this, initial investigation 
of the expression of the Vsxl gene was undertaken to see whether it may play a role in 
development. It was found that the annulus of collagen fibrils that plays an important role in 
maintaining the structure of the cornea starts to develop at postnatal day 10 in the mouse and 
continues until maturity. It was also found that there is a significant alteration in expression 
of Vsxl which occurs in development between postnatal day 5 and day 12.
Lastly a population of keratoconus patients in South Wales were screened for 
mutations in the Vsxl gene. Mutations in Vsxl have been observed in other studies and this 
investigation was undertaken in order to clarify the ongoing debate into mutations in Vsxl 
and their link to keratoconus. In the study presented here a number of previously identified 
polymorphisms were discovered in out cohort of patients but no polymorphism was deemed 
to be a disease causing mutation.
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Chapter 1: Introduction
Keratoconus is a bilateral comeal thinning disease that presents generally in 
the late teens and progresses until the third or fourth decade of life, when it usually 
arrests. There is no difference in the prevalence between males and females and it 
affects 1 in 2000 people (Claoue et al., 1990; Gorskova and Sevost’ianov, 1998; 
Haugen, 1992; Lindquist et al., 1991; Nielsen et al., 2007; Pearson et al., 2000; Rivera 
and Mendoza, 2004; Saini et al., 2004; Simmons et al., 1989; Yahalom et al., 2005). 
The disease causes the cornea to be misshapen and cone- like, protruding from the eye 
instead of having a uniformly curved surface. This changes the refractive properties 
of the cornea causing blurred vision. People with early keratoconus typically notice a 
minor blurring of their vision and initially seek corrective treatment. If keratoconus is 
suspected then slit lamp examination and comeal topography would reveal other signs 
associated with keratoconus such as distortions of the cornea and possible scarring. 
More advanced signs of keratoconus such as Fleischer ring, Vogt’s striae and 
Munson’s sign follow as the disease progresses (Castroviejo, 1949; Gorban, 1973; 
Green, 1947; Iwaszkiewicz et al., 1992; Knapp, 1929; Puchkowskaya and Titarenko, 
1986; Tomalla and Cagnolati, 2007; Wygledowska-Promienska, 2005).
The classification of keratoconus has always posed a problem in that the 
symptoms of keratoconus have all the traditional hallmarks of being an inflammatory 
disease, except that in keratoconus the damage caused is non-inflammatory. It is 
probably better to think of keratoconus as an ectasia, which is a change in shape. 
However, for the purposes of this thesis it shall be herein described as a disease rather 
than an ectasia. It is a little-understood disease with an uncertain cause, and its 
progression following diagnosis is unpredictable. Keratoconus normally presents in 
one eye first, however, keratoconus is a bilateral disorder. In reported cases of 
monocular keratoconus the progression in the ‘unaffected’ eye is usually at a much 
lower level than that of the other eye (Mahon and Kent, 2004; Phillips, 2003). The 
deterioration in the patients’ vision at later stages can be incredibly detrimental to 
their daily lives with some reaching a refractive error of 72 diopters. In most cases, 
and according to the severity, corrective contact lenses are effective enough to allow 
the patient to continue to function normally if they are able to wear them comfortably.
In early stages of the disease vision can be corrected with glasses, but there 
comes a point where the progression prevents any meaningful correction to be
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achieved and contact lenses are the only solution prior to surgery. Further progression 
of the disease may require surgery such as comeal grafting and in these cases there are 
a number of surgical techniques that exist to try to correct the patients’ vision.
Despite its uncertainties, keratoconus can be managed with a variety of clinical and 
surgical techniques, but this is less than ideal and ultimately early identification and 
prevention of onset would be the best solution. To this end, many researchers have 
been looking into the potential causes of keratoconus with the aim of finding a single 
or collection of targets that may be used as early identifiers and treatment points.
Genetics is increasingly becoming more important in the study of diseases and 
is playing an important role in the research on keratoconus. Current studies of 
keratoconus have involved collecting cohorts of patients, either individuals or families 
that have one or more sufferers with the condition (Aldave et al., 2007a; Aldave et al., 
2006; Bisceglia et al., 2005; Brancati et al., 2004; Heon et al., 2002; Hosseini et al., 
2008; Liskova et al., 2007a; Nguyen et al., 2007; Tang et al., 2008; Tang et al., 2005; 
Udar et al., 2006; Udar et al., 2004). Studies on cohorts of families are especially 
useful as a first step in identifying possible genes that could be involved in the 
disease. These studies aim to identify genes based on their inheritance patterns 
through linkage analysis. Linkage analysis allows areas of chromosomes to be 
tracked to see if they segregate between affected and non-affected individuals. Once 
an area has been found, it can be cross examined with established databases of genes 
within that area and candidate genes selected based on their functionality. Once these 
genes have been selected they are screened within affected patients to see if there are 
any mutations within the coding sequence. This is compared to the coding sequences 
of unaffected individuals who act as controls to see if the mutations segregate with the 
disease. If they do then it can be said with some certainty that the gene is disease 
causing and can be studied further.
In addition to genetics the use of biophysical techniques such as X-ray 
diffraction has been employed to examine the ultrastructure of corneas of both 
keratoconus affected and non-affected individuals. These results have provided 
unique insights into the collagen structures that make up the cornea and demonstrate 
the way the comeal shape is maintained though its structural arrangement (Beecher et 
al., 2005; Beecher et al., 2006; Boote et al., 2005; Boote et al., 2004; Boote et al., 
2003; Boote et al., 2006; Boote et al., 2008; Connon et al., 2003a; Coimon and Meek, 
2003; Connon et al., 2003b; Daxer and Fratzl, 1997; Fullwood and Meek, 1993;
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Fullwood et al., 1990; Fullwood et al., 1993; Fullwood et al., 1992; Hayes et al., 
2007a; Hayes et al., 2007b; Meek et al., 1987; Meek and Boote, 2004; Meek et al., 
1982; Meek et al., 1986; Meek et al., 1981; Meek and Newton, 1999; Meek and 
Quantock, 2001; Meek et al., 2003b; Meek et al., 2005). This has allowed researchers 
to demonstrate that the structure in keratoconus affected corneas is different from 
unaffected controls in that the cornea is thinner and demonstrates an altered collagen 
fibril alignment. This indicates that there could be underlying defects within the 
cornea of keratoconus patients, which may be linked to altered or impaired gene 
expression.
This thesis aims to investigate one of the identified candidate genes for 
keratoconus, Visual System Homeobox 1 (VSX1), and explore a potential animal 
model of keratoconus by structural and genetic investigations. It also aims to 
investigate the possible causes and development of keratoconus by examining the 
structure of mouse corneas using X-ray diffraction in development. Lastly, both sets 
of information will be combined to examine what role Vsxl has to play in the 
pathogenesis of keratoconus and whether the possible defects that could occur within 
keratoconus can be linked back to any genetic anomalies that are found in the gene.
1.1 The Cornea
1.1.1 Corneal Development
The formation of the cornea occurs during the last series of major inducing 
events of the eye during embryogenesis. These inducing events allow the surface 
ectoderm at the front of the eye to become a transparent, multilayered structure with a 
complex extracellular matrix (Carlson, 2004). The basal ectodermal cells increase in 
height and begin to secrete epithelial derived collagen types I, II and IX to form the 
primary stroma. Neural crest cells around the lip of the optic cup migrate centrally 
between the primary stroma and the lens capsule. These cells form the comeal 
endothelium which is the posterior- most layer of the cornea. The endothelium is 
important for the remaining developmental process to occur. Once fully formed the 
endothelium secretes into the primary stroma a large amount of hyaluronic acid. 
Hyaluronic acid has great water binding properties and causes the primary stroma to 
swell (See fig 1.1).
11
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Fig 1.1. Flow diagram of comeal development. Figure taken from (Graw and Loster, 
2003).
The stromal swelling provides a substrate for a second wave of cellular 
migration into the cornea. These cells are also derived from neural crest cells and are 
fibroblastic in nature. These cells migrate into the stroma between the layers of 
collagen and then secrete large amounts of hyaluronidase, which counteracts and 
breaks down the hyaluronic acid. This decreases the thickness of the cornea and the 
stroma is said to be in its secondary stage. The fibroblasts aid organisation of the 
collagen by secreting collagen into the stromal matrix. The endothelium and the 
epithelium continue to secrete acellular matrix constituents to form the rest of the 
cornea, the Descemef s membrane and Bowman’s layer respectively (Graw, 2003). 
This makes up the mature cornea It is worthwhile to note that the development of the 
cornea is not the same within all species. Avian corneas seem to have two distinct 
stromal stages of development, a primary stage and a secondary stage; although a 
process similar to this is found within murine and human corneas they do not have a 
primary stroma.
The last parts of comeal formation are the changes that allow a transparent 
pathway from the outside world to the retina without optical distortion. The amount 
of light that is transmitted increases from 40% to 100%. This is accomplished mainly 
in the stroma by the removal of water. This firstly occurs with the breakdown of 
hyaluronic acid, and secondly by thyroxine that is secreted from the thyroid.
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Thyroxine acts on the endothelium to pump sodium from the secondary stroma to the 
anterior chamber of the eye. This effectively removes the remaining water from the 
stroma. The final part of comeal development is the change of curvature of the 
cornea in relation to the rest of the eye ball. This change allows the light coming in to 
the eye to be focused to a far greater effect.
1.1.2 Function
The cornea is a tough completely transparent tissue at the front of the eye. It 
has two main functions, the first acting as a protective barrier for the eye. Its second 
function is perhaps the most remarkable. Being completely clear and precisely 
curved, it acts as the main transmitter and refractor of light. Over 60% of the light 
that enters the eye is refracted by the cornea after which subtle adjustments by the lens 
acts to focus the light on the retina that sends an image to be interpreted by the brain.
1.1.3 Structure o f  a normal cornea
The cornea is composed of five layers each serving a different function to 
maintain the refractive surface allowing for normal vision (see fig 1.2). The 
outermost surface that is in contact with air is the epithelium that is coated with a 
glycocalyx tear film, which is supported underneath by the epithelial basement 
membrane. The largest layer of the cornea is the stroma that resides in the middle of 
the cornea and is the main structural component. Below the stroma is the Descemet’s 
membrane and finally the endothelium that allows the cornea to take up nutrients and 
controls hydration.
epithelium
Bowman’s Layer
stroma
Descemet's membrane
endothelium
Fig 1.2. A schematic diagram of the different layers making up the cornea. Taken 
from the Ophthalmic Consultants of Boston website (www.eyeboston.com)
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The bulk of the cornea is composed of the stroma which is where most of the 
comeal collagens in the cornea are located. The comeal stroma is based on a matrix 
of water, proteoglycans, glycoproteins, keratocytes, inorganic salts and soluble 
proteins into which fibril forming collagens are embedded. Collagens are insoluble 
extracellular glycoproteins that are found in all animals. They are the most abundant 
protein within the human body and account for 70% of the cornea’s dry weight. They 
are essential structural components of all connective tissue and are an essential part of 
the cornea in terms of its structure and how it performs its function. So far 29 
different types of collagen have been found in the body but the cornea is mainly 
composed of collagen type I, III, V, VI and XII. The basic unit of fibril forming 
collagen is a polypeptide consisting of a repeating sequence ((Gly)-X-Y)n where X is 
often a proline residue and Y is often a hydroxyproline. This results in the secondary 
structure adopting a left handed helix.
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Fig 1.3 Assembly of collagen triple helix molecules into collagen fibrils. Figure taken 
from www.ccmbel.org/Chap5.html University of Brussels.
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Fig 1.4. Transmission electron micrograph showing the orientation of collagen fibrils 
in adjacent lamellae in the comeal stroma. The micrograph shows three lamellae 
from the central stroma. In the middle lamella, the collagen fibres are in cross-section 
(running toward the reader) and can be seen to be of regular diameter and spacing. In 
the top and bottom lamellae, the collagen fibres are in longitudinal section (running 
from side to side) and are at approximate right angles to the collagen fibres in the 
middle lamella. Scale bar-200 nm. Figure and legend taken from (Fullwood, 2004).
These triple helices assemble in a staggered pattern into collagen fibrils. The 
collagen fibrils within the corneal stroma, unlike in most other tissues, are regularly 
spaced and have a uniform diameter (see fig 1.30). They are arranged in belts termed 
lamellae and in a lamella are arranged parallel to one another; however they form 
large angles with fibrils in adjacent lamellae (see fig 1.4). It is important to make the 
distinction that collagens can be either fibril forming or non fibril forming. The non 
fibril forming collagens are just as important as the fibril forming collagens 
physiologically. It is known that collagen type VI exists in the interfibrillar matrix 
and acts in the underlying framework by interweaving between the type I fibrils. 
Another example is collagen type XII that is thought to stabilize the collagen fibril 
arrangement by directly bridging the collagen fibrils. There are many examples of 
diseases that are caused by mutant collagen genes such as Osteogenesis imperfect 
(brittle bone disease) and Ehler-Danlos syndrome all caused by mutant collagen type 
I. The central cornea contains between 200 and 400 lamellae, and it is thought that 
lamellar organisation and distribution must control comeal shape and curvature 
(Fulwood 2004).
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1.1.4 The structure o f  the cornea in humans
There have been many studies of the cornea on a variety of species (Hayes et 
al., 2007a); See appendix A) using X-ray diffraction and on humans (including 
patients) with keratoconus(Aghamohammadzadeh et al., 2004; Fullwood et al., 1992; 
Huang et al., 1996; Meek et al., 2003b; Meek et al., 2005). This has yielded 
information about the fine structure of the cornea and about the arrangement of 
collagen fibrils in both normal and keratoconus affected corneas. In February 2004 
Aghamohammadzadeh et al. published the first X-ray diffraction map of the human 
cornea, which showed the preferred alignment of collagen fibrils (see fig 1.5). This 
map shows is that the collagen fibrils are highly ordered and demonstrate different 
preferred alignments at different parts of the cornea, most likely due to the different 
mechanical demands that are placed on the structure as a whole.
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Fig 1.5. Collagen fibril orientation in a human cornea. Figure taken from 
(Aghamohammadzadeh et al., 2004).
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In the human cornea the arrangement of fibrils is very ordered across the 
central region of the cornea with definite horizontal and vertical preferential 
alignment. This changes as you proceed to the peripheral areas of the cornea, where
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the preferential alignment changes to a circumferential alignment. The alignment is 
thought to be due to an increase need for strength in the direction of the muscles that 
control ocular movement (Boote et al., 2006). The distribution of collagen within the 
cornea was elucidated via X- ray diffraction and shows that the central part of the 
cornea is fairly thin with an increase of collagen at the limbal regions that circles the 
entire cornea This also showed that there is a horizontal symmetry between the left 
and right eyes demonstrating a rhombus shaped distribution of the aligned collagen. 
The comeal ultrastructure for the human cornea has also been measured; the 
interfibrillar spacing has been reported to be about 57nm in the centre of the cornea 
with this increasing to about 62nm in the periphery and an even greater increase at the 
limbus (Boote et al., 2003). The average fibril diameter in the cornea is 3 lnm which 
increases with age and is largely uniform across the cornea but increases at the limbus 
(Boote et al., 2003; Meek et al., 2003a).
In keratoconus patients the fibril organisational pattern differs from that of the 
normal human cornea. The vertical and horizontal preferred orientations are absent in 
the areas where a cone has manifested which is clearly visible from its orientation 
map. The map also demonstrates that the fibril pattern circles the cone and is itself 
much thinner than the surrounding tissue (see fig 1.6). The interfibrillar spacing and 
average fibril diameter remain unchanged.
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Fig 1.6. Fibrillar organisational patterns between a normal control comeal button and 
a keratoconic button. Figure taken from (Meek et al., 2005)
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1.1.5 The structure o f the cornea in mice
In mice the average collagen fibril diameter was reported to be 35.5nm in 3 
month old balb/c mice and about 37nm in age matched SKC mice (Quantock et al.,
2003). The interfibrillar spacing was stated to be at an average of 50nm. The 
arrangement of collagen fibrils within different species are different, which is 
suggested to be linked to the differences in visual acuity. Species with high visual 
acuity seem to have a more complicated fibril patterning (Hayes et al. 2007). In the 
mouse the fibril patterning appears to be circumferential around the centre of the 
cornea which extends all the way to the limbus.
1.2 Keratoconus
1.2.1 Epidemiology
The characteristic onset of keratoconus occurs in the second decade of life and 
continues to progress for two decades when it usually arrests. It is the most prevalent 
comeal disorder in the western world and is the leading cause for comeal surgery.
The progression of the disease can vary from person to person and can also vary in 
severity. It is normally an isolated disease, but has been known to be linked to a 
variety of other disorders, such as Down syndrome (Rabinowitz, 1998). The 
incidence of keratoconus seems to vary between widely between reports and 
researchers have tried to see if there is any predisposition from race or gender without 
any success. Keratoconus normally presents in one eye and then becomes fully 
bilateral. Monocular cases are rare and are most likely bilateral with one eye below 
clinical detection.
1.2.2 Clinical features
The clinical features of KC are varied and depend on the stage of the disorder. 
In early stages patients could present with irregular astigmatism or a minor blurring of 
visions. In the moderate to late stages of keratoconus stromal thinning, conical 
protrusion, Fleischer’s ring and fine vertical lines in the deep stroma and Descemet’s
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that are parallel to the axis of the cone (Vogts striae see fig 1.7) are visible via slit 
lamp examination. Other signs are epithelial nebulae, anterior stromal scars, enlarged 
comeal nerves and increased intensity of the comeal endothelial reflex and sub 
epithelial fibrillary lines (Rabinowitz, 1998). External signs of keratoconus are 
Munson’s sign (see fig 1.7) and comeal hydrops. Patients with advanced keratoconus 
may present with hydrops, which is due to breaks in the Descemet’s membrane that 
allow the aqueous to enter the stroma This oedema may persist for a short duration 
but may eventually disappear, leaving scarring.
Fig 1.7. Examples of signs of keratoconus, A) External Munson’s sign, B) Fleischer’s 
ring, C) Vogt’s striae. Pictures taken from Edward S Harkness Eye Institute,
Columbia University.
Depending on the severity and stage of the disease every layer of the cornea 
can become involved. The epithelium may show basal cell degeneration, breaks in 
the Bowman’s layer due to down growth of the epithelium and an accumulation of 
ferritin particles that build up within and between the epithelial cells. The Bowman’s 
layer may show breaks that are filled by the underlying stromal collagen, periodic 
acid Schiff-positive nodules, and Z shaped interruptions possibly due to separation of 
collagen bundles and reticular scarring (Li et al., 2004).
1.3 Keratoconus and oxidative stress
There have been a number of theories proposed as to what causes keratoconus. 
They range from increased degradation of matrix metalloproteinases to links with 
magnesium deficiency (Thalasselis, 2005) and diabetes (Prakash et al., 2007). 
However, it appears that the theory that has been investigated above all others is the 
link between keratoconus and increased oxidative stress. Keratoconus, being a 
noninflammatory disease, shares many characteristics with inflammatory comeal
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diseases and wound healing, which has led investigators to think that oxidative stress 
plays a large role in its onset and progression. There are also indications that in 
keratoconus there are corneal components that are altered that reduce the eye’s 
capability to counteract generated free radicals and oxidative stress. ALDH3 and 
extracellular forms of superoxide dismutase (SOD) are reported to be reduced in 
keratoconus (Behndig et al., 2001; Behndig et al., 1998; Gondhowiardjo and van 
Haeringen, 1993; Gondhowiardjo et al., 1993). There has yet to be any evidence that 
demonstrates how these oxidative products accumulate in the cornea or how a 
detriment in these comeal components affects the cornea’s susceptibility to UV 
damage. Apart from the damage induced by UV light there is also evidence from 
stress induced reactive oxygen species. It has been suggested that the thinning 
process that occurs in the cornea is related to an increase in degradative enzymes such 
as catalase (Kenney et al., 2005) and a decrease in degradative inhibitors (Opbroek et 
al., 1993; Sawaguchi et al., 1990), both of which are linked to oxidative stress.
The studies on oxidative stress have led to an identification of a candidate 
gene on chromosome 21, the superoxide dismutase 1 (SOD1) gene. Superoxide 
dismutase catalyses the dismutation of superoxide into oxygen and hydrogen and is an 
important antioxidant defence in nearly all cells. A unique genomic deletion within 
intron 2 close to the 5* splice junction of the SOD1 gene was identified in three 
patients with keratoconus and mRNA from 1 affected individual had two transcript 
splice variants (LE2 and LE2E3) that others have shown to code for proteins lacking 
the active site of the SOD1 enzyme (Udar et al., 2006). The reported deletion 
segregated with affected individuals and was not present in 312 control chromosomes 
indicating it is a good candidate for future study.
1.4 Genetic associations of keratoconus
1.4.1 Mapped loci o f keratoconus
Keratoconus in the general population is sporadic, however positive family 
history has been reported in 6% to 8% of patients. In the families that have reported 
keratoconus it is mostly inherited in an autosomal dominant fashion, however there 
have been rare cases where autosomal recessive inheritance is the cause. It is also 
worth mentioning that rare sporadic cases have emerged where keratoconus has been 
associated with rare chromosomal translocations (Morrison et al., 2001). Several
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linkage studies have been carried out on families that have one or more members 
affected by keratoconus in an attempt to identify candidate genes and loci for the 
disease. Tyynismaa et al (2002) performed a genome wide linkage study on 42 
affected and 34 unaffected individuals in 20 Finnish families that were known to 
exhibit keratoconus. The family members affected presented with autosomal 
dominant keratoconus. The conclusion of the study was that a possible gene for the 
disease mapped to chromosome 16q23-q23.1. A possible gene family to emerge from 
this study is the ADAMT (a disintegrin and metalloproteinase with thrombospondin 
motif) gene family that does map to both the disease region in this study and in the 
study performed by (Tyynismaa et al., 2002). The linkage study ruled out loci for 
genes on 18p and 21q. This is interesting, as a study carried out by (Rabinowitz et al., 
1992) reported a locus for keratoconus near the centromere of chromosome 21. The 
study that identified the locus for 18p used an association approach on eight unrelated 
individuals with keratoconus (Fullerton et al., 2002).
Another study performed by Hughes et al (2003) described a family of 30 
individuals, 16 of which were affected. The affected individuals were assessed on 
two occasions with a five year interval. A genome wide linkage screen found a 
potential locus for the disease gene on chromosome 15q22.33-24.2. The disease 
interval mapped was 6.5Mb and four candidate genes were selected for screening; 
CTSH, CRABP1, IREB2 and RASGRF1. All were excluded through DNA 
sequencing as the cause of keratoconus in the family. Patients described in this study 
also presented with cataracts. The region that this gene maps to is exceedingly gene 
rich (Hughes et al., 2003) and so there are a number of possible candidate genes for 
cataracts and keratoconus. The disease interval was reduced further to 5.5Mb that 
excluded 28 positional candidates and a further 23 candidate genes were excluded 
through direct sequencing (Dash et al., 2006). This family of genes is interesting as it 
has both disintegrin and metalloproteinase activity which have both been reported to 
be altered in keratoconus (Hughes et al., 2003).
A fourth study identified an Italian pedigree with 11 members who had 
autosomal dominant keratoconus and identified a locus which mapped to chromosome 
3pl4-ql3 (Brancati et al., 2004). Seven individuals of this study were diagnosed with 
definite keratoconus and the other four were identified as having “forme fruste” 
keratoconus, which is a term used to describe subtle topographic anomalies in people 
related to keratoconus patients. A candidate gene within this locus is COL8A1, which
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codes for human a  1 (VIII) chain of type VIII collagen. The collagen encoding genes 
do make good candidates for keratoconus as other collagen genes have been 
implicated in two forms of comeal dystrophy Fuchs Endothelial Comeal Dystrophy 
(FECD) and Congenital Hereditary Comeal Dystrophy (CHED) (Biswas et al., 2001). 
However, mutation analysis of COL8A1 did not show any mutations that were 
considered to be disease causing, although a G to T change was detected in nine 
affected individuals. This was thought to be a polymorphic variant (Brancati et al.,
2004). Linkage to all other suspected keratoconus loci in this study was excluded.
1.4.2 Genes linked with keratoconus
There are a number of other candidate genes that may, by virtue of their 
position within mapped genetic loci (2p24, 3pl4-ql3, 15q22, 16q23, 20pl 1 and 21 q) 
(Biswas et al., 2001; Brancati et al., 2004; Hughes et al., 2003; Rabinowitz et al., 
1992; Tyynismaa et al., 2002) or by their proposed function, be implicated in the 
genetic aetiology of keratoconus. A list of possible candidate genes based on genetic 
mapping and function is provided in Table 1.
Locus Name Known function Ref. GenelD
3pl4—q l3 COL8A1 Human alphal(VIII) 
chain of type VIII 
collagen
(Brancati et al., 2004) 1295
15q22.33-
24.2
CTSH Cathepsin H gene, 
cysteine-dependent 
intracellular protease that 
is responsible for 
intracellular protein 
degradation and turnover
(Hughes et al., 2003) 1512
15q22.33-
24.2
CRABP1 Cellular retinoic acid 
binding protein 1 gene, 
its product is one of a 
family of six vitamin A - 
binding proteins. Is 
thought to be involved in 
retinoic acid-mediated 
differentiation 
and proliferation 
processes
Hughes et al. 2003 1381
15q22.33-
24.2
IREB2 iron-responsive element 
binding protein 2 gene
Hughes et al. 2003 3658
15q22.33-
24.2
RASGRF1 Ras guanine nucleotide 
releasing factor gene, 
shares homology with 
the guanine nucleotide 
exchange activator son- 
of-sevenless in
Hughes et al. 2003 5923
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Drosophila
melanogaster, which is 
involved in the sevenless 
signalling pathway in 
developing 
photoreceptors. It also 
shares similarity with 
mouse son-of-sevenless 
(Sosl), mutations of 
which dominantly 
enhance the weak allele 
of Egfr causing 
distinctive eye defects 
including lens opacity 
and eye dysmorphology
15q22.33-
24.2
DKFZP434H204 ADAMTS family, Hughes et al. 2003 11173
15q22.33-
24.2
ADAMTS7 ADA MTS family, 
disintegrin and 
metalloprotease activity
Hughes et al. 2003 11173
15q22.33-
24.2
ADAMTS18 ADAMTS family, 
disintegrin and 
metalloprotease activity
Hughes et al. 2003 170692
16q22.3-
q23.1
LCAT Leci thin-chol ester ol 
acyltransferase gene is 
responsible for fish-eye 
disease with comeal 
lesions
(Tyynismaa et al., 2002) 3931
16q22.3-
q23.1
TAT Tyrosine
aminotransferase gene 
causes tyrosinemia, 
which is characterised by 
herpetiform comeal 
ulcers.
(Tyynismaa et al., 2002) 6898
16q22.3-
q23.1
CHST6 Carbohydrate 
sulfotransferase 6 gene 
identified as the 
causative gene for 
macular comeal 
dystrophy types I and II
(Tyynismaa et al., 2002) 4166
2p24 0SR1 Encodes odd-skipped 
related 1, a putative 
transcription factor 
which possesses a 
homeobox domain
(Hutchings et al., 2005) 130497
2p24 ARHB (RhoB) Actin reorganisation. 
Possible candidate gene 
since it stimulates actin 
stress fibre formation and 
focal adhesion points. 
Mutations in RhoB could 
explain structural defects 
observed in KC corneas. 
However, this gene is 
expressed in many other 
tissues where its 
functions are highly 
important, so it seems 
unlikely that mutations 
would lead to symptoms
(Hutchings et al., 2005) 11852
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restricted to the cornea
2p24 GDF-7 Control of cell 
differentiation, GDF-7 
(growth differentiation 
factor 7) is a good 
candidate gene due to the 
existence of TGF-fi 
domains in its sequence. 
TGF-fi and related 
proteins have already 
been investigated for 
their possible implication 
in KC because of their 
importance in the comeal 
epithelium but to no 
avail. However, probable 
roles for GDF-7 have 
been identified so far in 
the rhesus monkey 
neocortex, in seminal 
vesicle differentiation, 
and in commissural 
intemeuron growth in the 
mouse spinal cord where 
dysfunction of this 
protein leads to aberrant 
development of the 
mouse embryo.
Therefore, it seems 
improbable that a gene 
essential to nervous 
system development 
could confer only a 
comeal phenotype when 
mutated in man.
(Hutchings et al., 2005) 151449
6p25 GMDS GDP-mannose 4,6- 
dehydratase, positional 
candidate
Ferrini et el. 2005 ARVO 
abstract
Id of a potential KC/PPCD 
locus on 6p25.
2762
6p25 SERPINB6 serine (or cysteine) 
proteinase inhibitor, 
clade B (ovalbumin), 
member 6
Ferrini et el. 2005 ARVO 
abstract
Id of a potential KC/PPCD 
locus on 6p25.
5269
6p25 RIPK1 receptor (TNFRSF> 
interacting serine- 
threonine kinase 1
Ferrini et el. 2005 ARVO 
abstract
Id of a potential KCIPPCD 
locus on 6p25.
8737
6p25 BPHL biphenyl hydrolase-like 
(serine hydrolase; breast 
epithelial mucin- 
associated antigen)
Ferrini et el. 2005 ARVO 
abstract
Id of a potential KC IPPCD 
locus on 6p25.
670
6p25 CDYL chromodomain protein, 
Y-like
Ferrini et el. 2005 ARVO 
abstract
Id of a potential KC IPPCD 
locus on 6p25.
9425
6p25 FARS2 phenylalanine-tRNA 
synthetase 1 
(mitochondrial)
Ferrini et el. 2005 ARVO 
abstract
Id of a potential KC IPPCD 
locus on 6p25.
10667
6p25 RREB1 ras responsive element Ferrini et el. 2005 ARVO 6239
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housekeeping and inducible genes (Dynan and Tjian, 1983; Whitelock et al., 1997). 
Spl expression is known to vary widely among different cell types and increased 
expression has been associated with late stage differentiation (Edmund, 1988; Saffer 
et al., 1991; Saffer et al., 1990). The increase of Spl was mostly observed in the 
epithelium of the cornea. However the specific role of Spl is unclear in keratoconus, 
but of interest is that the binding sites of Spl have been shown to be present in the 
regulatory sequences of many enzyme and inhibitory genes that are affected in 
keratoconus (Whitelock et al., 1997). The lack of any differences in expression of the 
other transcription factors tested in this study is interesting as two of these, API and 
NF-tcB, are known to be induced under stress conditions. Their lack of expression 
contests some theories that environmental factors such as eye rubbing play a role in 
the cause and progression of keratoconus (Sawaguchi et al., 1994; Whitelock et al., 
1997), although there is a great amount of evidence for both sides of the argument.
The degradative enzymes that were found to be up regulated in keratoconus 
corneas include lysosomal acid phosphates (LAP) acid esterase, acid lipase and 
cathepsins B and G (Sawaguchi et al., 1989; Zhou et al., 1998). The reduced 
inhibitors are a  1-proteinase inhibitor (al-PI) and a2-macroglobulin. Spl expression 
may be directly related to a l-P I down regulation in keratoconus corneas (Maruyama 
et al., 2001). It has been suggested that an increase in the net activities of serine and 
cysteine proteinases that are capable of digesting gelatin, casein and extracellular 
matrix elements may be responsible for the thinning and loss of protein in keratoconus 
corneas (Zhou et al., 1998).
1.5 Vsx1IVSX1 a gene implicated in ocular disorders
1.5.1 Chx/Vsx family
These genes belong to the paired-like class of homeodomain transcription 
factors and contain a homeodomain and a CVC domain. Among this class are the 
genes ChxlO, ceh-10, Vsxl and Vsx2. All are known to play a part in ocular 
development. As the CVC domain is highly conserved in its length and its position 
relative to the homeodomain, it has led these genes to be further categorised as Prd- 
L:CVC, to distinguish them from other Prd-L genes. Due to sequence homology 
ChxlO is suggested to be the mouse homologue of Vsx2 (Levine et al., 1997). 
Homozygous expression of ChxlO has been associated with micropthalmia in both
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mouse and human (Burmeister et al., 1996; Percin, 2001). In the retina loss of ChxlO 
impairs the proliferation of retinal progenitor cells and prevents the specification, 
differentiation or maintenance of rod and cone bi-polar cells (Bone-Larson et al.,
2000; Burmeister et al., 1996). Vsxl was first discovered in the goldfish retina and 
was found to have similarities to the ceh-10 gene of C.elegans in the homeodomain 
and the 55 amino acids that follow the homeodomain termed the CVC domain 
(Levine et al. 1997). The function of the CVC domain is unknown but it is thought 
that it might have DNA binding properties or be used in protein-protein interactions.
It was found to be expressed in the inner nuclear layer of the goldfish retina Vsxl 
expression was first found in a subset of progenitor cells that give rise to cells in the 
outer half of the retina (Levine et al. 1997).
1.5.2 Human homologue VSX1
Two independent studies have characterised the human homologue of VSXl. 
Semina et al (2000) used a degenerate PCR approach to isolate the VSX1 gene from a 
human embryonic craniofacial library. Also in the same year Hayashi et al (2000) 
found the same gene using a yeast one-hybrid screen of a bovine retinal cDNA library 
to isolate the bovine Vsxl and termed it RINX for retinal inner nuclear layer 
homeobox. They then performed RT-PCR on the human cDNA homologue of RINX 
to determine the human sequence. Expression analysis was carried out in both studies 
producing rather different results. Semina et al (2000) found that VSX1 transcripts 
were found in embryonic craniofacial, adult retinal and comeal cDNAs, which was 
thought accurate as it corresponds well with expression of other known CVC genes. 
However this contrasts with the expression analysis carried out by Hayashi et al 
(2000) who found that VSX1 was exclusively only found in the inner nuclear layer of 
the retina and did not find any expression anywhere else. This seems to be supported 
by Chow et al. (2001) who also didn’t find any expression of VSX1 in the cornea but 
only in the retina, specifically within the cone bipolar cells of the inner nuclear layer. 
A possible explanation for the difference in expression could be that both the work by 
Hayashi et al. (2000) and Chow et al (2001) were carried out on different cell lines 
and cDNA libraries than to that used by Semina et al. (2000). Their studies involved 
animal models to derive the human VSX1 sequence as well. This difference in 
expression seems to be controversial with no consensus in sight without additional
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work. Interestingly though expression of mouse Vsxl, which is thought to be 
orthologous to VSX1 (Chow et al., 2001), was found in many tissue types by RT-PCR 
during the late stages of embryonic development (Chow et al. 2001) although this 
study did not look at the cornea
1.5.3 VSX1 structure
VSX1 encodes a 365 amino acid protein and the gene comprises 5 exons (see 
fig 1.8). The exon-intron boundaries indicate that VSX1 is spliced by the GT/AG 
splicing mechanism (Hayashi et al., 2000; Mount, 1982). The initiation codon is 
found in the first exon and the homeodomain is found in the second, third and fourth 
exons. The CVC domain is found in the fourth and fifth exons (Semina et al., 2000).
Fig 1.8. Genomic structure of the VSX1 gene. The coding region is shown in grey,
and the homeobox region is shown in black. The sizes of introns are indicated.
Figure taken from Semina et al. (2000).
As with all homeodomain proteins, VSX1 contains a glutamine residue at 
position 50, which is characteristic of the aristaless-type paired-like homeobox 
proteins (Semina et al. 2000). As well as the homeodomain and CVC regions VSX1 
also contains a region of unknown function that is highly conserved between VSX1 
and goldfish Vsxl, termed the RV domain. There is also a proline-rich region and an 
acidic region that have been shown to have activation properties in the transcription 
factors AP-2 and CTF/NF-1. VSX1 also seems to have a possible nuclear localisation 
signal (Hayashi et al., 2000). There is also a small domain that in other studies has 
been called the octapeptide sequence. This function of this sequence has now been 
elucidated as a Crml-dependent nuclear export sequence that aids the export of the 
VSX1 gene outside of the cell (Knauer et al., 2005).
1.5.4 Known Junctions o f  VSX1
Due to the expression of Vsxl in differentiating and mature cone bipolar cells 
(Chow et al., 2001) the role of Vsxl in visual signalling was investigated. To this end 
Vsxl knockout mice were produced in a loss of function study (Chow et al., 2004).
ATG
096*h |  1 14kb
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They found that Vsxl was essential for late differentiation and function of OFF-cone 
bipolar cells by regulating, either directly or indirectly 4 proteins expressed by OFF- 
cone bipolar cells, recoverin, NK3R, Netol and CaB5. Vsxl is critical in the function 
of the OFF visual pathway, however not all OFF-cone bipolar function is dependent 
on Vsxl and there is a possibility that other molecules are responsible. There is 
evidence to suggest there is an intrinsic regulatory feedback loop for the generation of 
cone bipolar cells (Ohtoshi et al., 2004). There has been speculation and some 
evidence that VSX1 in humans works as a gene suppresser (Dorval et al., 2005). This 
study was conducted to investigate the similar transcription factor CHX10 and found 
that when tethered to a promoter by its HD it was able to repress multiple classes of 
activators in different immortalised cell lines. As the VSX1 gene contains closely 
related domains it was also able to repress transcription. It is interesting to find that 
the mutation R166W that impairs DNA binding hindered repressor function in this 
study.
1.5.5 VSXI mapping in humans
The human homologue of VSX1 has been mapped to chromosome 20pl 1 -ql 1 
by radiation hybrid mapping (Semina et al 2000). There can be no doubt as to its 
location as it was also mapped to 20pl 1.2 by Hayashi et al (2000) (See fig 1.9). Some 
other genes in this interval are thrombomodulin (Jackman et al., 1987) and cystatin 3 
& 5 (Abalain et al., 2000; Aghamohammadzadeh et al., 2004; Freije et al., 1993). The 
two other genes, VSXI and TcJ8 are known to be linked to ocular diseases, congenital 
hereditary endothelial dystrophy (CHED) (Toma et al., 1995) and PPCD (Heon et al., 
1995).
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Fig 1.9. Chromosomal localization of the human VSX1 gene. Diagram of human 
chromosome 20 showing location of the VSX1 gene relative to other markers of the 
Stanford Human Genome Centre (SHGC) used in radiation hybrid mapping and to 
markers of the Human Genome Database (GDB). VSX1 is closest to markers SHGC- 
58586 (9 cR ;315 kb), SHGC-52794 (11 cR), and SHGC-56520 (12cR). SHGC- 
58586 is located (unknown whether it is centromeric or telomeric) 35 cR from GDB 
markers D20S807 (SHGC-9480) and D20S802 (SHGC-8763), which have been 
mapped to 20pl 1.2. hsRINX = VSXL Figure adapted from Hayashi et al (2000).
1.5.6 Vsxl mapping in mouse
Using degenerate PCR on cDNA isolated from embryonic 7.5 day old mice 
Vsxl was mapped to the distal region on chromosome 2 of the mouse genome (see fig 
1.10) (Ohtoshi et al., 2001). Mouse Vsxl consists of 363 amino acid residues and 
contains a homeodomain and a CVC domain. The gene consists of 5 coding exons 
that span an approximately 6.3 kb region of genomic DNA, similar to human VSXl. 
The intron-exon boundaries of mouse Vsxl are conserved between the mouse and 
human and the expression profile o f mouse Vsxl is similar to the other homologues of 
Vsxl discovered in other species in that they are all expressed in the retina.
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Fig 1.10. Distal region of chromosome 2 showing location of mouse Vsxl. Graphic 
taken from Ohtoshi et al. 2001
1.6 Mutational studies on VSX1, a candidate gene for keratoconus
1.6.1 Mutations identified within Vsxl
Linkage analysis has been performed in several studies on families with 
posterior polymorphous comeal dystrophy (.PPCD), keratoconus or both, and the 
results of these studies are a number of loci of possible candidate genes, which are 
listed in Table 1. However, a link was made between keratoconus, PPCD and VSXl. 
Heon et al (2002) identified the first mutations in patients with PPCD/keratoconus by 
conducting linkage experiments on a cohort of families and then screening the coding 
sequences of VSX1 in these patients (4 Canadian families and 2 unrelated individuals). 
They identified at least 4 mutations that were considered to be directly disease causing 
(see fig 1.11).
Case Mutation Phenotype Familial disease7 
(no. of affected tested)
Control Indtstduals 
tested (no positive I
1 G160D* PPD ERC abnormal Yes (S) 277 (0)
2 R166W Keratoconus No 277 (0)
3 L159M Keralor ottos Yes (4) 277 (0)
4 D144E PPD awl keratoconus \f e (2 ) 277 (OT
S H244R Keratoconus Yes (3) 277 (2)
6 P247R* No clinical PPD or 
keratoconus. ERC abnormal
No 196(0)
*Cases 1 and fi art- the mother and father of the prohand of family A (Fig 1A).
T h e  D144E was seen In one glaucoma patient (1/991
PPD posterior polymorphous dystrophy ERC. eiectroretinogrm
Fig 1.11. Phenotype/Genotype Correlation. Table taken from H6on et al (2002).
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The G160D mutation lies on the N-terminal side of the homeodomain and the 
P247R mutation is a change to the CVC domain. These two mutations were found to 
be sequence changes that in combination produced a severe phenotype in the patient 
(Heon et al., 2002). The other two mutations, L159M and R166W, correspond to 
amino acid changes and with the G160D mutation lie within the positively charged 
nuclear localisation signal (Heon et al. 2002). Seven other polymorphic changes were 
identified but were not specific for any disease (Heon et al. 2002).
New mutations in VSXI were isolated in an African American family who also 
demonstrated craniofacial abnormalities. Mintz-Hittner et al (2004) found through 
sequencing of patients DNA two new variations in the VSX1 gene and characterised 
them to be disease causing, however this is a little speculative. For a mutation to be 
disease causing, the mutation has to be fully characterised and functional studies have 
to be performed. This was the first time that VSX1 has been demonstrated to have a 
mutation in conjunction with visible craniofacial abnormalities (Mintz-Hittner et al.,
2004). Clinical assessment showed that phenotypic variation between the patients 
varied greatly with a range of different changes: wide interpupillary distance, unusual 
pinnate, empty sella turcica, hypertelorism and other anterior segment disorders 
(Mintz-Hittner et al 2004). The patients were also found to have abnormal retinal and 
auditory bipolar cells, which in the case of retinal bi-polar cells are known to be 
reliant on correct VSX1 expression (Chow et al., 2004). The family in the study had 
both keratoconus and PPCD. The new mutation found was A256S and it occurs in 
the CVC domain of VSXl. The other mutation found was considered a variation as it 
does not occur in a critical region and was seen in a few control subjects (Mintz- 
Hittner et al., 2004).
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Fig 1.12. Structure of the VSX1 gene and location of known mutations. VSX1 
(RINX) gene and mutations detected with posterior polymorphous comeal dystrophy, 
keratoconus, abnormal electroretinograms, or a combination thereof. Composite 
summary of the genomic structure of the VSX1 gene with 5 exons. The coding region 
is shown in grey, and the following significant 7 regions are delineated by green 
letters and arrows (the amino acid numbers in parenthesis): the octapeptide sequence 
(OP; 31-38) is blue; the proline rich region (PR; 44-127) is yellow, the acidic region 
(AR; 142-152) is green; the nuclear localization signal (NLS; 162-167) is 
underlined; the homeodomain (H-D; 164-223) is black; the CVC-domain (CVC-D;
224-277) is red; and the RV-domain (RV-D; 322 336) is magenta. The sites of the 
mutations reported by Heon et al (2002) are indicated by blue letters and arrows. The 
variation identified by Mintz-Hittner et al (2004), is indicated by orange letters and 
arrow, and the site of the mutation is indicated by red letters and arrow. Mutations in 
brackets were isolated cases. Underlined mutations were not in critical regions.
Mutations with number signs were amino acids that were not well conserved in the 
evolution of the documented homologous sequences. Mutations with asterisks were 
detected in families but also in controls (*5 of 624, **2 of 277). Note that A256S is 
the only familial mutation that is in a critical region, is highly conserved in evolution, 
and is not found in any controls. Figure modified from Mintz-Hittner et al (2004).
Another recent study has mapped more mutations to the VSXJ gene, this time 
in a series of Italian families that have keratoconus. They confirmed the presence of 
three already described changes at D144E, G160D and P247R. They found a new 
mutation in 7 out of 80 unrelated patients at LI 7P (Bisceglia et al., 2005). This 
mutation is outside all critical domains. This brings the total known mutations in the 
VSX1 gene thought to be directly linked to keratoconus to six, three occurring in the 
CVC domain (see fig 1.12).
1.6.2. Studies that have not found mutations within the Vsxl gene
In recent years there have been a growing number of studies that have 
screened populations of patients for mutations in Vsxl. These studies however have 
not shown mutations in Vsxl leading to a certain amount of controversy as to whether 
Vsxl has been correctly associated with keratoconus and posterior polymorphous 
comeal dystrophy. There is mounting evidence that Vsxl is not associated with 
PPCD (Aldave et al., 2005; Gwilliam et al., 2005; Hosseini et al., 2008; Liskova et 
al., 2007a), yet the same for Vsxl cannot be said as there are still good arguments for
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its association with keratoconus. In a recent study three previously described 
sequence changes that were thought to be disease causing L159M, R166W and 
H244R were shown to appear in unaffected controls. This does not confirm the 
previous findings and casts serious doubt as to the associations between these changes 
and keratoconus (Tang et al. 2008). Also in a recent familial study where a large 
family with keratoconus affected individuals were screened no causative mutations 
were found when compared with non affected controls (Liskova et al. 2007). A 
similar experiment in 100 unrelated patients failed to find any associated sequence 
changes and only found one previously mentioned polymorphism (Aldave et al.,
2006). All the published material so far that casts doubt on VsxTs involvement 
suggest that other genetic factors are most likely involved but stop short at stating that 
VSX1 is not associated with keratoconus.
1.7 Current treatments
The current outlook for treatments for keratoconus is promising and can be 
broken down into two stages; refractive management and surgery. Keratoconus 
cannot be cured but it can be managed up to a point before its severity forces surgery 
to be the only option to maintain vision for the patient. When the progression 
becomes too severe the only option is surgical treatment. Currently there are many 
options depending on the severity of the disease and they all involve strengthening the 
weakened areas of the cornea and slowing or halting its progression further. The 
standard technique is surgery that looks to replace part or the whole of the cornea 
although this method has its disadvantages. The newest technique that has been 
developed involves enhancing the rigidity of the cornea in the stroma by inducing 
cross links to form between the collagen fibrils. This locks the cornea in place 
preventing further progression. For comeal collagen cross linking the technique that 
has received most study is the use of ultraviolet A and riboflavin although this 
technique is in its infancy and is not in mainstream use.
The basic principle of the technique is to induce cross links to form between 
the collagen fibrils that act to harden and stabilize the tissue so that the overall shape 
of the cornea is prevented from degenerating further. Cross linking in this way is a 
widespread method that sees applications in a range of disciplines from materials
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science to dentistry. The treatment works by generating reactive oxygen species 
(ROS) using UVA at 370nm and the photosensitiser riboflavin that induce covalent 
bonds bridging amino groups of fibrils (Wollensak, 2006). Clinical studies of this 
procedure are positive with studies encompassing over 200 patients to date indicating 
a halt and sometimes slight reversal of progression (Wollensak et al., 2003). In one 
study it was demonstrated in vivo that there was an increase in rigidity (Braun et al.
2005). As well as clinical studies the biochemical, mechanical and morphological 
effects have also been examined although more testing is probably needed. This 
method of treatment is the most promising to date but does require long term 
evaluation to see if it is going to become the treatment of choice for keratoconus 
patients at least until a method of reversal or identification and prevention can be 
found.
The largest drawback with this technique is that it works by generating ROS 
and the effects of this have already started to be investigated. Keratocyte apoptosis 
has been observed down to 300pm 1 day postoperatively and this is sometimes seen 
clinically by a mild cornea edema (Wollensak et al., 2004). Also the location of the 
induced crosslinks plays a factor in this treatment, as it is suggested that the 
crosslinking effect is mainly seen in the anterior part of the stroma Although this 
does not pose that much of a problem in the general population of patients the 
treatment may not work for acute keratoconus patients as the crosslinking effect does 
not happen at a sufficient enough depth as was observed in single patient (Wollensak 
et al., 2004). As with all treatments it is not without its side effects and risks 
especially to the eye with the involvement of UV light. The phototoxic damage of 
UV light is well known however the majority of it is filtered out, with nearly all UVB 
light absorbed by the epithelium. As the treatment uses UVA light this risk is 
removed and the damage posed by UVA itself is drastically minimised in the 
crosslinking process with the use of riboflavin. This results in only 7% of UVA 
transmission across the cornea (Wollensak 2006). Experiments on rabbit corneas 
have demonstrated that any subsequent damage can be avoided if the stromal 
thickness of the cornea is greater that 400pm thick. This can be achieved by 
performing pachymetry on the patient before each operation.
More established operations exist although they are more invasive than 
collagen crosslinking. The techniques that exist all aim to either enhance/correct 
rigidity or involve replacing the cornea altogether. To enhance the rigidity of the
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cornea intracomeal ring segments (Intacs IRCS) can be placed into the cornea. They 
work on the basis of acting like a splint for the cornea increasing the mechanical 
strength and increasing the comeal symmetry (depending on their placement) to 
correct the curvature of the cornea and restore vision. This method of treatment is 
useful for patients that are contact lens intolerant and this method of correction may 
delay or remove the need for a full penetrating comeal operation. This method of 
correcting disease is still being improved on and may take several iterations in order 
to get right for each patient, depending on the segment size, placement or number of 
segments to be used. The effect of IRCS appears to be effective through at least 2 
years following their insertion (Colin et al., 2000) however there is evidence that 
central region thinning continues, either due to the natural progression of the disease 
or due to comeal stretching from segment insertion.
Once the progression of keratoconus is beyond the use of IRCS then comeal 
augmentation or replacement is the next solution. These methods provide a 
permanent replacement on the weakened comeal tissue which can be generally 
divided into two categories, lamellar keratoplasty or penetrating keratoplasty. Full 
penetrating keratoplasty is associated with good long-term outcomes with graft 
survival of over 90% (Pramanik et al., 2006). However the underlying reasons for the 
remaining 10% of graft rejection are due to removal of the comeal endothelium, 
which is generally unnecessary as keratoconus is a stromal disorder. An anterior 
lamellar keratoplasty that only replaces the front of the cornea is ideal. Currently full 
penetrating keratoplasty produces better post operative vision but the use of 
automated surgical techniques and the development and refinement of lamellar 
keratoplasty is making the gap smaller. It is thought that lamellar keratoplasty will 
eventually become the method of choice for treating the disease at later stages with 
the exception of corneas that have previously developed hydrops.
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1.8 A summary of methods used in disease investigation
1.8.1 The use o f  animal models to study human diseases
One of the best (if not only) way to study genetic changes is through the use of 
an animal model of a disease. There are many other techniques that exist looking 
often at the simple interactions between two molecules, but these interactions do not 
take into account the environment in which they exist. It is for this reason that even 
the use of cell and organ cultures are not useful as cell cultures lack the complex 
interactions across cell types and tissues and organ cultures cannot be sustained for 
the long periods of time often necessary to study disease. Therefore it is left to 
generated animal models to provide the conditions and interactions needed to test 
hypotheses about disease. The generation of a specific animal model for a particular 
disease is very time consuming and needs thorough investigations to firstly determine 
whether it is an accurate model for a specific disease; then secondly to see what 
changes are present when matched to a healthy wild type of the same genetic 
backgrounds. Currently many different animals have been used as models for disease, 
but the main one of interest when connected with keratoconus is the mouse.
Mouse models have been developed since the early 1980’s and have always 
been one of the favoured animal species to be used as disease models mainly due to 
their gestation time, size, lifespan and constant use in scientific experimentation.
From a genetic standpoint, the mouse has major advantages over other experimental 
animals as its genome is better known than that of other species and has been fully 
mapped and sequenced in recent years. It can be manipulated by the modem 
techniques of genetic engineering and is easy, quick and relatively cheap to produce 
large quantities of mice for systematic studies. Thus, transgenic techniques have made 
it possible to study consequences of specific mutations in genes coding for structural 
components of ocular connective tissues in mice. As these changes in mice have been 
shown to resemble those in human diseases, mouse models are likely to provide 
efficient tools for pathogenetic studies on human disorders affecting the extracellular 
matrix. Despite this there are drawbacks in using mice to study comeal diseases in 
humans.
Some species of mice have some inbred abnormalities themselves that must be 
bred out in order to provide a clean background to work with, so it is much easier to
37
Jack Sheppard
explore any new characteristics that manifest after any changes have been made to its 
genome. Two strains of note are the C57/black 6 strain and the 129/s 1 strain (Jackson 
Laboratories ME). The genetic background of the mice being used is often important 
as they do differ slightly and some are prone to inherent conditions such as blindness.
1.8.2 Generation o f mutant mouse models for disease investigation
The generation of knockout mice is important for the analysis of the function 
of many unknown genes. A knockout mouse or transgenic animal is generated by 
replacing both alleles of a particular gene with an inactive allele. This is done by 
using homologous recombination to replace one allele which is then followed by two 
or more generations of selective breeding until a breeding pair is isolated that has both 
alleles of the targeted gene knocked out. These knockout mice allow researchers to 
determine the role of a particular gene by observing the phenotype of individuals that 
lack the gene completely.
In many cases, the functions of a particular gene can be fully understood only 
if a mutant animal that does not express the gene can be obtained. Whereas genes 
used to be discovered through identification of mutant phenotypes, it is now far more 
common to discover and isolate the normal gene and then determine its function by 
replacing it in vivo with a defective copy. This procedure is has been made possible 
by two fairly recent developments: a powerful strategy to select for targeted mutation 
by homologous recombination, and the development of continuously growing lines of 
embryonic stem cells (ES cells) (Evans and Kaufman, 1981). These are embryonic 
cells which, on implantation into a blastocyst, can give rise to all cell lineages in a 
chimeric mouse.
The technique of gene targeting takes advantage of homologous 
recombination. Cloned copies of the target gene are altered to make them 
nonfunctional, for example by the introduction of a stop codon that truncates the 
protein making it inactive, and are then introduced into the ES cell where they 
recombine with the homologous gene in the cell’s genome, replacing the normal gene 
with a nonfunctional copy. Homologous recombination is a rare event in mammalian 
cells, and thus a powerful selection strategy is required to detect those cells in which it 
has occurred. Most commonly, the introduced gene construct has its sequence 
disrupted by an inserted antibiotic resistance gene such as that for neomycin
38
Jack Sheppard
resistance. If this construct undergoes homologous recombination with the 
endogenous copy of the gene, the endogenous gene is disrupted but the antibiotic 
resistance gene remains functional, allowing cells that have incorporated the gene to 
be selected in culture for resistance to the neomycin like drug G418. However, 
antibiotic resistance on its own shows only that the cells have taken up and integrated 
the neomycin-resistance gene. To be able to select for those cells in which 
homologous recombination has occurred, the ends of the construct usually carry the 
thymidine kinase gene from the herpes simplex virus (HSV-tk). Cells that incorporate 
DNA randomly usually retain the entire DNA construct including HSV-tk, whereas 
homologous recombination between the construct and cellular DNA, the desired 
result, involves the exchange of homologous DNA sequences so that the non- 
homologous HSV-tk genes at the ends of the construct are eliminated. Cells carrying 
HSV-tk are killed by the antiviral drug gancyclovir, and so cells that have undergone 
homologous recombination have the unique feature of being resistant to both 
neomycin and gancyclovir, allowing them to be selected efficiently when these drugs 
are added to the cultures.
This technique can be used to produce homozygous mutant cells in which the 
effects of knocking-out a specific gene can be analyzed. Diploid cells in which both 
copies of a gene have been mutated by homologous recombination can be selected 
after transfection with a mixture of constructs in which the gene to be targeted has 
been disrupted by one or other of two different antibiotic-resistance genes. Having 
obtained a mutant cell with a functional defect, the defect can be ascribed definitively 
to the mutated gene if the mutant phenotype can be reverted with a copy of the normal 
gene transfected into the mutant cell. Restoration of function means that the defect in 
the mutant gene has been complemented by the normal gene’s function. This 
technique is very powerful as it allows the gene that is being transferred to be mutated 
in precise ways to determine which parts of the protein are required for function.
To knock out a gene in vivo, it is only necessary to disrupt one copy of the 
cellular gene in an ES cell. ES cells carrying the mutant gene are produced by 
targeted mutation, and injected into a blastocyst which is incorporated into the 
developing embryo and contribute to all tissues of the resulting chimeric offspring, 
including those of the germline. The mutated gene can therefore be transmitted to 
some of the offspring of the original chimera, and further breeding of the mutant gene 
to produce homozygous mice that completely lack the expression of that particular
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gene product. The effects of the absence of the gene’s function can then be studied.
In addition, the parts of the gene which are essential for its function can be identified 
by determining whether function can be restored by introducing different mutated 
copies of the gene back into the genome by transgenesis.
A second powerful technique achieves tissue-specific or developmentally 
regulated gene deletion by employing the DNA sequences and enzymes used by 
bacteriophage PI to excise itself from a host cell’s genome. Integrated bacteriophage 
PI DNA is flanked by recombination signal sequences called loxP sites. A 
recombinase, Cre, recognizes these sites, cuts the DNA and joins the two ends, thus 
excising the intervening DNA in the form of a circle. This mechanism can be adapted 
to allow the deletion of specific genes in a transgenic animal only in certain tissues or 
at certain times development. First, loxP sites flanking a gene, or perhaps just a single 
exon, are introduced by homologous recombination. Usually, the introduction of 
these sequences into flanking or intronic DNA does not disrupt the normal function of 
the gene. Mice containing such loxP mutant genes are then mated with mice made 
transgenic for the Cre recombinase, under the control of a tissue specific or inducible 
promoter. When the Cre recombinase is active, either in the appropriate tissue or 
when induced, it excises the DNA between the inserted loxP sites, thus inactivating 
the gene or exon. Thus, for example, using a T-cell specific promoter to drive 
expression of the Cre recombinase, a gene can be deleted only in T cells, while 
remaining functional in all other cells of the animal.
1.8.3 Generation o f a knockout model for keratoconus
It is easier to create a mouse model for a disease when that particular disease 
has a well characterised mode of inheritance established via family tree studies and 
linkage analysis has established a link with a causative gene. It is much more difficult 
to assess the potential value of a created model for a disease if the cause of die disease 
is complex or if you are trying to study a collection of changes that present themselves 
as a wrapped up syndrome or disorder. As keratoconus is such a disease creating a 
model for it in the past has been quite difficult. Currently, a single mouse model has 
been proposed for keratoconus based on the resulting mouse’s clinical features 
(Tachibana et al., 2002) and 2 models have the potential to be disease models based
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on the virtue of the gene that was knocked out in order to create them (Chow et al., 
2004; Ohtoshi et al., 2004; Ramalho et al., 2004).
In 2002 a mouse model was derived for keratoconus that used an inbred line of 
spontaneous mutant mice with keratoconus-like corneas as progenitors for an eventual 
use as a keratoconus model; this was achieved through repeated sibling mating 
(Tachibana et al. 2002). Morphology, cell growth, apoptosis of keratocytes and 
protein expression was examined in the corneas of these mice. Androgen dependency 
was also examined in this model as it was observed that the keratoconus phenotype 
was observed almost exclusively in sexually mature male mice. The phenotype in 
these mice is inherited in an autosomal recessive manner and the link with androgen 
dependency was investigated. In order to test their hypothesis male mice underwent 
castration and female mice were injected with testosterone at approximately 4 weeks 
of age. This resulted in female mice displaying the keratoconus phenotype at a much 
weaker level then in their male counterparts. However keratoconus did not develop in 
the castrated males. Macroscopically corneas were graded for their appearance and to 
the extent that a cone formed. It was found that at the early stages the corneas became 
cloudy and was then followed by protrusion. The changes seen appeared to be only 
occurring in the males with few female mice developing cones. Histological 
examinations revealed that the central regions of the cornea in the males were often 
thinned although they ranged and could also be edematous and thick. Where thinning 
was observed it was mainly due to a decrease of thickness in the stroma Expression 
of c-fos was enhanced in these corneas mirroring the findings in human keratoconic 
patients. Collagen fibril diameters and interfibrillar spacings were examined in these 
mice and found to be slightly larger than wiid type controls (Quantock et al. 2003).
1.8.4 Vsxl knock-out mouse model
Recently two knock out mouse models for Vsxl have been created to study the 
effects of silencing the expression of the Vsxl gene (Chow et al., 2004; Ohtoshi et al., 
2004). The mouse model created by Chow et al. was initially created to determine the 
function of Vsxl in the formation of the retina as previous expression studies indicated 
that it was expressed in the inner nuclear layer. Although this model was created with 
the retina in mind it is a valuable tool in assisting any investigation where this gene is 
concerned. However at present no comeal defects have been reported in the Vsxl null
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mice (Chow et al. 2004) but no thorough examinations or studies were carried out.
This leaves a great opportunity to further study this model.
In generation of the null mice gene targeting by homologous recombination 
was performed in R1 embryonic stem cells using established techniques (Chow et al. 
2004). Targeting constructs were derived from the pPNT vector containing a 
neomycin resistance cassette for G418-mediated positive selection and a thymidine 
kinase cassette for gancyclovir-mediated negative selection of embryonic stem cell 
homologous recombinants. After homologous recombination a mutated Vsxl allele 
lacking 359bp from exon 1 and all of exons 2-4 was created. This completely 
eliminates the homeodomain and the first 46 amino acids of the CVC domain 
rendering the gene a complete null (Chow et al. 2004). Chimeric mice were generated 
by blastocyst injection of homologous recombinant embryonic stem cells and the 
resulting mice were bred with either the 129/S vlmJ mouse strain or the outbred Black 
Swiss mice (Chow et al. 2004).
The Vsxl null mice produced demonstrated no behavioural or neurological 
defects and in contrast with human missense mutations the null mice had no comeal 
abnormalities grossly or at the histological level using light microscopy and EM 
(Chow et al. 2004). Comeal tissues from two month old Vsxl KO and WT controls 
were examined by haematoxylin/eosin staining and transmission electron microscopy. 
No significant changes were observed in the comeal epithelium, stroma or 
endothelium by light microscopy and no changes were observed under electron 
microscopy. However it should be noted that the areas examined by electron 
microscopy was the centre of the cornea (personal communication, Dr Chow) and this 
is not the site where one would expect any structural defects to occur in keratoconus 
as they are mostly seen in the paracentral regions in human keratoconics. Also with 
the inherent thinness of murine corneas the thinning that is observed with keratoconus 
corneas in humans may also not be apparent. Publications on the other mouse model 
were released a month after the KO model produced by Chow et al. This mouse 
model was also created to look at Vsxl in retinal expression and two mouse mutants 
were created; the first replacing the homeodomain and CVC domain with a loxP 
sequence. The second mutant was created by replacing part of the homeodomain with 
a lacZ expression cassette. They too observed that Vsxl is necessary for late stage 
differentiation of cone bipolar cells (Ohtoshi et al. 2004). The mechanisms offered to 
explain the regulation of off cone bipolar cells is that Vsxl could be part of a negative
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feedback loop acting as a self regulator. Examination of the cornea in this model was 
not included in the phenotyping
1.8.5 Studies on the cornea using X-ray diffraction
X-ray diffraction is a technique that allows a detailed description of the 
macromolecular structure of a substance if it has structural regularity. If X-rays are 
directed against a regular array of scattering units then diffraction occurs. The 
diffracted X-rays can then be used to determine information about the scattering unit. 
For example if the scattering unit was cylindrical then the scattering pattern obtained 
can be used to tell the orientation of that unit (See fig 1.13).
&
Fig 1.13. A theoretical diffraction pattern from a single cylindrical scattering unit.
The yellow star represents a source of electromagnetic radiation. The cylinder the 
scattering object and the 2 black dots on the square the diffraction pattern on a 
detector.
This diffraction pattern would occur if the distance between the scattering 
units in a structure (e.g. collagen tissue) is the same order o f magnitude as the 
wavelength of the waves. As X-rays are small enough they can be used to resolve 
structures at the nanometre scale. This method has many applications especially in 
finding out crystal structures as crystals are regular arrays, or the arrangement of 
molecules on less well ordered fibrous structures. In this report this method is used to 
examine the fibril structures in the comeal stroma Figure 1.12 is an example of a 
diffraction pattern obtained if a single diffracting structure (collagen fibril) were being 
examined. If the cylinder in fig 1.12 were rotated in a plane at right angles to the x-
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ray beam, the positions of the diffraction spots (reflections) would rotate similarly. If 
there were cylinders at different angles each would diffract independently, so the 
diffraction spots would be smeared into arcs, the degree of arcing representing the 
angular distribution of the cylinders.
Incoming X-rays make an angle 0 with the diffracting planes and are reflected 
at an equal angle 0 (see fig 1.14).
ld/2
Fig 1.14. Bragg's law provides the condition for a plane wave to be diffracted by a 
family of lattice planes, d  is the lattice spacing, 0 the angle between the wave vector 
of the incident plane wave, k*, and the lattice planes, X its wave length and n is an 
integer, the order of the reflection. Figure taken from www.wikipedia.com/braggs 
law and (P.PEwald 1962,1999)
If the distance between two adjacent planes is d, constructive interference occurs 
when the difference in optical path length is an integer multiple of the wavelength.
The maxima (spots) are observed in the direction 0 given by:
2d sin 0 = rik
X -  wavelength of the X-ray beam 
d -  the plane distances
This is the Bragg relationship. It shows that for a fixed wavelength, there is an 
inverse relationship between spacing and diffraction angle. Thus structures with 
larger spacings (such as collagen fibrils) diffract at small angles and structures with 
small spacings (such as collagen molecules) diffract at wide angles. In this report, X- 
ray diffraction is used to measure the values of (d) corresponding to the 
intermolecular separation within collagen fibrils, the centre-to-centre distance 
between collagen fibrils, the average fibril diameter and orientation.
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1.9 Aims of thesis
• To provide data on the development of the mouse cornea using various 
investigative techniques with focus on a few key genes of interest.
• To test the idea that keratoconus has a genetic cause through use of existing 
animal models and investigative techniques.
• To screen a local population of keratoconus patients to investigate whether 
mutations in Vsxl can be found.
• To expand on the possible causes of keratoconus and identify any potential 
targets for therapy.
1.10 Hypothesis
1. Vsxl is involved in normal corneal formation
2. Vsxl mutations are associated with keratoconus
3. Vsxl Knockout mice demonstrate phenotypic features of keratoconus
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Chapter 2: General materials and methods
2.1 Semi-quantitative PCR
PCR was carried out using 12.5(41 of PCR BioMix™ Red kit (Bioline, UK). 
The reaction kit comprises BIOTAQ™ DNA Polymerase, 2mM dNTPs, 32mM 
(NH4) 2SO, 125mM Tris-HCl (pH 8.8 at 25°C), 0.02% Tween 20,4mM MgC12, 
Stabilizer and an inert dye. To this was added 2pl of DNA and 1.5 pi 20pM of both 
forward and reverse primers. The total reaction volume was brought up to 25pi with 
the addition of 8pl of sdH20 and then the samples were vortexed and spun down. 
They were then placed in a thermocycler for 35 cycles of denaturing at 97°C, 
annealing and strand extension at 72°C. Annealing temperatures as well as sequence 
for primers are given separately in each chapter. PCR products were then stored in 
the fridge or held at 4°C until separated via agarose gel electrophoresis.
2.2 Agarose gel electrophoresis
PCR product samples were separated on either a 2% agarose gel prepared by 
adding 4g of agarose to 200ml of lxTBE buffer. Products were stained by ethidium 
bromide (2 pi, lOmg/ml) and separated in TBE buffer at 150 volts for ~ 40 minutes. 
Quantification of bands and size estimates were made possible by running out 7pi of 
DNA Hyperladder™ IV (Bioline, UK) on each gel.
2.3 Quantitative RT-PCR
Quantitative PCR was carried out on the Roto-Gene™ (Corbett Research) in a 
similar fashion to semi-quantitative PCR described above. The difference lies in the 
detection method and incorporation of a fluorescent dye that monitors the level of 
product in real time as the reaction is running. In all reactions cDNA was amplified 
using Sigma SYBR® Green Jumpstart™ Taq ReadyMix™ (20 mM Tris-HCl, pH 8.3, 
100 mM KC1, 3 mM MgC12, 0.002% gelatin, 0.4 mM of each dNTP, stabilizers, 0.06 
unit/ml Taq DNA Polymerase, JumpStart Taq antibody). The reaction mixes 
consisted of 2pl of cDNA, 1.25pl 20pM of the forward and reverse primers 
respectively, 12.5pl of the ready mix and 8pl of dd H2O to bring the reaction to a total
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volume of 25pl, which is half of the recommended manufacturer’s instructions. The 
most important part of quantitative PCR is in the analysis of the product. There is an 
initial hold of 95°C for 2 minutes followed by denaturation at 95°C, annealing and 
extension at 72°C. Annealing temperatures are dependent on primer sequences and 
are given in the relevant methods sections in subsequent chapters.
2.3.1 Establishing which method to use for analysis o f  amplified products
The quantification of gene-specific mRNA expression is one of the major 
issues in life sciences research. Quantitative real-time RT-PCR (qPCR) has been 
widely used, allowing fast, accurate and sensitive mRNA quantification with a high 
throughput of samples. Unfortunately, the issue of real-time PCR data analysis is 
often underestimated by researchers leading to inaccurate expression levels. The two 
most commonly used methods of data analysis for the expression of genes are the 
standard curve method and the comparative CT cycle threshold (2'AACj) method. Both 
of these methods have their advantages and disadvantages, which is why other 
researchers have tried to look at better methods for data analysis. A third method 
called the comparative quantification method (Ramakers et al., 2003) was also 
considered for the data analysis.
The standard curve method of qPCR data analysis uses a standard curve of 
known concentrations for each gene that is being examined and the housekeeping 
gene. This absolute method of quantification looks to establish the copy number of an 
amplicon when compared to the standard curve. The disadvantages of this method is 
that it is very resource consuming as standard curves must be used for each time the 
target sample is amplified. There is also a need to have consistent and repeatable 
standards that do not reflect the true nature of sample amplification (see fig 2.1).
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Fig 2.1. Raw expression curves of Aqp5 at postnatal days 5, 12 and 17 in murine 
corneas. A - expression at p5, B - expression at p i2, C - expression at pl7. Numbers 
indicate dilution factors of the standard curve. X -  NTCs and no RT controls.
The expression curves from each sample are then used to form a standard 
curve in order to determine the concentration of the unknown samples being tested. It 
is important for this do have a low standard deviation in order to produce a standard 
curve with good efficiency (see fig 2.2).
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Fig 2.2. Standard curve formed from the raw expression curves of Aqp5
The second method is the 2'AACr method. The main advantage of this method 
is that only one set of standard curves needs to be prepared and can be used for 
multiple amplifications. This method always assumes perfect PCR conditions and the 
efficiency to always be 100%, which is not the case. This assumption of efficiency 
leads to an over estimation of expression and is therefore less accurate than the
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Fig 2.1. Raw expression curves of Aqp5 at postnatal days 5,12 and 17 in murine 
corneas. A - expression at p5, B - expression at pi 2, C - expression at p i7. Numbers 
indicate dilution factors of the standard curve. X -  NTCs and no RT controls.
The expression curves from each sample are then used to form a standard 
curve in order to determine the concentration of the unknown samples being tested. It 
is important for this do have a low standard deviation in order to produce a standard 
curve with good efficiency (see fig 2.2).
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Fig 2.2. Standard curve formed from the raw expression curves of Aqp5
The second method is the 2'AACr method. The main advantage of this method 
is that only one set of standard curves needs to be prepared and can be used for 
multiple amplifications. This method always assumes perfect PCR conditions and the 
efficiency to always be 100%, which is not the case. This assumption of efficiency 
leads to an over estimation of expression and is therefore less accurate than the
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standard curve method but uses less resources than the standard curve method (Schefe 
et al., 2006).
Gene expression in this study was analysed using the comparative 
quantification method (Ramakers et al. 2003). This method examines gene expression 
by looking at the second differential of the expression curve and uses linear regression 
to establish efficiencies (E) for each sample separately and uses this to calculate the Ct 
values. This method has fewer disadvantages when compared with the other two 
methods; the advantages are that it obtains a more accurate efficiency value for each 
reaction by using the second differential and compares the test sample directly to the 
control. There is no need for standard curves and take off values are more consistent. 
This means that less tissue is needed, which is a major advantage in this study as the 
amount of tissue is very limited. It should be noted that in all RT-PCR reactions three 
time points are used: postnatal days 5, 12 and 17. For each experiment data is firstly 
normalised to the housekeeping gene then calibrated to the lowest time point, which 
in all cases is postnatal day 5. This time point is assigned a value of 1 and all 
subsequent reaction values for other time points are ratios to it.
2.3.2 Establishing significance in quantitative PCR (qPCR)
Ct values (Cn, Cn, Cn) are obtained for each gene of interest and the 
housekeeping gene. One of the measured samples is defined as the reference sample 
(ref). To compare two samples we calculate three different relative expression ratios 
rERs. It is assumed that the calculated rERs for one sample-of-interest are part of a 
normal distribution. This is determined as the Ct values and efficiencies for each gene 
are normally distributed. This allows us to calculate an average for a particular gene. 
In this case to establish whether expression results are significant all samples were 
tested in triplicate and repeated on three separate experiments. To calculate the 
significance of expression an unpaired 2-tail t test was applied. Significance was 
established to be P<0.05.
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2.4 Solution preparation
2.4.1 4% paraformaldehyde
8g of solid PFA was added to 100ml of lxPBS in a conical flask. This was 
then placed on a heated stirrer for 2 hours making sure the heat does not exceed 65°C. 
If the PFA has not entered the solution then sodium hydroxide was added drop-wise 
to the solution until it became clear. This was then filtered into a fresh conical flask. 
pH was adjusted to 7.4 and the solution was placed into aliquots and frozen at -20°C 
for future use. This method generates 8% paraformaldehyde so to use at its final 
concentration of 4% it is diluted with fresh lxPBS on a heater stirrer as before.
2.4.2 Phosphate buffered solution
PBS was made from the tablet form available from according to the 
manufacturer’s instructions.
2.5 Small angle X-Ray Data Collection
Small-angle X-ray diffraction (SAXS) patterns were collected on Station 2.1 at 
the UK Synchrotron Source (Daresbury, UK), using a 9m-long camera equipped with 
a multi wire gas detector. The X-ray beam had a wavelength of 0 .154 nm and a cross 
section at the specimen measuring 0.5 mm vertically and 1 mm horizontally. 
Specimens were weighed before and after measurement to determine the difference in 
wet weight and ensure that samples did not become dehydrated during X-ray 
exposure. Samples were placed in airtight Perspex (Databank, UK) chambers with 
Mylar (DuPont-Teijin, UK) windows to further minimize tissue dehydration and keep 
the sample in a fixed position. Incident X-rays were passed through the anterior 
comeal face parallel to the optical axis. Single SAXS patterns were gained from the 
centre of each sample. If there was any ambiguity in position due to the size of the 
sample a small 0.1 mm correction was made and a second SAXS pattern gained. The 
pattern that measured the largest interfibrillar reflection value was then used.
Exposure time per data point was 3 minutes.
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2.6 Small angle X-Ray Data Analysis
X-ray patterns were gained from the centre of each of the samples. X-ray 
intensity profiles were measured along a vertical transect through the centre of each 
pattern because this was the direction in which the x-ray beam was most finely 
focused. Processing of samples was then carried out in 3 steps. Firstly a square- 
power law background curve was fitted to and subtracted from the experimental data. 
This removed scattering from stromal matrix components other than fibrillar collagen.
Secondly assuming cylindrical collagen fibrils, small-angle equatorial X-ray 
diffraction from a comeal lamella can be approximated as the fibril transform (i.e., 
scattering from a single fibril), multiplied by the interference function (deriving from 
the ordered arrangement of the cylinders). A theoretical fibril transform (Bessel 
function) was fitted to the experimental data by varying two parameters: the fibril 
radius and an arbitrary scaling factor.
Quit |
K
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Fig 2.2. A) Linear profile of scattering from an X-ray pattern. B) Bessel function 
applied to remove the background scatter.
Fitting was performed on the first subsidiary maximum of the experimental data,
because this peak derives entirely from the fibril transform, with no significant
contribution from the interference function (Worthington and Inouye, 1982). The
experimental data was then divided point-for-point by the calculated fibril transform
to leave the interference function, whose peak position is determined by the average
interfibrillar Bragg spacing.
Thirdly the interfibrillar Bragg spacing and fibril radius were calibrated from
the position of the 67-nm meridional reflection from a diffraction pattern of hydrated
rat tail tendon and finally the average center-to-center interfibrillar spacing (/) was
calculated from the interfibrillar Bragg spacing (p) with i = 1.12p, where 1.12 is a
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packing factor that assumes that the arrangement of fibrils in a lamella approximates 
the short-range order of a liquid (Boote et al. 2003).
2.7 Wide angle X-Ray Data collection
Wide angle X-ray diffraction (WAXS) data was collected at the UK 
Synchrotron Radiation Source (Daresbury, UK) at the 14.1 station using a 200pm x 
200pm X-ray beam of wavelength 0.1488 nm at right angles to the cornea Rasta 
scans were made of the entire surface of the cornea at 0.2mm intervals. In order to 
further minimise tissue dehydration during X-ray exposure, wrapped corneas were 
positioned in an airtight Perspex (Databank, UK) chambers with Mylar (Dupont- 
Teijin, UK) windows. X-ray beam position was determined before samples were 
examined. Rasta scans of the entire cornea were performed using a specimen 
translation stage (Newport, UK), interfaced with the X-ray camera shutter for 60 
second exposures per scan. The resulting WAXS patterns were recorded on a 
Quantum 4R CCD detector (ADSC, Poway, CA) located 150 mm behind the 
specimen. Depending on die size a minimum of 100 patterns were gained for each 
sample. Sample time exposure to the beam was dependent of the age of the tissue and 
determined by a test scan before the rasta scans were begun. All tissues used in 
WAXS experiments were frozen before testing.
2.8 Wide angle X-Ray data analysis
A typical WAXS pattern from a mouse cornea is shown in fig 2.3. It features 
lobes of intensity that are X-ray reflections formed by interference between X-rays 
scattered by the regularly arranged collagen molecules lying near-axially within the 
stromal fibrils (Meek and Quantock, 2001). The X-rays used penetrates the entire 
thickness of the cornea so the scattering that is detected is the sum is from fibrils from 
each lamella in the path of the beam. Scattering of X-rays occurs at 90° to the 
direction of the fibril so each single stromal lamella will produce a pair of diffraction 
spots either side of a line representing the long axis of its constituent fibrils. If the 
stacked lamellae in the stromal had a homogenous or unordered arrangement, a 
circular X-ray scattering pattern of uniform intensity would be produced at the
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appropriate angle defined by Bragg’s Law. If lamellae have preferred orientations, as 
in figure 2.3, the intensity around the scatter pattern will vary.
32)000
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Fig 2.3. A and B). A typical WAXS pattern from a mouse cornea. The lobes of 
intensity arising from X-ray reflections perpendicular to the alignment of fibrils are 
outlined in A  C) The intensity as function of angle. Intensity profile from (Meek et 
al., 2003b)
By measuring the distribution of intensity of the scatter pattern around the 
detector as a function of angle we can quantify firstly the relative mass of collagen at 
that specific point in the tissue and secondly determine whether the fibrils at that point 
in the tissue show any degree of preferential fibril alignment. It has previously been 
shown that mouse corneas exhibit a circular pattern of arrangement although it 
appears to be quite variable. For each WAXS pattern, the normalised intensity profile 
was obtained using Optimas 6.5 (MediaCybemetics, UK) image analysis software and 
Excel (Microsoft, UK) spreadsheets. Starting at 0° at the left of the reflection, the 
intensity of the scattered x-rays was measured as a function of angle. The result is a
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linear intensity profile of these reflections as shown in fig 2.3. The total area under the 
graph (the total scattered intensity) is proportional to the total mass of fibrillar 
collagen in the path of the X-ray beam, and this may be subdivided into two 
components. The first part of the scattering comes from the non-aligned (isotropic) 
fibrils. The second part of the scattering shows the mass of fibrils that have a 
preferential alignment of fibrils as seen in figure 2.3. By integrating the respective 
areas we can get a relative measure of the amount of collagen at that point in the 
tissue broken down into its constituent parts. This was repeated at 0.2mm intervals 
across the entire surface of the corneas being analysed and the data is represented as 
topography maps for both the aligned and non-aligned collagen. It should be noted 
that, in practice, the X-ray beam traverses the slightly curved comeal buttons in a 
direction parallel to the optical axis, so that the measurements obtained represent a 
projection of the tissue onto a two-dimensional plane at right angles to the direction of 
the x-ray beam.
As the data gathered is a function of angle we can extract information about 
the direction (if any) that fibrils have adopted when they are being laid down. Taking 
just the area under the curve representing preferentially aligned collagen, the 
distribution was then converted into a polar (vector) plot see fig 2.4, taking into 
account the fact that the x-ray intensity appears at right angles to the fibril axis 
(Aghamohammadzadeh et al., 2004). The radial length of the polar plot at a given 
angle is directly proportional to the mass of collagen fibrils aligned at that angle. The 
overall size of the plot is therefore related to the total mass of aligned collagen, and 
the asymmetry gives an indication of the preferential directions) of the collagen at 
that point in the tissue. Polar plots were produced from the scattering patterns 
obtained from each point of the cornea scanned, and were subsequently arranged 
according to their geometric positions on the cornea giving a directional map of the 
collagen across the entire comeal surface.
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Fig 2.4. X-ray intensity as a function of angle for collagen with a preferential 
alignment displayed as vector plots
Chapter 3. Mouse corneal development
3.1 Aim
• To profile the expression changes of several genes over postnatal murine 
comeal development including the paired-like.CVC gene murine homologue 
Vsxl and the collagen gene Col8A2.
• To profile the changes in collagen mass, distribution and fibril alignment in 
developing murine corneas in order to provide the background necessary for 
future genetic studies.
3.2 Introduction
It is important to establish a baseline for any kind of study so that the effects 
caused by induced changes, if any, can be identified. The production of mouse 
models in studying disease is an invaluable tool for investigating disease and offers 
possibilities to discover the first signs o f a disorder at a very early stage. One of the 
problems that exist with identifying and treating keratoconus is that by the time the 
symptoms appear, the progression o f the ectasia is already at a fairly advanced stage. 
Therefore a study of the development of the cornea is necessary in categorising the 
changes that naturally occur so that, later, disease models can be examined for any 
anomalies.
Vsxl is a gene that codes for a homeodomain transcription factor and was 
originally characterised in goldfish (Passini et al., 1997) and found to be expressed 
during retinogenesis. Other orthologous sequences have since been found in the 
zebrafish (Passini et al., 1998), chicken (Chen and Cepko, 2000), cow (Hayashi et al.,
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2000), mouse (Ohtoshi et al., 2001) and human (Hayashi et al., 2000; Ohtoshi et al., 
2001; Semina et al., 2000). Vsxl belongs to the paired-like:CVC class of homeobox 
genes, which in turn belongs to the dispersed superclass family of homeodomain 
proteins. Currently the functions of Vsxl in the cornea are unclear. However the 
known functions of Vsxl in the retina have been elucidated. Vsxl is crucial for the 
development of off-centre cone bipolar cells in the inner nuclear layer as the absence 
of expression of Vsxl leads to substantial reductions in the expression of at least 4 
cone bipolar cell proteins (Chow et al., 2004). Furthermore, mutations in VSX1 have 
been linked to both keratoconus (KC) (Bisceglia et al., 2005; Heon et al., 2002; 
Mintz-Hittner et al., 2004) and posterior polymorphous comeal dystrophy (PPCD) 
(Heon et al., 2002; Valleix et al., 2006). The expression profile of Vsxlhas mainly 
been investigated in the murine eye; currently the earliest detection of Vsxl has been 
at embryonic (E) day E l4. Current data mostly focuses on the expression of Vsxl in 
the retina (Chow et al., 2001; Hayashi et al., 2000; Ohtoshi et al., 2001) but it is also 
expressed in the cornea (Krafchak et al., 2005).
As described previously keratoconus is a major ocular disease in the western 
world and the main candidate for comeal surgery (Atilano et al., 2005). It is a non 
inflammatory, progressive comeal thinning disease leading to myopia and irregular 
astigmatism. As yet there is no known cure for keratoconus other than comeal 
grafting; however numerous studies are being carried out into the structure of 
keratoconic corneas and its developmental mechanisms. There is evidence that 
keratoconus is inherited in some patients and families and that the cause in all patients 
could have a genetic contribution. Current research suggests a number of possible 
genetic aetiologies for keratoconus caused by the interplay of environmental factors 
and different mutations in certain genes that lead to a predisposition for its 
development. Keratoconus probably develops in early life and is usually leads to 
clinical symptoms within the first few decades. This suggests that normal 
developmental mechanisms that stabilise the cornea within the first few years after 
birth, fail to occur in keratoconus. There is therefore an argument that studies need to 
be made in the developing stages of the cornea. Treating a cornea once the clinical 
symptoms have manifested can also be argued is too late in order to provide the best 
treatment. With the introduction of mouse models to disease it was thought necessary 
to establish a control characterising the structure of a normal developing cornea. This 
would allow any future mouse models for the disease to have a measure of what is
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normal so that any changes noted could be better defined as having arisen from the 
mutation. With mouse models there is an advantage in that the latter stages of their 
comeal development happen postnatally and one of the most crucial times in mouse 
comeal development is during eye opening.
Eye opening in the mouse (PI2-14) is preceded by large developmental 
changes in the cornea in preparation for interactions with the outer environment. 
Changes that have been characterised during this period include an increased 
proliferation of epithelial cell layers, a significant increase of stromal thickness and a 
decrease in stromal density (Song et al., 2003). The endothelium does not undergo as 
much change as the other layers. This critical time in development provides an 
excellent opportunity to examine gene expression and structural changes. The 
increase in activity would indicate that a number of genes are active and available for 
detection that would be otherwise difficult to do in an adult system. To investigate 
whether Vsxl and other genes have a role in the cornea during this period their 
expression profiles were examined using quantitative RT-PCR X-ray diffraction was 
used to determine how the mature structure of the cornea develops and to look at how 
the collagen organises itself throughout the developmental process. The expression of 
Vsxl in other tissues was also investigated to confirm what had already been 
published.
3 3  Methods and materials
3.3.1 Tissue collection and preparation
For quantitative PCR 129/S 1 wild type (WT) were raised within the lab with a 
14 hour light cycle and standard diet. 129/SI mice were chosen over other strains of 
mice as the Vsxl KO mouse produced my Chow et al. 2004 used this strain. As this 
KO model is examined later in this thesis developmental studies were conducted 
using this strain in order to make direct comparisons. Whole eyes, brain, liver, lung 
and heart from 4 mice were extracted and placed in RNAlater® (Ambion, Inc.) at 
postnatal (P) days P5, P12 and P17 of development. Corneas at each time point were 
dissected out and placed in RNAlater® and frozen for further isolation. For X-ray 
scattering experiments whole murine eyes of 4 wild type 129/S 1 (Jackson 
Laboratories) mice were isolated and the cornea rapidly excised and wrapped in 
clingfilm at 10-28 postnatal days of development. Excised corneas had their
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orientation maintained throughout removal and die 12 o’clock position and epithelial 
side were identified and marked using a surgical suture. Corneas upon removal were 
immediately wrapped in Clingfilm™ and frozen at -80°C for storage until future 
examination. Corneas were weighed before and after experimentation with no 
discemable decrease in weight. Mice were handled in accordance with the ARVO 
Statement for the Use of Animals in Ophthalmic and Vision Research.
3.3.2 RNA isolation, primer sequences and product amplification by QPCR
Total RNA was isolated using the RNEasy® Mini kit (Qiagen) according to 
the manufacturer’s protocol and extracted RNA was quantified using 
spectrophotometry. RNA was separated into aliquots to avoid the need of repeated 
freeze/thaw cycles and RNA was transcribed to cDNA using the Quantitect® Reverse 
Transcription Kit (Qiagen) according to the manufacturer’s instructions. cDNA was 
amplified using Sigma SYBR® Green Jump start™ Taq ReadyMix™ for Quantitative 
PCR on the Roto-Gene™ (Corbett Research). Isolated RNA was pooled for each 
time point and three sets of pooled RNA were examined and repeated three times. In 
order to ensure similar starting product concentrations each RNA sample was 
measured and then aliquoted so that each subsequent reaction was optimised for an 
RNA concentration of 0.5 pg. Genes were amplified using cDNA specific primers for 
the following genes:
Name Primer sequence 5’ - 3’ tmp °C
Vsxl F 5 ’-ACTGCCCAGTTACCC AC AAT-3 ’ 55
Vsxl R 5 -AAGTGGCGTAAGCGAGAGAA-3 ’ 55
Aqp5 F 5’- ATCTACTTCACCGGCTGTTCC-3 ’ 60
Aqp5 R 5’- GTCAGCTCGATGGTCTTCTTC-3 ’ 60
Aqpl F 5 ’-GAAGAAGCTCTT CT GG AGGGCT G-3 ’ 60
Aqpl R 5 -GGCTTCATCTCCACCCTGGAGTT-3 ’ 60
Col8a2 F 5 -GGTAAAGTATGTGCAGCCCA-3 ’ 60
Col8a2 R 5 ’-AGT AAT ACCTGAGGGACC AG-3 ’ 60
RpL19F 5 ’-GGGA AG AGGA AGGGT ACTGC-3 ’ 55
RpL19R 5 -GGACGCTTCATTTCTTGGTC-3 ’ 55
Table 2. Primer sequences used for amplification, F- forward, R -  reverse, tap -  
temperature. All primer sequences are 5’ to 3’.
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Rpll9 was used as a housekeeping gene for normalization and all primer sequences 
were designed to be intron spanning. Primers were designed using the Primer3 
program (Rozen and Skaletsky, 2000) to the Vsxl sequence accession # NM_054068. 
As significance is being compared between three different time points a standard t-test 
does not apply so a one way analysis of variance (ANOVA) test was used. 
Significance was determined to be P<0.05.
3.3.3 Conditions for Semi quantitative PCR
Name Primer sequence 5’ - 3’ tmp °C
Vsxl F 5 -ACTGCCCAGTTACCCACAAT-3 ’ 55
Vsxl R 5 -AAGTGGCGTAAGCGAGAGAA-3 ’ 55
Table 3. Primer sequences used for amplification of Vsxl for Semi quantitative PCR, 
F- forward, R -  reverse, tmp -  temperature. All primer sequences are 5’ to 3’.
All other conditions were the same as described in the methods chapter.
3.3.4 Band densitometry for semi quantitative PCR
Band densitometry was carried out using the Scion Image© program 
distributed by Scion. A mask of a fixed size was placed over a PCR fragment band of 
a digital picture of the gel taken using a UY gel dock. Once the mask was placed over 
the band an average intensity was measured. This measurement was then corrected 
by removing the background; this was achieved by taking a measurement of a blank 
part of the gel at an equivalent level of the band being measured. The subsequent 
value was then removed from the measurement of the PCR product band to give its 
final intensity. This was repeated for all the bands on the gel, and an average value 
for 3 repeats generated to give the overall value of intensity for that sample.
3.3.5 Histology
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Mouse whole globes were mounted in wax as described above. For histology 
sections were de-waxed in xylene for 2 x 5 mins then re-hydrated through a graded 
series of alcohols until free of wax (100% ims 20s, 100% ims 20s, 90% ims 20s, 70% 
ims 20s, 50% ims 20s). After this sections were place under running water for 1 
minute and immediately afterwards placed in haematoxylin for 5 mins. Sections were 
then rinsed in water until the water ran clear then immersed in eosin for 1 minute. 
Sections were rinsed again then quickly taken back through the alcohol gradient (50% 
ims 20s, 70% ims 20s, 90% ims 20s, 100% ims 20s, 100% ims 20s) until free of 
water. Finally the sections were immersed in xylene for 20s then mounted as 
described previously. Treated sections were then viewed under a light microscope. 
Sections were taken from the central region (0.5 mm) of the cornea
3.3.6 SAXS data collection
Data was analysed as described previously in the Methods chapter. Six 
corneas were isolated for each time point.
3.3.7 SAXS data analysis
Data was collected as described previously in the Methods chapter however 
due to the noisy nature of mouse data the theoretical fibril transform was not fitted. 
Instead, a secondary square power law background curve was fitted thus eliminating 
the background in 2 stages.
3.3.8 WAXS data collection
Data was collected as described previously in the Methods. Exposure time for 
each pattern was 60 seconds and a step size of 0.2mm was used. As the corneas are a 
fairly irregular shape an initial test pattern was gained from the centre of the cornea 
then the translation stage was moved until no scatter pattern was gained. In this way 
the edges were traced then rasta scans were made of the entire surface. Four corneas 
at each time point were used. No other changes were made from that of the general 
methods.
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3.3.9 WAXS data analysis
Scattering patterns were analysed as described previously in the Methods 
chapter.
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3.4 Results
3.4.1 Temporal expression profile during development
Two genes {Vsxl, Aqp5) were selected to be examined based either on their 
selection as possible candidate genes or as controls {Aqpl, Bpll9)as they are known to 
be expressed in the cornea Changes in expression can be seen in figures 3.1-3.4 and 
table 4.
I
1Kb
Pt2
NTC
Fig 3.1. Temporal expression profile of Col8A2. P5 - red, P12 - blue PI7 - green.
Raw expression data is given on the right whilst on the left is a graph of the products 
separated using agarose gel electrophoresis, lkb -  1 kilobase DNA marker ladder, P 
-  postnatal age.
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P1 P17 NTU
Fig 3.2. Temporal expression profile of A qpl. P5 - red, PI 2 - blue PI 7 -  green. Raw 
expression data is given on the right whilst on the left is a graph of the products 
separated using agarose gel electrophoresis, lkb -  1 kilobase DNA marker ladder, P 
-  postnatal age.
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1
1Kb
NTC No RT
Fig 3.3. Temporal expression profile of Aqp5. P5 - red, PI2 - blue PI7 -  green. Raw 
expression data is given cm the right whilst cm the left is a graph of the products 
separated using agarose gel electrophoresis, lkb -  1 kilobase DNA marker ladder, P 
-  postnatal age.
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Fig 3.4. Temporal expression profile of Vsxl. P5 - red, PI2 - blue P17 - green. Raw 
expression data is given on the right whilst on the left is a graph of the products 
separated using agarose gel electrophoresis. 1 kb -  1 kilobase DNA marker ladder, P 
-  postnatal age.
Gene P5 P12 P17 Sig
Vsxl 1 2.43 2.02 P = 0.0001
Aqpl 1 0.662 1.96 P = 0.0001
Aqp5 1 13.1 30.4 P = 0.0000001
Col8a2 1 0.318 2.09 P = 0.001
Table 4. Expression levels of all genes normalised to the housekeeper and calibrated 
to the lowest time point.
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The largest change seen during this period is by Aqp5 that has a 30 fold 
increase from postnatal day 5 to postnatal day 17 (see fig 3.3 & Table 4). It is during 
this time that the epithelium of the cornea develops and Aqp5 is a good marker for the 
epithelium as it is highly abundant. The expression of Aqp5 in the cornea has been 
greatly studied (Funaki et al., 1998; Thiagarajah and Verkman, 2002; Verkman,
2003), which makes it a good control for development. Vsxl and Col8a2 all have 
significant changes from postnatal day 5 to postnatal day 17 as they both have 2 fold 
changes (see figs 3.1,3.4 & Table 4). While a 2 fold increase in expression is 
relatively low it is a significant change, especially as it concerns RT genetic 
expression. The increase of Vsxl is interesting, as so far the functions of the gene in 
the cornea are unknown. It is known to be expressed in activated keratocytes during 
wound healing (Barbara et al., 2006) so it could be that the increased expression is 
indicative of active keratocytes at this time point. However it should be noted that at 
present it is difficult to say if the increase in expression is due to an up regulation of 
activity or to an increased number of keratocytes, which would be associated with the 
development of the cornea There is also a significant change in the expression of 
Col8a2 (see Table 4) which is a component of collagen. It is interesting that there is a 
decrease in expression at P12 which is not significant and then a 2 fold change at P I7, 
which is significant. When dealing with relative expression a 2 fold change or more 
is considered significant. This could be due to an increased generation of collagen at 
this point in development and may or may not connected to the change in expression 
of Vsxl, but without examination of the Col8a2 for possible Vsxl binding sites this 
connection at this point is speculative.
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3.4.2 Genetic expression profile during development
T is s u e  S p ec ific  V sx l E xp ression
£</>
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0
P12 P17
H L B Lv H L B Lv
Tissue types
Cornea
1Kb P17
Fig 3.5. Semi quantitative expression of Vsxl. H - heart, L - Lung, B - Brain, Lv - 
Liver, P -  postnatal, Ikb - size marker, normalised to Rpll9  expression.
Semi quantitative PCR could not detect Vsxl within any tissue at postnatal day 
five, although this is most likely due to the lack of sensitivity inherent in this method, 
as expression has been found using quantitative RT-PCR (see fig 3.4). From figure 
3.5 it can be seen that Vsxl is not expressed at all in the heart during the time points 
studied or within the lung at postnatal day 12 of development. According to the gel 
electrophoresis there appears to be a large difference in the expression of Vsxl in the 
liver from postnatal day 12 to day 17 although there is no statistical significance.
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3.4.3 Interfibrillar spacing o f collagen fibrils. 
Average Interfibrillar S pacing
70.00 n
60.00 -
£ 50.00 -
40.00 -
|
©
30 00 -
z 20.00 -
10.00 -
000
9 1011 1213 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Age Avg Interfibrillar 
Bragg sp (nm)
10 61.29 ±2.93
11 55.51 ± 5.29
12 48.22 ± 4.02
13 46.52 ± 4.31
14 45.45 ±4.53
15 50.47 ± 3.76
21 51.07 ±3.19
28 49.23 ± 4.66
Ag« - Postnatal days
Fig 3 .6. The average interfibrillar spacing of collagen fibrils during mouse comeal 
development. Values in the table are mean ± SD. Age values are postnatal.
The average interfibrillar spacing for the mice in this study over postnatal days 
10-28 decreases from ~ 61nm to ~ 49nm (see fig 3.6). There is an apparent increase 
at postnatal day 15 although this is not significant. This gentle decline in interfibrillar 
spacing mirrors a previous study that looked at interfibrillar spacing over this time 
period although the values stated in this thesis are lower than previously described 
(Beecher et al., 2006). This can be explained as the samples used here were preserved 
by freezing instead chemical fixation. Freezing corneas and then thawing prior to 
experimentation has been shown to not affect the ultrastructure of the cornea 
(Fullwood and Meek, 1994).
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3.4.4 Aligned Collagen distribution and collagen fibril patterning
0-2 2-4 4-6
6-8 ■ 8-10 ■ 10-12
■ 12-14 ■ 14-16
D10 D11
M A  X
D12 D13
D14 D15 D28
Fig 3 .7. Relative mass distributions of preferentially aligned collagen in the 
developing cornea. Measurements are made in arbitrary units, the key indicates the 
darker the colour the greater the mass of collagen. D -  Postnatal days.
Figure 3.7 shows the increase and distribution of aligned collagen as the 
mouse cornea develops. At postnatal day ten the increase in aligned collagen first 
starts to appear in the superior half of the cornea at the limbus. The increase in 
collagen appears to develop in opposite places to each other around the cornea in the 
limbus, as can be seen at PI 1 (Fig 3.7). This development continues until postnatal 
day 28 until an annulus of collagen fibrils at the limbus is fully formed; this 
preferential alignment at the limbus in mouse was first described by (Quantock et al., 
2003). The increase in collagen around the centre of the cornea is most likely due to 
extra comeal fibrils being laid down to add to the structural strength at this region 
where the sclera meets the cornea. As collagen fibrils are strongest along their axis
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you would expect a circular pattern for these fibrils to form, as is observed in human 
corneas (Aghamohammadzadeh et al. 2004) (See fig 3.8).
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Fig 3.8. Preferential alignment of collagen during development. Measurements are in 
arbitrary units. Polar plots have been scaled to make them the same size for ease of 
viewing. The scaling factor is given by the legend with the higher numbers 
representing more collagen at that particular position. D -  Postnatal days
Figure 3.8 shows that mouse corneas have a circumferential comeal fibril 
pattern throughout unlike the human cornea, which has a circular annulus of collagen 
fibrils that surround collagen fibrils that have a horizontal and vertical alignment in 
the central region of the cornea. This is most noticeable with an annulus of fibrils at 
the limbus.
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3.5 Discussion
This is the first developmental study of mouse corneas that uses X-ray 
diffraction to examine collagen fibril distribution and arrangement. The variances in 
temporal gene expression shown offer an intriguing idea as to their roles in the 
development of the cornea although more data is needed. Previous studies on Vsxl 
have showed its expression to be quite varied; expression was found by RT-PCR only 
in the retina and not in the lens or cornea in adult mice and detected in the brain, lung, 
heart spleen and testes between embryonic day 14 and birth (Chow et al., 2001). 
Expression was not found in the cornea; however, later expression studies have found 
Vsxl to be expressed there (Barbara et al., 2006; Krafchak et al., 2005). The 
difference in detection of expression could be down to the location of expression 
within the cornea VSX1 has been expressed in human activated keratocytes during 
would healing and it maybe that its expression can only be detected in situations 
where they are activated, such as during development. This suggests that similar 
pathways are involved in both mechanisms. If this is the case, then studying the 
cornea in development offers further insights into the effects of wound healing
3.5.1 Gene expression changes between postnatal days 5, 12 and 17.
The differences in expression found in the genes examined offer insights into 
their possible actions. The decrease of Col8a2 that follows the increase in Vsxl could 
indicate that these two genes may be ‘linked’ and this possibility is strengthened by 
the report that Vsxl acts as a repressor of other genes, although these potential 
downstream targets are not known. A potential downstream target is the transcription 
factor HSF1 that acts to regulate heat shock proteins under non stressed conditions. 
This gene is also found in the cornea and acts on the heat shock protein HSP47, which 
is a chaperone for collagen type I precursors. It could also act directly with a collagen 
gene itself, as Vsxl has many similarities to another important ocular gene, Tcf8. This 
gene has been previously linked to the disease posterior polymorphous comeal 
dystrophy and acts as a repressor of Col4a3 ((Krafchak et al., 2005). One could 
therefore hypothesise that Vsxl and Col8a2 have the same interaction and are both 
important in tissue development and maintenance. Further testing of this hypothesis 
would be desirable. This could be achieved initially through bioinformatics to
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identify any Vsxl binding sites in the promoter of the Col8a2 gene. After evaluation 
of possible binding sites and if they match statistically significant criteria then further 
testing can be explored. The most logical course of action would be to evaluate 
activation via a CAT assay, using the promoter region of the Col8a2. The increase in 
Col8a2 at postnatal day 17 is similar in the peak of collagen mass witnessed in 
developing mice (Song et al., 2003). This is yet a further indication of a possible 
interaction between the noted gene changes and a change in structure of the cornea.
There are many methods that have been used to quantify gene expression, all 
with their benefits and limitations. The comparative quantitative method used in this 
study is the most advantageous to use in this case as it is more accurate and uses less 
resources than the others. The disadvantages of using this method is that it relies on 
having a low standard deviation between samples but this only adds to strengthen the 
repeatability of the reactions as they would need to be of a higher standard. This is 
especially important as the changes expected were thought to be small as the 
experiment is examining a transcription factor. Both positive and negative controls 
were used throughout the reactions. No template controls were used to see whether 
the products that were being amplified were of the correct size and not due to non­
specific binding of primers. Melt curves were used in all reactions to determine if 
products amplified were of the correct size. To prevent the amplification of genomic 
or erroneous DNA from being amplified no RT controls were used to optimise the 
RNA extraction and amplification to eliminate them from the reaction. No RT 
controls were then amplified along side and separated on an agarose gel to see if 
amplification had taken place.
All reactions were normalised to a housekeeping gene, which in these 
experiments was the ribosomal protein subunit 19 (Rpll9). This housekeeper was 
chosen over more traditionally used housekeepers such as GAPDH because there has 
been some ambiguity as to whether the expression of GAPDH fluctuates through 
development (Al-Bader and Al-Sarraf, 2005). Rpll9 was demonstrated to have 
similar expression in the cornea throughout development and has previously been 
used in other published experiments involving the cornea (Krafchak et al 2005). 
Real-time quantitative PCR was chosen over semi quantitative because it is far more 
accurate for small expression changes and has better detection.
The changes noted here, while few, do indicate that the period just prior to eye 
opening of mice is a time of genetic activity and merits further exploration into which
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genes are active. The flurry of activity that is concentrated into such a small time 
span offers good opportunities to study a great number of gene changes, which if 
significant, could be an alternative way in seeking candidate genes for diseases based 
not on their mapped loci but on their temporal functionality. It would be very difficult 
in looking for disease causing genes at the time of disease presentation, if the initial 
defect had already occurred previously during development. A proposed disease 
causing gene would be screened via conventional methods and report no changes at 
time of presentation but the defect could have been in its activation due to a 
dysfunctional activator, such as a transcription factor. This could explain why no 
mutations have been found in Col8a2 in conjunction with keratoconus and its 
association has been dismissed (Aldave et al., 2007b). However if this was true then 
changes would have to be found in the transcription factor. This is the case with 
Vsxl.
Ectopic expression of transcription factors in these diseases could be the big 
factor in disease progression that may well relate back to earlier defects. At the very 
least this study proposes that microarray experiments be performed on mouse corneas 
and other tissues in the days prior to eye opening at postnatal day 12. The problem 
with this is that Microarrays do not detect the presence of transcription factors as the 
expression is too low but it is a good starting point in the continued research into 
development and its links with disease.
3.5.2 Spatial expression o f Vsxl
From the semi quantitative data presented here Vsxl has differential 
expression in the lung and liver and is not expressed in the heart. It is expressed in the 
brain at both P12 and P17 with similar levels. This data while offering insights into 
the location of expression of Vsxl could be strengthened by repeating the experiment 
using real-time quantitative PCR as this would be much more accurate. Indeed 
expression in the heart cannot be ruled out as semi-quantitative PCR is most likely not 
sensitive enough to detect it. If expression is present then it can be thought that the 
expression level is similar to that of expression in the cornea at postnatal day 5, as this 
was also not detected using this method but found using real-time. However this data 
should not be discarded as it still shows changes in expression. For the purposes of 
this thesis it was thought that it did not need confirmation using real-time as the focus
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of this thesis is on the cornea It must be noted though that any future study on Vsxl 
in other tissues should confirm expression using a more sensitive method.
3.5.3 Collagen fibrillar arrangement
The circumcomeal annul us that had previously been alluded to by Quantock et 
al. (2003) has been unambiguously demonstrated by this study. This structure starts 
to develop in the mouse at postnatal day 10 and continues to develop until a fully 
mature annulus is formed at postnatal day 28 (see fig 26). Looking at the full pattern 
of preferential alignment it appears that the circular fibril patterning that can be seen 
in mice develops from opposite quadrants of the cornea and continues until the pattern 
is evident across the entire surface. As the corneas used are from the right eye of 
mice, the increase in preferentially aligned collagen fibrils appears to start from the 
superior-nasal and inferior temporal quadrants of the eye. Thus most of the increase 
in tissue mass at this stage is due to the increase of aligned fibrils rather than isotropic 
fibrils, indicating that the final fibril arrangement is built up in stages as new tissue is 
laid down and organised.
The difference in structure between the mouse and the human cornea has been 
thought to be linked to the differences in visual acuity between the two species, with 
greater visual acuity requiring a greater deal of collagen organisation (Hayes et al. 
2007). It is also been suggested that the orthogonal arrangement of fibrils seen in 
humans is pointed towards the insertion of the rectus muscles on the globe to add 
additional strength against globe distortion during eye movement (Daxer and Fratzl, 
1997; Hayes et al., 2007a). This would support the lack of orthogonal or any 
preferential pattern of alignment within the mouse cornea, as eye movement is often 
secondary if not absent completely in favour of head movement. The change in 
collagen organisation is also not related to size, radius of curvature or thickness of the 
cornea (Hayes et al. 2007).
The circumcomeal annulus appears to be a common feature among 
mammalian species being present in cows, rats, chickens, marmosets, rabbits and 
pigs. Despite the large differences in change in radii of curvature between the species 
the annulus appears to play the same function, which is to strengthen the cornea 
against the changes in curvature from the sclera to the cornea. Its development at plO 
suggests that it may play additional strengthening roles as it is the predominant
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developing feature and most of the collagen mass that is being laid down contributes 
to its development. This would also suggest that parallel functions are acting to 
organise whilst laying down the annular fibrillar collagen rather than the organisation 
occurring afterwards, which happens with cartilage formation (Williams et al., 2008). 
The fact that the development of the annulus continues during eye opening until its 
fully developed state at postnatal day 28 may suggest that the organisational processes 
require reactions with the outside environment. An obvious experiment to test this 
would be to prevent the eyes from opening and see if a mature annulus is developed 
although this is outside the scope of this study.
In conducting X-ray diffraction experiments with developmental samples 
several limitations must be overcome to ensure consistent and reliable results. 
Although measures can be taken to minimise and prevent these limitations some still 
persist. However when using this species for X-ray experiments the benefits of 
having the mouse as a model system far outweigh any difficulty in its use for these 
types of procedures. The mouse cornea has several drawbacks when compared with 
other species due to the small size of the cornea and its thickness and these must be 
taken into consideration when used. For WAXS experiments that look at the overall 
mass distribution in the cornea it is not possible to get strong enough diffraction 
patterns below the age of postnatal day 8. Even though you can get data for postnatal 
mice aged 7 to 9 the patterns gained are too noisy get any meaningful results (data not 
shown). Stronger patterns for X-ray diffraction can be gained by modifying the 
sample exposure time however care must be taken to ensure that the intensity of the 
beam does not destroy the tissue. The size of the cornea in relation to the size of the 
beam means that a higher resolution for WAXS experiments could not be reached 
although this would have given better determination of the location of the annulus.
The beam size and the step size of the rasta scans were the smallest they could have 
been given the experimental setup. An alternative does exist at the ESRF synchrotron 
facility however extensive optimisation to the equipment is needed in order to recreate 
the study.
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3.5.4 Interfibrillar spacing o f the mouse cornea in development
The change in interfibrillar spacings from day to day is not significant and the 
conclusions do not differ from the lower resolution developmental study performed by 
Beecher et al. (2006). It is reassuring to see that there were no trends that were being 
masked by the resolution of the earlier study, especially around the time of eye 
opening, a critical developmental time point. However the difference in the values 
between this developmental study and the study performed by Beecher et al. is quite 
interesting. It emphasises the care needed when handling mouse corneas when 
performing X-ray diffraction experiments. In this study to measure the interfibrillar 
spacing an X-ray beam 1mm wide and 0.5mm in height was used. This would cover a 
large amount of the cornea as an adult mouse cornea has a diameter approximately of 
2.2mm. It has been shown using fine focus X-ray beams that the interfibrillar spacing 
can vary remarkably across the surface of the cornea (Meek et. al private 
communication). This would mean that very precise positioning of die X-ray beam 
within the cornea is necessary in order to achieve an accurate result and difficult to 
achieve with any sort of reliable accuracy. What this also means is that any 
measurement of corneas with a diameter under the size of the beam would be 
pointless as the margins of error would be so large as to make any result gained 
meaningless. It is believed that the results here represent a truer reflection of the 
values of interfibrillar spacing for mouse corneas as they have been confirmed in 
additional studies (see chapter 4 and Meek et al. private communication).
3.6 Conclusion
In terms of progressive diseases such as keratoconus there is a case to begin 
looking for initial causes in developmental stages rather then when symptoms present, 
as the progression has got beyond the point the body can correct. Although this 
would be the time that the problem can be first identified it leaves diagnosis of 
progressive diseases very difficult. Nevertheless through identifying genes that are 
active in controlling and organising structures in development it may be possible at a 
later date to use them in treatment methods currently beyond technical expertise. A 
follow up study to this one to determine whether the expression changes found here in
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Vsxl and Col8a2 would be to examine their expression and look at the changes in 
comeal ultrastructure in developmental knock out mouse models.
Comeal structure develops from postnatal day 10 and continues through eye 
opening until postnatal day 28. These structural changes should be taken into account 
when examining the development of the cornea and similar experiments in other 
species are encouraged. This would not only begin to form a good foundation for 
future research but perhaps offer explanations as to how the different orientation 
patterns in different species emerges. It is hoped that this may reveal some common 
mechanisms that govern the organisation of collagen fibrils. The current study 
conducted here does add the knowledge of how the comeal structure develops and this 
may provide future researchers with a good background in conducting their own 
experiments.
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Chapter 4. Evaluation of Vsxl KO corneas
4.1 Aims
• To compare the average fibril diameter, interfibrillar and intermolecular 
spacings between Vsxl -/- mice and background-matched WT controls.
• To compare collagen fibril patterning, preferred orientations and collagen 
distribution between Vsxl -/- and background matched controls to see if 
similar differences to human keratoconic corneas can be found.
• To measure the expression levels of various genes including the heat shock 
protein Hsp47, the transcription factor HSFlmd  the collagen gene Col8A2 in 
Vsxl -/- mice and to compare them with background-matched wild types by 
QPCR.
• To measure the amount of collagen breakdown products (crosslaps) in the tear 
film of Vsxl -/- mice and to compare them to background-matched controls.
4.2 Introduction
In 2004 Chow et al. generated a Vsxl -/- mouse that showed Vsxl was crucial 
for late stage differentiation of cone bipolar cells; however gross examination of the 
cornea revealed no obvious abnormalities. Nevertheless, the production of a Vsxl 
knock out provided an excellent opportunity to thoroughly examine the corneas of 
these mice with techniques and methods that have been previously employed to study 
corneas from keratoconic patients. If similar data could be gathered from the knock 
out corneas that is found in keratoconic human corneas it would be a very strong 
indication that we would have found the best model for keratoconus that has been 
produced so far and thus help to get closer to an understanding of the mechanisms 
behind the ectasia and eventually a cure or preventative measure. The Vsxl knock out 
model also affords the opportunity to study any possible pathway of how Vsxl could 
be involved with keratoconus. Existing evidence does not offer any possible 
explanations of the pathophysiology of Vsxl -  associated keratoconus, and only 
makes associations.
In keratoconic patients there is a reported 2- to 5-fold increase of collagen type 
I breakdown products in the tear film compared to normal controls (Abalain et al., 
2000). The experiment was initially carried out to see whether the breakdown of
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collagen could be used as a diagnostic tool for keratoconus. There have been many 
studies of keratoconus that try to categorise the biological changes that occur in the 
cornea and these have led to numerous hypotheses on the causes of keratoconus. Vsxl 
has been linked to keratoconus and PPCD as mutational studies have found mutations 
in Vsxl segregating with individuals with these conditions. To date there are 8 
published missense mutations (Bisceglia et al., 2005; Heon et al., 2002; Mintz-Hittner 
et al., 2004; Valleix et al., 2006). In some patients where these mutations have been 
found there have also been indications of decreased retinal function (Heon et al.,
2002; Valleix et al., 2006).
The present study is the first to try and elucidate a possible mechanism for the 
involvement of Vsxl in keratoconus. Vsxl has been shown to be expressed in the 
mouse cornea (Krafchak et al., 2005), and VSX1 has been shown to be expressed in 
activated keratocytes in human corneas that are undergoing wound healing (Barbara 
et al., 2006). In a recent study looking at the transcriptional activity of ChxlO and 
Vxsl it was found that Vsxl acts in some part as a repressor of genes and has been 
shown to bind to and repress the activity of heat shock transcription factor 1 (HSF1) 
(Dorval et al., 2005). HSF1 is a transcription factor that up-regulates heat shock 
proteins and, in the cornea as well as other tissues, up-regulates the heat shock protein 
Hsp47, a chaperone of collagen type I precursors. As well as its chaperone activities, 
Hsp47 acts on keratocytes to up-regulate the production of collagen type I.
The above sequence of events prompts the hypothesis that the absence of 
functional Vsxl would lead to keratoconus through a deficient collagen production 
pathway in a subset of patients. This would not explain why keratoconus happens in 
all patients as it is a complex disease, but it offers an explanation as to why the 
mutations that were found in the Vsxl gene have been associated with keratoconus.
As Vsxl is nonfunctional, it is unable to repress the function of HSF1, which in turn 
increases Hsp47 that leads to an increase of collagen type I synthesis. In any system 
that acts to maintain a controlled level of its constituent parts when it needs an 
increase of collagen production, it will activate measures to decrease production to 
normal homeostatic levels. In this case, as there is more collagen, there will be an 
increase of matrix metalloproteinases that act to breakdown the collagen thus leading 
to an increase of collagen breakdown products that accumulate in the tear film (see fig 
4.1).
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Fig 4.1. Flow diagram illustrating one hypothetical function of Vsxl in the cornea 
and the consequences of its inactivation. Arrows pointing up indicate an increase of 
amount/expression; the open flat arrow shows repression.
4.2.1 Hypothesis
The paired-like homeobox gene Vsxl acts as a repressor of genes in the 
cornea. It has been shown to bind and repress the transcription factor HSF1 that up- 
regulates the production of collagen type I via the up-regulation of heat shock protein 
47. In keratoconic patients there is a 2- to 5-fold increase of collagen type I 
breakdown products (crosslaps) in the tear film. In Vsxl -/- mice there is no 
mechanism to repress the up-regulation of collagen type I and therefore there will be 
an increase in crosslaps in the tear film of these mice.
4.3 Methods
4.3.1 Specimen collection
Mouse tissue of 129/sl background KO and WT was kindly provided by Dr 
Bob Chow at the University Of Victoria, Canada. Adult corneas were rapidly excised 
and wrapped in Clingfilm™. Excised corneas had their orientation maintained 
throughout removal and the 12 o’clock position and epithelial side were identified and 
marked. After wrapping they were immediately frozen at -80°C for storage and 
transport and stored until needed for examination. Whole murine globes of WT and 
KO mice were extracted and immediately placed in RNAlater® (Ambion, Inc.) for 
transport. Mice were handled in accordance with the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research.
ffession
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4.3.2 SAXS data collection
Data was collected as described previously in the general Methods section. To 
ensure that any results that were gained were real and not due to a change in hydration 
the wet weight of the cornea was measured before and after scanning.
4.3.3 SAXS analysis
Data was analysed as described previously in the Methods. Statistical 
significance of the means was compared using a standard student’s t-test.
4.3.4 WAXS data collection
Data was collected as described previously in the Methods. Exposure time for 
each pattern was 45 seconds and a step size of 0.2mm was used. Rasta scans were 
used to scan the entire surface of the cornea. No other changes were made from that 
of the general methods.
4.3.5 WAXS analysis
Data was analysed as described previously in the Methods.
4.3.6 Statistical analysis o f WAXS patterns
In order to determine the variation between WT and KO mouse patterns that 
takes into account the inherent variability in murine comeal X-ray patterns, additional 
quantification was needed. Mice, as with other species, exhibit a certain distribution 
and pattern of collagen that makes up their corneas and although this is a distinct 
pattern it is found to be more intrinsically variable than corneas for higher order 
species such as humans and chickens. It became clear that an established control of a 
wild type cornea was needed in order to identify the common elements that make up 
this distinct pattern in mice. These control patterns would include a map of the 
preferred fibrillar orientation that is particular to mice; a topography map of the 
correlation between corneas at each point of the map and a topography map of the 
average distribution of aligned collagen. Unfortunately no methodology existed to
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quantify the preferential alignment in order to establish statistical differences between 
two data sets so this was developed in order to quantify the data gathered here.
The procedure developed was as follows. Taking the linear intensity profiles 
for any two individual X-ray scatter patterns allows them to be correlated against each 
other as seen in figures 4.2-4.3. As we are mainly interested in the preferred fibrillar 
direction, the important part of these intensity profiles that we are looking at is the 
position of the peaks rather than their size, as size is indicative of collagen mass as 
seen in figures 4.4. By correlating the two plots we get a correlation coefficient that 
tells us how similar the preferred direction is between them, with a correlation >0 
giving us positive correlation and <0 negative correlation. By using this method for 
all plots we can construct correlation coefficients for all polar plots in each sample 
provided that they are in the same geometric location within the cornea.
In order to establish a control comeal pattern, the exact centres of each 
individually mapped cornea were identified overlaid with their orientation maps. A 
central grid of 11 x 11 patterns was taken from each cornea in order to make sure that 
the positions of each WAXS pattern are comparable to each other (see fig 4.5). The 
aligned data for each pattern was then taken and a correlation coefficient was 
calculated between paired samples. This pair-wise correlation was then repeated for 
each cornea in a genotype resulting in a grid of coefficients between all the samples 
(see fig 4.6). An average correlation coefficient was then calculated for each point in 
the central square grid generating a grid of averaged correlation coefficients for the 
central 2.2mm of a hypothetical control cornea. This was displayed graphically as a 
topography map. In addition, the points from each KO sample were then compared 
with the average to see if there were any statistical differences at that point. In 
addition to the topographic map showing correlation a second topography map was 
constructed to show the differences in the distribution of the average aligned collagen 
mass. This was constructed by simply averaging the data for each point from each of 
the individual samples across the whole surface of the cornea.
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Fig 4.2. Linear intensity profiles and correlation between 2 polar plots.
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Fig 4.3. Linear intensity profiles and correlation between 2 polar plots that have 
different fibrillar alignments.
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Fig 4.4. Polar plots showing their size and their preferred fibrillar alignment. The 
arrows show the direction of preferential alignment.
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In order to construct a map of the average preferred alignment the intensity 
profiles for each cornea were consolidated for all WT samples, in that at each of the 
256 points within an individual polar plot were averaged and from these points a new 
polar plot was formed. These plots were then arrange according to their position on 
the grid and a map constructed. Plots were then scaled so that they fit on the map.
Fig 4.5. A) Photograph of an excised mouse cornea with comeal and scleral edge 
enhanced, and overlay of its resultant fibrillar alignment map. B) The same cornea 
with an 1 lxl 1 grid demarking the centre of the cornea.
W T cornea W T cornea W T cornea WT cornea W T cornea
W T cornea 
W T cornea 
W T cornea 
W T cornea 
W T cornea
1 0.27803 0.783935 0.267609 0.32497
- 0.27803 1 - 0.34669 - 0.21867 0.21725
0.783935 0.34669 1 0.771891 0.66428
0.267609 0.21867 0.771891 1 0.79733
- 0.32497 0.21725 - 0.66428 - 0.79733 1
Fig 4.6. A grid showing the pair wise correlations between samples at a single point
In the example from figure 4.6 this would give an average correlation value of 
-0.10238 for this particular point.
84
Jack Sheppard
4.3.7 RNA isolation and amplification
Total RNA was isolated using the RNEasy® Mini kit (Qiagen) according to 
the manufacturer’s protocol and extracted RNA was quantified using 
spectrophotometry. RNA was separated into aliquots to avoid the need of repeated 
freeze/thaw cycles and RNA was transcribed to cDNA using the Quantitect® Reverse 
Transcription Kit (Qiagen) according to the manufacturer’s instructions. 
cDNA was amplified using Sigma SYBR® Green Jumpstart™ Taq Ready Mix™ for 
Quantitative PCR on the Roto-Gene™ (Corbett Research). Samples were performed 
in triplicate and each reaction was repeated three times. In order to ensure similar 
starting product concentrations each RNA sample was measured and then aliquoted so 
that each subsequent reaction was optimised for an RNA concentration of 0.5pg 
Genes were amplified using cDNA specific primers for the following genes:
Name Primer sequence 5’ - 3’ temp
°C
Vsxl F 5 -ACTGCCCAGTTACCCACAAT-3 ’ 55
VsxlR 5 -AAGTGGCGTAAGCGAGAGAA-3 ’ 55
Aqp5 F 5’- ATCTACTTCACCGGCTGTTCC-3’ 60
Aqp5 R 5’- GTCAGCTCGATGGTCTTCTTC-3 ’ 60
Hsfl F 5’- TGATGAAGGGGAAAC AGGAG-3 ’ 60
Hsfl R 5’- CTGCACC AGTGAGATC AGGA-3 ’ 60
Hsp47F 5’- CCTGAGGTCACCAAGGATGT-3 ’ 60
Hsp47R 5’- CCATCTGCAGCTTCTCCTTC-3’ 60
Col8a2 F 5 ’-GGTAAAGTATGTGC AGCCCA-3 ’ 60
Col8a2 R 5 ’-AGT AAT ACCTGAGGGACC AG-3 ’ 60
RpL19F 5 ’-GGGAAGAGGAAGGGT ACTGC-3 ’ 55
RpL19R 5-GGACGCTTC ATTTCTTGGTC-3 ’ 55
Table 5. Primer sequences used for amplification, F- forward, R -  reverse, tmp -  
temperature. All primer sequences are 5’ to 3’.
Rpll9 was used as a housekeeping gene for normalization and all primer
sequences were designed to be intron spanning. Primer sequences were designed
against the following accession sequences:
Vsxl - #NM_054068 
Aqp5 - # NM_009701 
HSF1 - # NM 008296 
Hsp47 - # NM 001111043 
Col8a2 - # NM_199473 
RPL19 - # NM 009078
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4.4 Results
Heterozygous samples were tested along with the WT and KO samples but 
only 2 were available so they were included here for completeness.
4.4.1 Differences in interfibrillar (IFS) and intermolecular (ImS) spacings and 
average fibril diameters (FD) between genotypes.
Genotype Cornea # UR
Avg FD 
(nm) IFS (nm) IMS (A)
WT 1 R 31.0 43.0 16.4
WT 2 L 30.7 45.5 17.2
WT 11 R 31.3 42.3 17.2
WT 12 L 32.8 47.7 17.2
WT 13 R 30.7 43.7 14.5
WT 14 L 29.3 43.6 17.2
Mean —------------- ----- 30.9 ±1.13 44.3 ±1.98 16.7 ±1.1
KO 5 R 30.2 42.3 16.4
KO 6 L 35.1 40.4 17.2
KO 7 R 30.6 45.5 17.2
KO 8 L 30.1 45.7 16.5
KO 9 R 31.1 45.1 17.2
KO 10 L 32.4 45.7 17.2
KO 15 R 30.6 41.0 17.2
KO 16 L 31.6 45.1 16.5
Mean -------------- ------ 31.5 ±1.65 43.9 ±2.24 16.9 ±0.39
Het 3 R 31.6 43.8 17.2
Het 4 L 30.4 43.1 17.2
Mean -------------- ------ 31.0 ±0.89 43.5 ±0.87 17.2 ±0
Table 6. Measurements taken for all comeal samples measured. FD -  Fibril 
diameter, IFS -  Interfibrillar spacing, IMS -  intermolecular spacing. Measurements 
are Bragg spacings. Measurements are ±SD.
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Fig 4.7. Measurements of the cornea comparing the effect of Vsxl deletion. 
Measurements of the interfibrillar spacing and the average fibril diameter are in 
nanometres while the intermolecular spacing is measured in angstroms. 
Measurements shown are means ± SD. WT -  wild type +/+, KO -  knock out Het 
-  heterozygous +/-.
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Figure 4.7 shows that there are no significant differences in the interfibrillar 
spacings and average fibril diameter between any of the genotypes (students Mest 
average fibril diameter P = 0.244, interfibrillar spacing P = 0.365, intermolecular 
spacing P = 0.246). It should be noted that heterozygous animals were included in the 
study to aid in identifying any erroneous results if any differences found were on the 
border line of significance.
4.4.2 Distribution o f  total collagen between genotypes
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Fig 4.8. Topography maps of isotropic scatter for all corneas sampled. M -  name of 
the sample, KO -  Vsxl knock out cornea, WT -  wild type. Scale is given by the 
legend.
Shown here in figure 4.8 are the topography maps for all genotypes. All 
corneas show a higher scattering in the limbal areas. There is a degree of difference 
in the intensity of scatter around the edges of these corneas that by itself does not 
offer any qualitative difference between the genotypes. The increases in intensity are 
themselves explained by an increase in actual collagen mass in the peripheral regions 
of the cornea
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4.4.3 Distribution o f  collagen that shows a preferred alignment
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Fig 4.9. Topography maps of aligned scatter for all corneas sampled. M -  Name of 
the sample, KO -  Vsxl knock out cornea, WT -  wild type. Scale is given by the 
legend and the scatter is measured in arbitrary units.
The distribution o f aligned collagen as seen here in figure 4.9 does not seem to 
offer any qualitative differences between the genotypes. Most show areas of high 
scattering intensity as seen by the red and darker shaded areas. There is an argument 
that the KO corneas possibly show a higher mass along certain peripheral edges as 
seen with K 04 and K 03 but then a similar pattern to a WT is demonstrated with 
K06. From just looking at the distribution of aligned collagen alone or even 
combined with data for isotropic collagen distribution there is not enough o f a 
difference that segregates between the genotypes to say that knocking out Vsxl makes 
a difference. However as seen in figure 4.9 the distribution of collagen varies, even 
amongst the WT, so this inherent variability could be masking a difference and further 
analysis of the direction of alignment is needed.
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4.4.4 Preferred fibrillar alignment
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Fig 4.10. The preferred fibrillar orientation of collagen of all samples grouped 
according to their genotype. Samples are scaled so that polar plots are clearly visible 
on each map. Plots are scaled according to the legend given. WT -  wild type, het -  
Heterozygous, KO -  knock out.
Polar maps were created as previously described in the Methods section. The 
polar plots from all samples show that mouse collagen orientations in the cornea are 
quite variable from sample to sample and this can be seen across genotypes. As can 
be seen in figure 4 .10 the WT samples demonstrate a great deal of variation in the 
centres but all demonstrate a circular pattern of orientation as you move away from 
the centre out towards the limbus. The same can be said from the other genotypes, 
there is a strong circular orientation of fibrils around the limbal and peripheral regions 
of the corneas as opposed to the centres. In all samples the circular patterns are 
themselves surrounded by plots that show lateral alignment leading away from the 
corneas, which is similar to what is found in other species including humans (Hayes et 
al., 2007a). The orientation maps make it very difficult to determine if there is a 
difference between genotypes as the WT samples are themselves quite variable.
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4.4.5 Establishment o f  a WT control and statistical analysis o f  the preferred fibrillar 
alignment.
In order to establish a WT control the maximal scatter for each WT cornea at 
similar positions on the cornea were taken and averaged. A map of the averaged 
aligned collagen was then formed according the grid of the central square of the 
cornea. At each point in the grid is a polar plot showing the average preferred 
orientation. If the orientations at a specific point for different WT corneas did not 
correlate then it would produce an average pattern that demonstrated no preferred 
alignment in a particular direction as in
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Fig 4.11. Map of aligned collagen showing directions of preferential alignment. 
Individual plots are scaled according to the amount of collagen present at each point. 
Alignment mass is measured in arbitrary units. A). Polar plot showing no preferred 
fibrillar alignment. B). Polar plot showing a high degree of fibrillar alignment.The pa tern produced f r the average WT mouse cor ea is remarkably 
circular around the limbus and the peripheral areas of the cornea with very little 
alignment in the centre. This is as expected very similar to the pattern of mouse 
corneas previously published (Quantock et al., 2003). This gives a very good control 
for the fibrillar alignment in the cornea
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Fig 4.12. Distribution map of averaged aligned collagen for WT 129/sl control mice. 
Amounts of collagen are measured in arbitrary units and are shown in the key.
Figure 4.12 shows that most o f the preferentially aligned collagen mass lies on 
the outside towards the limbus of the cornea. There is a fair degree of aligned mass in 
the centre (yellow and orange regions) that increases as the limbus is approached.
The topography o f distributed collagen is consistent with its fibrillar orientation 
showing a circular pattern o f intensity.
With the establishment of a WT control, individual Vsxl-I- corneas can be 
correlated to the average to see if there are any discemable deviations from the 
alignment.
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Fig 4.13. Topography map of the average correlation between individual points from 
different corneas. The amount of correlation is given in the accompanying legend.
Figure 4.13 shows that the average correlation for preferential alignment 
increases away from the centre and is very high round the area of the limbus. What 
figure 4.13 also shows is that the correlation outside the centre does not drop below 0 
indicating that the fibrils from each of the wild type samples do not show any negative 
correlation, i.e. that the fibrils do not show an altered preferential alignment. The
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centre o f the averaged corneas appears to have very little or no correlation indicating 
that the fibrils are randomly orientated within the centre.
Vsxl-I- corneas were then correlated to the WT average to see if there was a 
similar pattern and to see if there was any statistically significant divergence in the 
preferential alignment, which is shown in figure 4.14.
High
Correlation
Negative
correlation
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Fig 4.14. Correlation of each single KO cornea against the average WT. Areas of 
correlation are given by the scale bar at the side. Avg -  Average WT cornea, KO -  
Vsxl-I- knockout. Black dotted lines mark the area of no or negative correlation.
Figure 4.14 shows that in each cornea there are regions that show very high 
areas o f correlation with the WT, which would indicate that the collagen fibrils in the 
knock-outs show a very similar preferred orientation. This can mainly be seen in the 
limbal regions (light yellow-orange colours). There also appears to be very little
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correlation in the centres of the corneas which is also seen within the WTs, however 
almost all maps seem to demonstrate a diagonal schism in their orientation with large 
regions (red -  blue colours) that do not correlate and even show a negative 
correlation. This is demonstrated most clearly in figures 4.14 E and H. This would 
indicate that the fibrils in these areas can demonstrate a preferred orientation almost 
perpendicular to that of the wild types depending on their correlation values. The 
reasons for fibrils to be preferentially aligned in a different direction could be down to 
handling of the samples but this is highly unlikely as the differences found segregate 
and show distinct degree of negative correlation with the different genotypes. It could 
be that the mechanism of support that the WT corneas require is possibly lacking 
within the knockouts or that there is a strain on the corneas that is forcing an alternate 
alignment. On its own the topography maps of the distribution of collagen for each of 
the knockouts and the wild types combined with the alignment map is not enough to 
be able to distinguish a clear difference just qualitatively; but combined with 
correlating the fibril directions against each other offers a clear distinction that can 
only be explained as arising from the difference in genotype. This is highlighted by 
figure 4.15 as the correlation between the Average WT map and the WT samples is 
very high and does not demonstrate the differences found in the knockouts. All The 
corneas that were evaluated were right eyes indicating that any differences found were 
not due to differences between right and left corneas.
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Fig 4.15. Correlation of each single WT cornea against the average WT. Areas of 
correlation are given by the scale bar at the side. Avg -  Average WT cornea
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In contrast to the knockout corneas the wild type corneas demonstrate large areas 
where the correlation to the average wild type is very high and there is a distinct lack 
of any negative correlation.
4.4.6 RT-PCR expression changes between the Vsxl knockout mouse and background 
matched littermate controls.
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Fig 4.16. Raw expression profiles for HSF1. The wild type (WT) and knock out 
(KO) profiles are indicated by the arrows. NTC -  no template control.
Fig 4.17. Amplification products of HSFl separated on an agarose gel. The wild type 
(WT) and knock out (KO) products are indicated by the red brackets
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Fig 4.18. Raw expression profiles for Hsp47. The wild type (WT) and knock out 
(KO) profiles are indicated by the arrows. NTC -  no template control.
WTKO
Fig 4.19. Amplification products of Hsp47 separated on an agarose gel. The wild 
type (WT) and knock out (KO) products are indicated by the red brackets
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Fig 4.20. Raw expression profiles for Aqp5. The wild type (WT) and knock out (KO) 
profiles are indicated by the arrows. NTC -  no template control.
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Fig 4.21. Amplification products of Aqp5 separated on an agarose gel. The wild type 
(WT) and knock out (KO) products are indicated by the red brackets
Gene/ Sample Avg rER Avg gene rER Sig P<0.05
HSF1
Sample 1 0.106
Sample 2 0.087 8.16e-2 P = 0.00001
Sample 3 0.0592
Hsp47
Sample 1 0.0528
Sample 2 0.0528 5.5e-2 P = 0.00001
Sample 3 0.0461
Aqp5
Sample 1 0.178
Sample 2 0.526 0.43 P = 0.011
Sample 3 0.586
Table 7. Average relative expression ratios for changes in expression of HSF1, 
Hsp47 and Aqp5 between WT and KO mice. Significance is calculated using an 
unpaired two-tailed t test, significance was determined at PO.05. Samples repeated 
3 times and on 3 separate occasions.
Table seven shows that there are significant expression changes between the 
WT mice and the KO mice for HSF1 and Hsp47 (see figs 4.16 & 4.18). Aqp5 also has 
a significantly decreased expression in the KO compared to the WT but not to such a 
level as the other genes tested (see fig 4.20). In all cases mRNA expression is lower 
in the KO system compared to the WT control. The expression data is supported by 
separation of amplification products by agarose gel electrophoresis, which shows that 
the WT products have a stronger intensity indicating greater product. It is believed 
these results are real as repetitions and both positive and negative controls were used. 
All expression changes were normalised against the housekeeper and calibrated to the 
WT. The WT was given an expression of 1 and the KO was measured as a fold 
change against the WT. Expression of Col8a2 was not detected in the WT or the KO 
(see appendix B)
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4.5 Discussion
There is a debate as to whether the changes in collagen structure are what 
trigger keratoconus or whether it is keratoconus that causes the collagen changes. 
Keratoconus is a complex disorder; however it would be far more accurate to describe 
it as a pure ectasia as it has many associations with other diseases so it is more likely 
to be a general umbrella term for the clinical appearance rather than a specific 
condition. Current information about the changes that are being associated with 
keratoconus is pointing towards a picture of how die ectasia develops. The theory in 
the mainstream literature is that oxidative stress is the causative factor that leads to the 
degradation and the thinning, and while this has strong supporting evidence, it does 
not explain why it occurs in the first place. There must be an initial change that starts 
the process that divulges from normal development and maintenance to ectasia or at 
least a breakdown in the system that causes these changes to occur. The actions of 
oxidative stress would appear to act as an accelerator of the condition rather than the 
cause. The Vsxl model offers and explanation as to what this initial change could be 
in a particular subset o f keratoconus.
At first inspection the Vsxl knockout does not appear to be a good candidate 
as a keratoconus model as initial examination of the cornea using light microscopy 
and EM did not show anything unusual (Chow et al. 2004). However the findings 
cannot be dismissed entirely as the mice that were examined were of a relatively 
young age. This is an important point as keratoconus as previously mentioned does 
not present from birth and progresses over a course of many years. It could be that 
the mice examined were too young to show any gross changes that would be picked 
up at the histological level or the progression was below the threshold for 
classification. EM pictures (Chow et al. 2004) taken of the cornea were taken from 
the central regions of the cornea covering -20% of the total surface area of the cornea 
(Bob Chow private communication). This potentially misses the initial area of change 
in the cornea as results presented in this chapter show that the greatest area of change 
happens in the periphery. The EM results also show altered cell and mitochondria 
ratios but this has not been analysed further (Bob Chow private communication). The 
findings and observations of the cornea in these mice have lowered the interest in 
pursuing a possible connection with keratoconus and at present appear to be the only
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information that does not favour the idea that it is a good model. In fact this 
information has been cited in the literature on many occasions by other researchers to 
bolster an argument that the Vsxl gene should be dismissed from its involvement with 
keratoconus altogether (Aldave et al. 2007). However it is still a worthy model for 
studying Vsxl in conjunction with keratoconus as the results presented here 
demonstrate.
The only other mouse model proposed for keratoconus is the MHC-linked 
mouse model (Tachibana et al. 2002), which has not been evaluated through X-ray 
diffraction so it is unknown what the collagen structures in this model look like.
These mice were examined at 4 weeks of age, which is a fairly young age when 
compared to when a human keratoconic would start to present and the animals 
demonstrated quite large and visible changes in the appearance of their corneas. 
However it is possible that the degree of change in such a short period of time is a 
point against its suitability as a model or at least is a case for the small percentage of 
keratoconics that have rapid progression. It would be interesting to see what would be 
found using X ray diffraction in the corneas of these mice and is a possible future 
piece of work that lies outside the scope of this study.
4.5.1 Collagen fibril patterning is statistically different from WT littermate controls
X-ray analysis combined with a novel method of quantifying preferential 
alignment presented in this study shows that there is a significant difference in the 
direction of collagen fibrils between the knockout and its wild type counterparts. It is 
possible that the fibril changes that are being seen in the knockout mice are preceding 
signs that these mice would develop a keratoconic phenotype in later stages of life. 
This is similar to studies on human clinical recurrent keratoconus where they first 
show signs o f fibril orientation changes before any visible thinning has occurred 
(Hayes et al. private communication). The patients were diagnosed as recurrent 
keratoconus through videokeratography and so obvious thinning of the corneas were 
not apparent. The X-ray study was carried out on the excised comeal button 8mm in 
diameter, which covers the entire cornea and part of the sclera.
The knock out mouse patterns presented (see figures 4.16 - 4.20) all have areas 
where the alignment of collagen fibrils is statistically different when compared to an 
average wild type mouse pattern. These differences seem to be demonstrating a
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diagonal area of disruption across the cornea from the superior-nasal quadrant to the 
inferior-temporal quadrant. This could indicate stretching that the cornea is 
undergoing. Instead of the fibrils appearing in a circumferential pattern they appear to 
be distorted and skewed. Some individual fibril directions even appear to be 
tangential to the wild type fibril. This is most apparent in the peripheral areas of the 
cornea where the correlation o f fibrils within wild type mice is highest. This possibly 
indicates a mechanical weakness that other forces, such as eye pressure, are acting on 
(see fig 4.22).
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Fig 4.22. Statistically different preferential alignment of collagen fibrils as they relate 
to an individual cornea. A) A contour map showing the areas of statistically different 
fibril orientation of knock out cornea 3 (K03) with an schematic overlay of the 
circular alignment of the WT cornea. B) Actual orientation of fibrils as measured in 
a cornea. The area being compared in all corneas is the area inside the square, so the 
central part of the cornea. The overlay of the WT cornea is also displayed within the 
square. Arrows highlight the areas that are different with some fibril orientations 
tangential to the WT schematic. Sample shown is knockout 3.
As can be seen in figure 4.22 the preferential alignment of fibrils is sometimes 
tangential to the normal circular orientation, which could indicate stretching of the 
cornea in that directioa It is not believed that this stretching effect is due to the 
stretching of the tissue during sample preparation as all samples were prepared in the 
same way and this effect is only seen with the knockout corneas. The changes in 
fibril direction would precede any visible signs of thinning in the cornea; the fibrils 
distort as the intraocular pressure starts to act on the weakened collagen structure. It 
would be interesting to examine very old mice to see whether this effect is more 
apparent as well as any signs of visible thinning, either through histology or X-ray 
diffraction
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4.5.2 Limitations o f  performing X-ray difraction experiments on mouse corneas
The greatest limitations imposed on these experiments are due to the inherent 
properties of mouse corneas. Mouse corneas are much more difficult to handle then 
human corneas due to their small size and thickness so special care had to be taken in 
order to preserve the shape of the cornea when excised from the globe. Compared to 
other species’ corneas that have been used for X-ray diffraction experiments, mice 
corneas are the smallest with an average diameter of 2-2.5mm. In order to overcome 
these limitations excisions and to make sure that the most accurate maps were 
obtained a 0.5 mm rim of sclera was also excised with the cornea in order to provide 
additionally strength to the excised tissue. These tissues were wrapped in clingfilm to 
preserve the hydration of the tissue and the 12 o’ clock position marked on the 
clingfilm as well as the epithelial side of the tissue. This helped to maintain the gross 
structure of the cornea and also aided the handling of the sample later during the X- 
ray diffraction experiments. Ensuring precise handling of the tissue at this early stage 
limited the possibility of artefacts that could have arisen during image processing. 
However this did not completely eliminate all the problems associated with isolating 
mouse corneas.
The method of preservation of mouse corneas is an important question when 
preparing for X-ray diffraction experiments. In this study we wanted to collect data 
about the interfibrillar, intermolecular spacings and the average fibril diameter using 
small angle X-ray diffraction (SAXS) and match them with their data exploring the 
collagen fibrils using wide angle X-ray diffraction (WAXS). In order to get both sets 
of data on the same corneas the samples had to be frozen after the corneas had been 
excised. This would not have been possible if the corneas had been chemically fixed 
as this alters the interfibrillar and intermolecular spacings (Fullwood et al., 1992). It 
should be noted however that chemical fixation preserves mouse tissues for WAXS 
better than freezing as the shape and curvature of the cornea are preserved, but this 
would not allow you to gather both WAXS and SAXS data sets of the same cornea 
In order to take full advantage of using chemical fixation new cells for holding the 
sample in place during the experiments would have to be constructed; but the 
advantages you get in terms of the data are minor if you take full precautions in 
preparing frozen samples and cost of the design and construction of new sample cells.
106
Jack Sheppard
The problem associated with the size of the sample is somewhat mitigated 
after this stage as the cornea is wrapped in clingfilm for the entirety of the experiment. 
This is primarily to maintain the hydration of the. The aid of a clingfilm wrap eases 
handling issues and maintains the shape of the cornea for the duration of the 
experiment. The corneas are wrapped is such a way that only a single layer is either 
side of the specimen. This is then further stabilised by two Mylar sheets that hold the 
clingfilm parcel in place in front of the X-ray beam. Although Mylar and clingfilm 
both produce diffraction patterns they are outside of the pattern produced by collagen 
fibrils and so are not detrimental to the experiment. The clingfilm also offers a degree 
of protection from the beam itself, where prolonged exposure can bum through the 
specimen; however the possibility is remote as the exposure time for each diffraction 
pattern was kept low.
4.5.3 Developing a novel method for quantifying the degree ofpreferential alignment 
in order to compare it to an average control
In order to create an average wild type map to use as a control several steps 
were needed in order to ensure that each individual point in a map could be accurately 
compared with others at the same position. Photographs were used to precisely 
determine the centres of each cornea so that exact positions in each cornea tested 
could be compared to each other. Samples were then compared using the central 
point as a reference and a grid of 11 diffraction patterns by 11 diffraction patterns 
were selected on each cornea. This was the optimal way in ensuring that similar 
points in each cornea were being compared. It was necessary to calculate the central 
point using photographic overlays rather than ensuring the same positions were 
measured during diffraction as although the central areas of the corneas were 
maintained during tissue preparation the overall shape of the tissue being extracted 
was not. It is not possible to distinguish scleral collagen from comeal collagen fibres 
until after data processing.
The process of comparing each fibril patterning used the raw data from each 
diffraction pattern, which is a process that has been developed by our lab and is well 
established. Comparing the data points was automated using an algorithm which was 
written specifically for this purpose and was rigorously tested prior to application.
This eliminated human error from the calculation and sped up the process by several
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months. The largest problem to overcome in calculating whether the points in one set 
of data were statistically significant to the other was the largest limitation that needed 
to be overcome. This was especially important as the data, which in its present forms 
is essentially qualitatative, cannot be statistically compared without greater additional 
calculations. The techniques that were available look at pattern differentiation and K- 
nearest neighbour pattern analysis, which is unsuitable for this type of data However 
the data permitted the use of correlation to compare single like-for-like points that 
could be averaged over an entire data set, avoiding compound errors. The correlation 
coefficient can be a highly variable statistic. Very large sample sizes can reduce its 
variability; however, such samples are not always available in empirical settings. One 
means of addressing the problem of variability is repeatedly to compute correlation 
coefficients and take the average as a more accurate estimate of the population 
correlation, which was achieved in this case.
It should be noted though that a set of data is actually a single point in the 
same location from each of the corneas in a genotype, not a number of data points for 
the same cornea. This is important as a single correlation value cannot be assigned to 
an individual cornea, which would be the best solution, but what this does give is the 
ability to tell if regions within a knock out cornea are statistically different and by 
extension the cornea itself as a whole. When wild type control corneas are compared 
to their computed average they do not highlight any areas that are statistically 
different, although it is conceivable that artefacts within the cornea may produce areas 
that appear to be statistically different when using this method of analysis. However 
these types of aberrations and artefacts are usually quite obvious and can be accounted 
for. This method o f analysis works because the standard deviations of the preferred 
orientations in the wild type are quite low and so this is thought to be the largest 
limiting factor. This further enhances the need for careful preparation of samples 
when dealing with mouse models. Conceivably this method of analysis can be 
converted to use with any other species and would produce better results as the tissues 
from other species are not as delicate as mouse. It should be kept in mind that if the 
intention is to use this method of analysis then this should be planned for as 
preparation of the files can be lengthy depending the number of diffraction patterns 
taken for each cornea
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4.5.4 Collagen mass distribution shows indications o f changes between wild type and 
knockout mice
There are indications that the distribution of both total and aligned collagen 
masses are different between the two genotypes however nothing can be shown to be 
significant in the data’s current form. This shows that there is a large amount of 
collagen being laid down around the periphery of the cornea forming an annulus 
around it, which is similar to human corneas. The total collagen maps appear similar 
in both the wild type and knockout corneas with the majority of mass around the 
annulus of the cornea. The central regions o f the cornea in both genotypes seem to 
show some degree of variability as the collagen mass is not uniform in most cases.
The greatest indication that there is a significant difference in the distribution of 
collagen mass comes from the aligned collagen. The wild type corneas all display an 
even distribution of aligned collagen around the periphery of the cornea. When this is 
compared to the aligned collagen from the knockout mice, there is evidence that the 
distribution of aligned collagen shows a preference for one side of cornea (see fig 4.23 
& 4.24).
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Fig 4.23. Possible effect on the distribution of aligned collagen by the removal of 
Vsxl. WT- wild type cornea #4, KO- knock out cornea #4. Black dashed circles 
show the area of the cornea. Red circle shows the possible location of a developing 
cone.
Figure 4.23 demonstrates a possible effect on the distribution of aligned 
collagen due to the removal o f Vsxl. Most of the knockout corneas examined 
demonstrate a preference o f aligned collagen to be distributed along one side of the 
cornea. This effect is similar although not so pronounced to human keratoconic 
corneas (see fig 4.24).
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Fig 4.24. Aligned collagen distribution compared in normal and keratoconic comeal 
buttons. N -  normal human cornea. K -  Keratoconic cornea. Red circle indicates the 
position of the developed cone, Blue arrow shows the reduced mass of collagen 
tissue. Black arrow shows the area of increased aligned collagen mass. S,N,I,T 
indicate quadrants of the cornea, Superior, Nasal, Inferior and temporal. Figure 
adapted from Meek et al. 2005.
However it is difficult to determine whether this effect is real or just due to the 
inherent variability of mouse corneas as the data is not very conclusive due to inherent 
mouse variability. This could be determined through a larger sample size; however 
for this study it was not possible. It is suggested that this effect is due to 
redistribution of the aligned collagen fibrils as the cone develops, pulling the fibrils 
down leading to an aggregation below the cone.
4.5.5 Interfibrillar spacing, average fibril diameters and intermolecular spacings 
remain unchanged
There are no significant differences found between the intermolecular and 
interfibrillar spacings or the average fibril diameter between genotypes. This mirrors 
the findings between human keratoconics and clinically normal patients (Meek et al.,
2005) further strengthening the argument that this is indeed a good model for the 
disease. In this study we have calculated the average interfibrillar spacing for a 
normal WT mouse as 44.29nm which is lower than previously stated (Beecher et al.
2006). This has since been confirmed independently (Meek et al. private 
communication) and is suggested to be a truer value for the average interfibrillar 
spacing. The average fibril diameter and intermolecular spacings were similar to 
previously reported.
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4.5.6 Changes in expression o f  Aqp5, Hsp47, and HSF1 in the Vsxl knockout mouse 
model
Following on from the developmental expression studies on Vsxl three 
potential downstream candidates were selected to see if their expression varied 
between wild type and knockout Vsxl genotypes. Additional candidates were 
selected based on literature searches that gave good indications for their involvement 
In the Vsxl knockout cornea there is a significant reduction in expression of Hsp47 
and HSF1. The reduced expression of HSF1 and Hsp47 is opposite to what was 
expected in the initial hypothesis that stated that with the removal of Vsxl expression 
should increase the expression of Hsp47 and HSF1. The initial rationale for this 
hypothesis was based on findings that showed that Vsxl binds acts as a repressor of 
genes. This was demonstrated using GAL4-FISF1 binding assays to assess the 
transcriptional activity of both Vsxl and ChxlO (Vsx2) (Dorval et al., 2005).
However it appears here that Vsxl or a Vsxl related mechanism is acting to enhance 
expression of HSF1 and Hsp47 as their expression is reduced in the knockout It is 
not unknown for genes to have both enhancing and repressive functions based on their 
binding capabilities and binding positions. Hsp47 is a direct target of HSF1 and its 
decrease in expression is explained by the proportional decrease in expression of its 
activator.
Heat shock factors (HSFs) are transcriptional regulators of heat shock proteins 
(Hsps), which function as molecular chaperones in protecting cells against proteotoxic 
damage. Mammals have three different HSFs that have been considered functionally 
distinct: HSF1 is essential for the heat shock response and is also required for 
developmental processes, whereas HSF2 and HSF4 are important for differentiation 
and development (Akerfelt et al., 2007). Currently it is not known whether HSF1 is a 
direct target of Vsxl or the reduction in expression is due to other changes affected by 
VsxFs removal. There are certain indicators that it could be a direct target or at least 
present in a signalling cascade downstream from Vsxl. The amount of reduction in 
expression of HSF1 is significant compared to the reduced expression of Aqp5 
indicating that the gene itself could be affected. However the action of HSF1 changes 
depaiding on its situation and it is the change in function that could vary across the 
cornea. HSF1 is expressed in keratocytes. Under stressed conditions it acts to 
activate the heat shock response due to various stresses. Under non stressed
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conditions however it acts in the collagen production pathway by helping to 
chaperone pro collagens for assembly into fibrils. In keratoconus there is a non­
stressed inflammatory response so the action of HSF1 could be working in both ways. 
On the one hand it is helping to produce collagen but on the other it is reacting to 
stresses such as increased mechanical and oxidative stress. This could contribute to 
the lengthy progression of the disease as competing functions of the same protein 
mean that neither is being undertaken at their full capacity. The actions of HSF1 in 
the cornea under both stressed and non stressed conditions in the Vsxl model would 
be a valuable next step in determining if this is the case.
There is also a reduced expression of Aqp5, although the reduction is not as 
significant as HSF1 or Hsp47. It is difficult to know the role of Aqp5 in keratoconus 
and its relationship with Vsxl. The aquaporin family of proteins (AQPs) constitute a 
collection of water channel proteins that play a critical role in transcellular water 
movement in many tissues (Liu et al., 2005; Liu and Li, 2005). It appears that AQPs 
are increasingly playing a role in comeal diseases such as Fuchs dystrophy and 
Bullous keratopathy (Kenney et al., 2004). Aqp5 has been characterised as a water 
channel protein that only transports water and excludes small solutes (Oen et al.,
2006). At least 5 AQPs are found in the eye, of which only Aqpl and Aqp5 are found 
in the cornea. In Fuchs dystrophy and Bullous Keratopathy Aqp4 was found to have 
lower expression (Kenney et al. 2004). Aqp5 transcripts were later found to be absent 
during gene expression profiling for keratoconus and this has led to speculation that 
the disruption in the cornea in keratoconus could, in part be due to reduced water 
movement. Despite this study very little research has been conducted to investigate 
the possible role of Aqp5 in keratoconus. The study presented here shows that there is 
reduced expression of Aqp5 in Vsxl knockout corneas. This reduction is puzzling as 
there have been no previous indications of any interactions between the two genes.
I do not believe that the change in Aqp5 is due to any direct relationship 
between Vsxl and Aqp5 nor for that matter HSF1 or Hsp47. It is more likely that the 
change in Aqp5 expression is due to the structural changes that are occurring within 
the cornea as a result of the removal of Vsxl. The lack of transcripts for Aqp5 was 
proposed to be used as a marker for keratoconus (Rabinowitz et al., 2005). Direct 
sequencing of the gene revealed no changes in the Aqp5 so it was suggested that the 
gene was being suppressed in keratoconus corneas. However two separate studies 
have not identified any difference in expression levels between Apq5 in human
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keratoconus and normal controls (Garfias et al., 2008; Kenney et al., 2004). The 
reduction shown within the results presented here seems to add to the controversy of 
Aqp5 involvement. However die reduced or lack of expression could be explained in 
the situations that regulate Aqp5 expression. Both shear stress and nitric oxide have 
been shown to regulate Aqp5 expression (Nagai et al., 2007; Sidhaye et al., 2008). 
Both act to reduce cell surface Aqp5. It appears that shear stress has a great impact on 
epithelial function, which could be as a result of keratoconus cone formation. If this 
is true then it is another indication that the removal of Vsxl plays an important role in 
the development of a keratoconus like phenotype.
The lack of expression of Col8a2 in both the normal and the knockout would 
appear to suggest that the expression of Col8a2 is temporally regulated. Expression 
of Col8a2 has been found in the cornea during development (see chapter 3). There is 
no evidence in the literature to state that Col8a2 is expressed in adult tissue only that 
the expression of Col8a2 is found within the eye, more specifically as a large 
constituent of Descemet’s membrane (Hopfer et al., 2005). Col8a2 has been 
previously associated with PPCD (Biswas et al., 2001) and to a lesser extent 
keratoconus by virtue of the link between Vsxl, PPCD and keratoconus. Sequencing 
of the Col8a2 gene in patients with keratoconus has not revealed any pathological 
mutation (Aldave et al., 2007a; Yellore et al., 2005). The lack of expression in the 
Vsxl knockout mouse is intriguing as it offers support to the theory that the two genes 
are linked. The expression of Vsxl and Col8a2 in development (see chapter 3) offers 
suggestions that Col8a2 is a direct downstream target of Vsxl and this has also been 
speculated upon elsewhere (Hopfer et al. 2005). The possibility of this interaction is 
strengthened by studies performed on Col8a2 knockout mice that demonstrate that 
these mice have a keratoglobus-like protrusion of the anterior chamber with a thin 
corneal stroma (Hopfer et al. 2005). Although mutations in this Col8a2 do not seem 
to cause disease, the complete ablation leads to sever anterior segment dysgenesis.
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4.6 Conclusion
It can be concluded from the X-ray diffraction data conducted on the Vsxl 
knockout that the removal of Vsxl does cause a structural change to occur within the 
cornea, although further investigation is needed to see exactly what components are 
affected. In the Vsxl knockout mice the average interfibrillar, intermolecular spacings 
and average fibril diameters do not change, which is also the case with keratoconic 
and normal human corneas. It has been suggested that fibril orientation is linked with 
the visual acuity, but this disruption of the fibrils is apparent in both human and mice, 
that have very different fibril alignments. Therefore, even though both human and 
mouse are different the effect of this possible underlying defect is the same. Fibril 
orientations are statistically different in the knockout, which gives possible indications 
of the onset of a keratoconus phenotype mirroring data gained from recurrent 
keratoconus phenotypes. There are also indications that the distribution of collagen 
mass is different between wild type and knockout mice, which are one of the main 
features of keratoconus. Vsxl knockout mice have reduced expression of HSF1, 
Hsp47 and Aqp5. Previous studies have linked reduced Aqp5 expression with 
keratoconus and this is demonstrated within the knockout mice. This is the first study 
to show a decreased expression of HSF1 and Hsp47, genes that are involved in the 
collagen production pathway. When combined with the X-ray, data these findings act 
to strengthen the view that the Vsxl knockout mouse is a potential model for 
keratoconus. If confirmed by the wider scientific community that this is indeed a 
good model then the data presented in this thesis offers potential avenues of future 
experimentation.
114
Jack Sheppard
Chapter 5. Mutational study of human VSX1
5.1 Aims
• To screen a cohort of patients with keratoconus and compare them to matched 
background controls to see whether there are any changes present in the VSX1 
gene.
5.2 Introduction
There is an increasing amount of evidence that keratoconus is inherited in 
some patients and families and that the cause in all patients could have a genetic 
contribution. A number of candidate loci have been documented for keratoconus 
including 2p24, 3pl4-ql3, 15q22, 16q23, 20pll and 21q (Brancati et al., 2004; 
Hughes et al., 2003; Rabinowitz et al., 1992; Rabinowitz et al., 2000; Tyynismaa et 
al., 2002). Current research suggests a number of possible genetic aetiologies for 
keratoconus; on the one hand keratoconus may be a multifactorial disease, caused by 
the interplay of environmental factors and many genes, but on the other hand it may 
be primarily monogenic in some rare families and individuals. To date two candidate 
genes, VSX1 and SOD1, have been associated with keratoconus and mutations in these 
gene have been determined to be disease causing (Bisceglia et al., 2005; Heon et al., 
2002; Mintz-Hittner et al., 2004) for VSX1 and (Udar et al., 2006) for SOD1. A total 
of nine different mutations have been documented between the two genes with eight 
of them appearing in VSXl. Mutations in VSX1 have also shown to lead to 
craniofacial anomalies in addition to keratoconus in one family (Mintz-Hittner et al. 
2004).
There has been much debate as to whether the associated mutations found with 
VSXJ are actually disease causing, as subsequent screening of VSX1 in much larger 
sample groups has found the reported disease-causing changes in normal controls 
(Aldave et al., 2007b; Liskova et al., 2007a; Tang et al., 2008). The principle 
hypothesis that we are investigating is that keratoconus is a disease in which 
mutations in single genes may cause disease. Our rationale for this is that, in the gene 
VSXJ, eight mutations have been found segregating in families and have been shown
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to cause keratoconus. The mutations were also shown to be inherited within these 
families and although we believe that there may be other genes like VSX1 that play a 
role in this disease this is our candidate of choice by virtue of its reported links and 
previous mutational studies. By gathering our own cohort of keratoconus patients we 
planned to search for novel mutations as well as confirm existing mutations in a 
population within the UK.
5.2.1 Hypothesis
•  Sequence changes within the VSX1 gene cause keratoconus.
5.3 Methods
5.3.1 Patient recruitment and ethical approval
Initially ethical approval was granted to recruit patients locally by an internal 
ethical committee (see appendix D). Later ethical approval was gained from the 
Cardiff and Vale NHS Trust and the National Multicentre Research and ethics 
committee (MREC) granting multi-centre ethical approval for recruitment (see 
appendix E). Patients with keratoconus were either recruited locally from the 
University Eye Clinic (Cardiff University) or were referred to the study from the 
University Hospital (Cardiff and Vale NHS Trust) by Dr Vinod Kumar with 
additional patients recruited from Bristol Eye Hospital by Dr Mike Johnsoa Once 
informed consent was given, patients were enrolled into the study. In total 19 patients 
with clinical keratoconus at various stages of the disease were recruited. 53 normal 
background-matched controls were also recruited, representing 106 chromosomal 
controls. There were no exclusion criteria with regards to age, sex, race or family 
history. If there was a family history of keratoconus present then family members 
were asked to participate as well if they were known sufferers. Patients were only 
included if they had clinically diagnosed keratoconus either from the University Eye 
Clinic or recommended by collaborating consultants. All stages of keratoconus were 
included in the study, and the stages for each patient was known.
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5.3.2 Proteinase K  buffer preparation
lOmM tris-HCl pH 8.0 was added to 700ml of dd H2O on a vortex stirrer. To 
this ImM EDTA and 0.5% SDS was also added then the solution was brought to a pH 
of 7.8 and made up to a total volume of 1 litre.
5.3.3 Proteinase K  extraction for buccal cells
Buccal cells were obtained either via a mouthwash of 0.9% saline or via a 
cheek swab that was then placed into 15ml of 0.9% saline. Samples were then left to 
settle at 4°C for 30 minutes then centrifuged at 3500rpm for 5-7 minutes. The 
supernatant was then poured off and 380pl of Proteinase K lysis buffer was added and 
mixed by pipetting to ensure the pellet dissolved. Samples were then frozen and 
stored at -20°C. After thawing at 37°C, the samples were vortexed and spun, 20pi of 
Proteinase K lOmg/ml was added to each, and they were incubated for 2 hours at 
37°C in a water bath with continuous shake (-lOOrpm). Samples were then 
centrifuged at 14000rpm to pellet insoluble material and the supernatant transferred to 
a silicon grease eppendorf tube. Finally, the samples were cleaned via a 
phenol/chloroform extraction, resuspended in 51 pi of TE (lOmM Tris, ImM EDTA) 
and incubated for 15minutes at 37°C to ensure the DNA dissolved. Quantification 
was then performed to obtain DNA concentration.
5.3.4 Primer Design and PCR conditions
The primers used were taken from Bisceglia et al. 2005. They were optimised 
across a gradient of 20°C. Optimisation of human primers was carried out on normal 
human genomic DNA supplied by Dr Votruba, School of Optometry at Cardiff 
University. A list of human primers is given in table 8.
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Exon Sequence 5’-3’ Product 
size (bp)
Annealing 
tmp (°C)
Exon 1 F CAGCTGATTGGAGCCCTTC — -------------------- 58
Exon 1 R CTCAGAGCCTAGGGGACAGG 599 58
Exon 2 F GCACTAAAAATGCTGGCTCA 59
Exon 2 R GCCTCCTAGGAACTGCAGAA 393 59
Exon 3 F CATTCAGAGGTGGGGTGTT 62
Exon 3 R TCTTGTGGTGCCTTCAGCTA 419 62
Exon 4 F GATCATGCTCGGGAGAGAAG 59
Exon 4 R CGTTGCTTTGCTTTGGAAAT 394 59
Exon 5 F CCCCAGAGATAGGCACTGAC ------------------------------ 59
Exon 5 R TGGAC AATTTTTGTCTTTTGG 495 59
Table 8. VSX1 primers and primer conditions. Primers taken from Bisceglia et al. 
2005.
PCR products were then separated on an agarose gel as previously stated.
5.3.5 Sample preparation for sequencing
PCR products were prepared for sequencing using the SureClean PCR product 
cleaning kit (Bioline Pic). Three times the volume of the SureClean reagent was 
added to the sample and a colour change of purple to yellow was observed. The PCR 
product sample was then spun down and a pellet was produced according to the 
manufacturers’ instructions. The pellet was then resuspended in 12pl of sdFfeO and 
frozen ready to be sequenced.
5.3.6 Mutation detection and direct sequencing
Mutation detection and sequencing were carried out at the Wales Gene Park 
Facility (Cardiff UK). Prepared PCR samples were cleaned and sent to the facility to 
undergo SNP detection and verification followed by sequencing and characterisation 
of variants found. PCR setup is carried out in an amplicon free environment on a 
Beckman Biomek FX platform (Beckman Coulter Inc). Following amplification on 
MJ Tetrad thermocyclers (GMI Inc), the products are analysed on 3 HT Transgenomic 
Wave platforms using automated software. This includes automated pattern 
recognition software for the identification of heteroduplexes. SNP verification is 
carried out through sequencing of PCR product on an ABI3100 DNA Sequencer.
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5.4 Results
5.4.1 All VSX1 sequence changes found in this study
Gene Fragment
Base change with 20 bases 
upstream Seq change
aa
change
VSX1 X1 ACC AT G ACCGGC CGGGACT C K c. 18G>T S6S
VSX1 X3 CCC AGGGGAC AT GT GCCC AC Y c.3 -24 C>T Intronic
VSX1 X3 CTGGAAGAGTTGGAGAAGGC R c.546A>G A182A
VSX1 X3* GTC TGGGGTCCCTTTTCTCC R c.650G>A R217H
VSX1 X3* GTGAGCCAATCAGCAGTCCC W c.711T>A P237P
VSX1 X5* TCCTTTTTATTTTTTTTTTT T c. 809 -6 ins T Intronic
Table 9. Sequence changes found by screening the VSXJ gene. Fragment denotes 
what exon the sequence change was found in, XI shows exon 1, X3 -  exon 3, X5 -  
exon 5. The bold letter shows the base that is altered. K -  G or T, Y -  C or T, R -  A 
or G -  W -  A or T. * indicates that this sequence change was found only in the short 
isoform, # indicates that this sequence change was only found in the long isoform.
In total 6 polymorphisms were detected in the patients screened (see Table 9). 
This included two intronic sequence changes in both the third and fifth exon. Three 
of the sequence changes found, 18G>T in exon one, 546A>G in exon three and 
711T>A also in exon three, code for silent changes resulting in no change in amino 
acid. The other change found in exon three codes for an amino acid change of an 
Arginine to a Histidine (650G>A) which is likely to be a polymorphism as it occurs in 
both normal and affected populations (for chromatograms of mutations found see 
appendix F).
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5.4.2 Existing sequence changes ofVSXl
Position in the gene Nucleotide change Protein change
K e i e i e u c e  i u
reported by Variant l Variant 2 Variant 1 Variant 2 Isofonn A
rsS123716 Exon l Exon l C .1BG>T C . 1BG>T p-(S€S)
Aldave et al - [34) Exon 1 Exon 1 C . 174G>T C .174G»T p-(P58P)
rs6115023 Exon l Exon l C .315C>A C.315C>A p.D10EE
rs6037O16 Exon 1 Exon 1 C .339C>T C.339C>T p-{G113G)
rs€050307 Exon 1 Exon 1 C.391C>A C .391C>A p.RlllS
Heon et al. [17) Exon 2 Exon 2 C .432C>G C.432C>G P.D144E
Novel l Intron 2 Intron 2 C.504-10G>A C .504-10G>A -
Novel 2 Intron 2 Intron 2 C .E04-24C>T C .  504-24C?-T -
rsl24S0307 Exon 3 Exon 3 C . 54€A>G c.54€A>G p-(A1B2A)
rs€13B4B2 Intron 3 Exon 3 C . €27i-23G>* C .f iE O  G>A *
Blsceglla et al. Intron 3 Exon 3 C . 627-t-B4T>A c.7iir>A _
[31)
p-jses)
Table 10. Existing sequence changes found by screening the VSX1 gene in either 
familial studies or cohorts of unrelated individuals. Table adapted from Liskova et 
al. 2007.
p-!PSBP)
p.DlOSB
P-IG113G)
p.R13L£
P-D144E
p.R217H
p-{P227P)
As can be seen from table 10, most of the reported changes found in this study 
have all been previously reported. There are two new intronic sequences that are 
novel for VSX1, these are the 809 -6 ins T for exon 5 and the 3 -24 C>T. It is 
interesting that the majority of changes that occur in exon three are in the short 
isoform.
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5.4.3 Demographic o f  sequence changes found in this study
Gene Fragment Seq change
aa
change
genotype 
ab bb
# normal 
controls
#
keratoconics
VSX1 X1 c. 18G>T S6S 10 1 11/53 0/19
VSX1 X3 X3 -24 C>T Intronic 1 0 1/53 0/19
VSX1 X3 c.546A>G A182A 20 1 21/53 2/19
VSX1 X3 c.650G>A R217H 23 3 26/53 3/19
VSX1 X3 c.711T>A P237P 20 1 21/53 2/19
VSX1 X5 c. 809 -6 ins T Intronic 11 1 12/53 0/19
B Gene Fragment Seq change
aa
change
%
incidence 
in controls
% incidence in 
keratoconics
VSX1 X1 c.18G>T S6S 20.8 % 0%
VSX1 X3 X3 -24 C>T Intronic 1.9% 0 %
VSX1 X3 c. 546A>G A182A 39.6% 10.5%
VSX1 X3 c.650G>A R217H 49.1% 15.7%
VSX1 X3 c.711T>A P237P 39.6% 10.5%
VSX1 X5 c. 809 -6 ins T Intronic 22.6% 0%
Tables 11 A. Patient numbers who have VSXl sequence changes. Genotype refers to 
the sequence change as follows: allele ‘a’ is the nucleotide of the reference sequence 
so ‘aa’ is an unaffected individual, ‘ab’ is a heterozygous sequence change, ‘bb’ is a 
homozygous sequence change. B. Table showing % incidence of polymorphism in 
normal and affected populations
In total only 3 polymorphisms were found in keratoconic patients in the VSXl gene. 
The polymorphisms found in exon 3 have a high incidence in unaffected controls, 
each occurring in over 35% of normal controls screened.
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5.4.4 Demographic o f  existing sequence changes
R e f e r e n c e  SNP ID  
r e p o r t e d  b y
N u c l e o t i d e c h a n g e P r o t e i n  c h a n g e
o b s e r v e d
g e n o c y p e a E t h n i c i t y  o f  
p r o b a n d B  w i t h  
a l l e l e *  a b  o r  b bv a r i a n t  l v a r i a n t  2 I s c f c r m  A i a o f o r n  8 a a a b b b
r a a L 2 J 7 i e C .1 B G > T C .1 B G > T p - < S 6 S ) p - ! S 6 S ) 76 9 0 A s la n .  (3 )  , 
w h i t e  ( 5 ) ,  
u n c l a s s i f i e d  ( i ;
A l d a v e  e t  a l . [ 3 4 ] c . 17 4 G > T C . 1 7 4 G > r p -  ( P 5B P ) p - ( P E B P ) S3 2 0 W h i t e  (2 )
r s 6 1 1 5 0 2 3 C . 31EC:»A C .3 1 E C ? A p .D I C E S p .  D ICES 83 2 0 B la c k .  (2 )
r s € 0 3 7 Q l € C .1 3 9 C > T C .3 3 9 C > T p - i G l l 3 G ) p - : g h 3G) 83 2 0 B la c k .  (21
r s « 0 5 0 3 0 7 C . 39 1 C > A C .3 9 1 C > A P - R 1 3 1 S P .B 1 3 1 E 80 4 1 B la c k .  (5 )
B e a n  e t  a l . [ 1 7 ] C .4  32C>G C .4 3 2 C > G P -D 1 4 4 E P .D 1 4 4 E 84 1 0 W h i t e  (1 )
H o v e l  1 C .S 0 4 - 1 0 G > A C . 5 C 4 -1 G G ? A - - 84 1 0 u n c l a s s i f i e d  ( l ;
N o v e l  2 C . 5 0 4 - 2 4 O T C . S C 4 -2 4 C > T - - 82 3 0 A s i a n  (3 )
rs l2 4 S C '3 C '7 C .  54«A > G C .5 4 6 A > G p - . ; a i b 2a j p .[ A lB 2 A J 32 44 9 A s i a n  (1 5 )  , 
W h i t e  ( 2 4 1 ,  
B la c k .  ( 1 1 ) ,  
u n c l a s s i f i e d  ( 3 ;
r a S 1 3 9 4 9 2 C .€ 2 7 * 2 3 G > A C .6 E 0  G>A P .R 2 1 7 H 67 17 1 A s l a n  ( 4 ) ,  
W h i t e  ( 1 3 ) ,  
B l a c k  (1 )
B l s c e g l l a  e t  a l .
[ 3 1 ]
C .« 2 7 * -B 4 T > A C . 7 1 1 T * A p - ( P 2 3 7 P ) 32 4 4 9 A s i a n  ( 1 5 ) ,  
W h i t e  (2 4 )  , 
B l a c k  ( 1 1 ) ,  
u n c l a s s i f i e d  (3 ]
Table 12. Numbers of patients affected by each sequence change according to 
inherited allele and ethnicity. Genotypes are as follows, allele ‘a’ represent the 
nucleotide of the reference sequence so ‘ab’ represents an individual who has a 
heterozygous sequence change and ‘bb’ an individual who has a homozygous 
sequence change. Table adapted from Liskova et al. 2007.
From tables 9 and 10 it can be seen that the changes found within this study 
are not thought to be disease-causing as they appear in control individuals and do not 
meet the criteria for pathological mutation.
5.5 Discussion
5.5.1 Changes found in the VSXl gene in a population o f  patients from South Wales.
In this study a total of 19 patients representing 38 tested chromosomes with 
clinically diagnosed keratoconus were screened for changes in the VSXl gene. This 
was compared with 53 background-matched control patients representing a control 
panel of 106 chromosomes. There were no sequence changes found in this study in 
the VSXl gene that can be said to be disease-causing as they occur in both the normal 
and control populations. Two of the polymorphisms that have been found in both 
keratoconic and normal patients are silent polymorphisms in that the change in base 
does not cause a change in amino acid. This means that the Vsxl protein would be 
unchanged. The final polymorphism, R217H causes an Arginine residue to be 
exchanged for a Histidine residue. Arginine residues carry the strongest positive 
charge and this is being replaced with a residue that has a weak charge. This could
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theoretically affect binding and the polymorphism occurs in the homeobox domain. 
However the residue is flanked by another Arginine residue and an Aspartate residue 
indicating a change from a positive to a negative charge. The loss of an Arginine 
residue at this point would not be that severe, which is possibly why this 
polymorphism does not have a great impact on function as some of the other reported 
sequence changes. Several previously reported polymorphisms were also found (see 
table 19). The reported polymorphisms appear to be very abundant in the control 
population and all but one of the polymorphisms has been documented in previous 
studies. It is interesting that there appears to be a high incidence of synonymous 
polymorphisms in this gene in the normal population and in keratoconus. The high 
incidences of polymorphisms demonstrate that the VSXJ gene could be quite robust in 
its sequence and is not greatly hindered by small changes to its sequence. VSXJ may 
not be a crucial gene in development as removing it does not cause lethality (Cow et 
al., 2004) but may be far more crucial as a temporally expressed gene needed for 
maintenance and repair. This could offer an explanation as to why mutations are not 
so detrimental and these changes have been able to propagate among the general 
population.
5.5.2 Previous mutations in VSXJ
The ongoing debate surrounding the VSXJ gene and its association with 
keratoconus lies in the previously reported sequence changes within the gene that are 
said to be disease-causing. The controversy surrounding VSXJ is whether the 
sequence alterations are disease causing or whether they are silent polymorphisms.
Six changes have been reported in VSXJ, leading to protein changes that are 
suggested to be pathogenic or disease-causing. These are:
p.L17P, Leucine - Proline 
p.D144E, Aspartate - Glutamate 
p.L159M, Leucine - Methionine 
p.R166W, Arginine - Tryptophan 
P.H244R, Histidine - Arginine 
P.P247R, Proline - Arginine
There are several factors that suggest that sequence alterations are disease- 
causing. The main reason for a change to be highlighted in a study is that the change 
only appears in an affected individual, and not within the control group. However,
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this on its own is not enough to justify its status as disease-causing. The change must 
also be shown to segregate within a family of affected individuals and happen in an 
area of the gene that is thought to affect the final structure of the protein; for example 
a base change in the gene that codes for a residue in an important domain such as a 
binding domain and that the changed residue will impair the final function of the 
protein. Another example of this would be a change in the gene that codes for a stop 
codon resulting in a truncated protein that is non functional. Of the changes that have 
been suggested as disease-causing (above), D144E, L159M, R166W, H244R and 
P247R have now also been reported in unaffected control individuals in larger studies 
that have been carried out in addition to the studies that originally proposed them as 
disease-causing (Aldave et al., 2005; Gwilliam et al., 2005; Tang et al., 2008) 
Although these changes have been found in control individuals their presence 
indicates that the VSXJ gene is undergoing rapid changes and future polymorphisms if 
found, could produce stronger associations with keratoconus.
The L17P change (Bisceglia et al. 2005) results in a change from a Leucine 
residue to a Proline residue and occurs in the first exon, which means that it lies 
outside of the crucial homeodomain and CVC domain. However the mutation results 
in a change in amino acid that is highly conserved in all species where VSXJ has been 
identified (Bisceglia et al. 2005). As yet no studies have attempted to explain what 
may be the actions of these mutations within the gene, such as do the amino acid 
changes seen affect the folding of the protein? A possible theory explaining the effect 
of this particular mutation is that it affects the binding of other proteins that help to 
chaperone the nuclear export of the protein. The mutation occurs outside all the 
domains identified thus far in the gene. The closest domain to the mutation is the 
highly conserved nuclear export signal (NES) that is coded for in the first exon 
(Knauer et al., 2005). The presence of a NES is often sufficient to cause nuclear 
export of a protein. However the activity of the NES of some proteins e.g., the 
protein kinase inhibitor (PKI) and the adenovirus E4 34-kDa protein, only becomes 
exposed after the binding of another protein (Dobbelstein et al., 1997; Wen et al.,
1994; Wen et al., 1995). This exposure is normally affected by an adjacent effector 
domain. Such a domain has not yet been characterised in the VSXJ gene but it is 
possible that the action of this mutation is to affect this domain and subsequently, the 
nuclear export of VSXJ. In order to determine if this were the case then a nuclear 
export assay that compares normal VSXJ to the L17P mutated variant would need to
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be carried out. The amino acid change could also give a clue as to the gene’s 
dysfunction. Leucine is an amino acid that has no charge and is an isomer of 
Isoleucine and both are hydrophobic. In contrast Proline is not hydrophobic and 
promotes turns in the transcribed protein. This could potentially influence the 
secondary and tertiary structure of the protein causing impaired function.
The D144E change results in a missense mutation that changes the amino acid 
from an Aspartate to a Glutamate residue. This mutation has been shown to lead to 
keratoconus and a wide expression of the disease, from very severe cases to mild 
aberrations (Bisceglia et al., 2005; Eran et al., 2008; Heon et al., 2002). It is difficult 
to say whether this mutation itself leads to keratoconus due to the varying forms of 
keratoconus that this mutation has been associated with. This mutation was also 
identified in a patient with glaucoma who had a normal cornea (Heon et al. 2002).
The position of this amino acid is highly conserved throughout all species (Heon et al. 
2002) and lies in the second exon upstream of the homeodomain. Functionally 
Aspartate and Glutamate share many traits, they are both negatively charged 
hydrophilic and acidic residues with similar molecular weights. The difference lies in 
Glutamate that has an extra CH2 chain in the centre of the residue. This could alter 
the binding properties of the protein or affect exon splicing, as the residue is close to 
the intron/exon boundary.
The L159M variant demonstrated segregation in four families with 
keratoconus. The residue at this position is not highly conserved between species 
however the change in amino acid at this point is the most drastic change seen 
compared to the other mutations reported. The aliphatic Leucine residue is replaced 
by a sulphur-containing Methionine residue. There is no difference in the pH or 
charge of the residue at this position but Methionine is an initiator on translation. 
Methionine is one of two amino acids that are coded for by a single codon and is 
normally found in all proteins at the N-terminus. The change from Leucine to 
Methionine in this case could be responsible for initiating translation of VSX1 in the 
incorrect place in the gene, resulting in a truncated and incomplete protein. This 
would help to explain why it was found among many families. However this 
mutation has been found in normal controls (Tang et al. 2008). The action of this 
mutation is difficult to interpret as the change must not be that severe as to cause KC 
on its own. It may help that Methionine is not produced by the body so other external 
factors work to counteract the deficiencies this mutation creates.
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Arginine to Tryptophan occurs at position 166 in the VSXJ protein and 
crucially occurs in the homeodomain (Heon et al. 2002). In titration experiments it 
was shown that proteins bind to the VSXJ WT gene with greater affinity than to the 
mutated R166W variant (Heon et al. 2002). This mutation has also been examined in 
the possible functions of VSXJ ; functional assays have revealed that the R166W 
variant represses expression at a much lower level compared to the wild type protein 
(Dorval et al. 2005). The Arginine residue has the strongest positive charge and like 
other charged residues is hydrophilic, which greatly aids binding. Tryptophan on the 
other hand is the largest amino acid and is uncharged. The presence of a Tryptophan 
residue in the homeodomain, which is the main binding domain of VSXJ, would 
reduce the binding of VSXJ significantly. Given this it is surprising that later 
experiments have demonstrated this mutation in normal controls (Tang et al. 2008). A 
possible explanation for this is that Tryptophan promotes hydrogen bonding, which 
may overcome the conventional binding properties given by an Arginine residue.
The remaining two mutations that have been found occur in normal control 
populations. The H244R mutation occurs in the highly conserved and critical CVC 
domain, which is thought to play a part in binding and repression (Dorval et al. 2005). 
The Histidine at this position is 100% conserved between all species so it is 
interesting that while this mutation was detected in keratoconus patients it was also 
detected in normal controls. If it is suggested that the CVC domain is a binding 
domain then the presence of and Arginine residue at this position would strengthen 
the binding. Both Histidine and Arginine are charge amino adds, however Arginine 
has a much stronger charge due to the differing side chains. It is conceivable that the 
action of this change would be to prevent or reduce dissociation of VSXJ from its 
target protein once it has bound and repressed its target. The P247R mutation was 
initially found co segregating with the G160D mutatioa The mutation had been 
inherited by a keratoconus proband from her father who was unaffected. The 
mutation was later found to segregate with keratoconus patients in another study.
This mutation also occurs in the CVC domain results in a change from a Proline 
residue to an Arginine residue. Proline residues as mentioned previously promote 
turns in the protein sequence and are not charged or hydrophobic. Replacing this with 
an Arginine would create a residue that has strong binding capabilities. This could 
conceivably affect the secondary or tertiary structure of the protein increasing its 
binding affinity for its target, which could disrupt dissociation. If the action of the
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VSXJ CVC domain is to repress then this increased affinity could lead to longer 
inactivation of the target. Other external factors appear to play a part as by itself the 
mutation does not unconditionally cause keratoconus but it may affect the 
susceptibility keratoconus to occur.
5.5.3 Importance o f  Single Nucleotide Polymorphism (SNP) changes
SNPs have conventionally been used as markers within the genome and due to 
their size as single nucleotides very fine mapping can be carried out. However the 
importance of SNPs in genes already under investigation changes as now it is the 
properties that these changes bring to a gene that is of interest. The amount of SNPs 
found within a gene is a reflection of how fast the gene is evolving. With age the 
amount of SNPs in a gene can increase and this can lead to changes in its behaviour. 
In the past it has been thought that synonymous single nucleotide polymorphisms 
(sSNP) were silent, in that their change did not have an effect on the overall structure 
of a protein. These polymorphisms are often found whilst searching for disease 
causing mutations within a gene. These changes are often disregarded in the disease- 
affected individual because they are found in the control population. This begs the 
question what is the point of listing polymorphic variants that are not disease causing? 
It is gradually emerging that these silent changes are becoming more important than 
was once thought. Cumulatively SNP changes that, individually are silent, could add 
to the susceptibility to a particular disease. Recently it was found that synonymous 
SNP changes within the ABCB1 gene can affect protein conformation and function 
(Sauna et al., 2007). In the case of keratoconus, which is a complex disorder, the 
silent polymorphisms that are occurring could be acting to increase the susceptibility 
of patients with sSNPs to keratoconus. If this is the case, it would help to explain 
why mutations that were previously thought to be disease-causing in VSXJ have been 
found in a small number of unaffected controls leading them to be questioned in the 
disease’s involvement.
127
Jack Sheppard
5.5.4 Limitations o f  screening unrelated patient samples in mutation screening.
There is a difficulty in recruiting patients for genetic studies of a disease such 
as keratoconus despite the prevalence of keratoconus being high. Patient reliability in 
terms of completing the mouthwash themselves and the rate of participation often is 
poor, which means that the effectiveness of obtaining samples is relatively low. In 
this study, DNA was gained from buccal cell samples obtained from a mouthwash. 
The sample was either gained from the patient on site or via the post. Samples from 
either method yielded suitable quantities of DNA as well as viable amplification 
products. Specificity of product was ensured through human-specific primers. It was 
felt that these measures were sufficient in order to obtain accurate sequences for each 
sample. DNA remained stable for lengthy periods of time frozen at -20°C however 
samples were good enough not to warrant multiple uses. It should be noted however 
that if samples are to be stored for longer periods of time then storage at -80°C is 
recommended. Recruiting unrelated patients has disadvantages compared to finding 
large families that appear to have an inherited form of keratoconus. Familial 
keratoconus offers the opportunity to explore any polymorphisms to a greater extent 
such as seeing whether any mutation found segregates with the disease. Familial 
studies also let us determine if any inheritance pattern of a gene can be found.
Despite the disadvantages of screening unrelated patients the information this type of 
screening study can provide is useful in that it can help to determine if existing 
mutations that have been identified are real. It has mainly been through unrelated 
patient screens that have questioned some of the polymorphisms found so far.
5.5.5 Should screening ofVSXl continue?
Despite the studies that are suggesting the contrary, the screening of VSX1 
should continue alongside the investigation of other candidate genes. Subsequent 
studies question some of the mutations uncovered thus far, however there are still 
mutations that are thought to be disease-causing within the VSX1 gene. Future 
screening will also discover more polymorphisms, which in light of the increasing 
roles they are playing makes the screening doubly important. A recent study has also 
revealed two new variants of the VSXJ gene with two new exons (Hosseini et al.
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2008). These have yet to be characterised and could potentially reveal different roles 
the gene is thought to play. It is unlikely that keratoconus is a single gene disorder 
and that a single polymorphism within that gene would result in the disease. It is 
more likely that changes within the VSXJ gene alter the susceptibility of that patient to 
developing keratoconus through a VSXJ -linked disruption. From the mutation studies 
alone VSXJ should definitely remain a candidate gene for this disease, maybe not 
necessarily as direct causative gene but perhaps as a susceptibility gene for the 
disease. Combined with functional studies, further molecular characterisation will in 
time elucidate the roles VSXJ has to play. However to dismiss the gene entirely from 
the keratoconus story at this stage would be short-sighted.
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Chapter 6. General Discussion
6.1 Summary of results
• Vsxl expression was examined during mouse postnatal development at P 5 ,12 
and 17. Significant differences in expression were found between postnatal 
day 5 and postnatal day 12.
• Col8a2 expression increased significantly from postnatal days 12 to 17.
• Mouse comeal fibrils develop at postnatal day 10, with the circumcomeal 
annulus forming at this time point as well.
• Mouse comeal structure continues to develop until fully formed at postnatal 
day 28.
• Mouse corneas demonstrate a circumferential fibrillar orientation pattern.
• Vsxl KO corneas have a statistically significant difference in the fibrillar 
alignment compared with normal WT controls.
• There is evidence that comeal collagen mass distribution is altered between 
KO and WT mice. Regions of thinning in the posterior region of the cornea 
are apparent in the Vsxl -I- mice
• There are no significant differences detected in the intermolecular and 
interfibrillar spacings and no difference in the average fibril diameters 
between the Vsxl KO mouse and WT controls. This mirrors findings with 
human keratoconic corneas and normal controls using X-ray diffraction.
• There are significant reductions in expression oiAqpS, HSF1 and HSP47 
between the KO and the WT corneas.
• Col8a2 in not detected in either WT or KO corneas in adult mice.
• Mutational screening of keratoconus patients in South Wales increases the 
number of SNP detected in the VSX1 gene but failed to find any novel 
mutations.
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6.2 The Vsxl KO mouse as a keratoconus model
In terms of keratoconus, the Vsxl KO mouse model offers a good stepping 
stone for investigation into keratoconus. Although the visual phenotype needs 
characterising at an older age, the similarities between human keratoconic corneas and 
mouse Vsxl KO corneas are quite striking (see chapter 4). When compared with the 
other mouse models, such as the MHC keratoconus model, there are greater 
similarities between KC and the Vsxl KO model. Human keratoconus has yet to be 
linked in any way to the MHC, whereas there is an association with human VSXL 
The X-ray studies provide strong evidence to support the Vsxl knockout mouse model 
and show statistically different alterations to the structure. Of course, any animal 
model can only be a stepping stone as a tool to investigate the ectasia and does not 
offer a full basis for comparison, but it is the best currently available.
The combination of gene expression changes in the model offers possible 
insights into previously published changes found in keratoconus. Aqp5 transcripts 
were found to be absent in keratoconus (Rabinowitz et al. 2005), however, mutations 
in Aqp5 in keratoconic corneas were absent (Garfias et al. 2008). From the expression 
work carried out in this study (see chapter 3 & 4)Aqp5 itself is not a causative factor 
in keratoconus; however removal of Vsxl in mouse corneas causes the reduction of its 
expression. It has been reported that shear forces exerted by keratoconic comeal 
progression and increases in oxidative stress act to reduce the expression of Aqp5 
(Sidhaye et al. 2008, Nagai et al. 2007) and it is logical to assume that this is 
happening in this case. It should be noted that while Vsxl expression has been 
documented during wound healing in the cornea (Barbaro et al. 2006) Aqp5 
expression during wound healing in the cornea remains unchanged (Song et al. 2004). 
This strengthens the viewpoint that Aqp5 expression is not mediated by VSX1 directly, 
but by a ‘keratoconic environment’, which is an environment that leads to formation 
of a cone. It would be advisable to include Aqp5 expression tests in any future models 
of keratoconus to see whether this is indeed caused by the changes in environment 
rather then by direct action of Vsxl. The reductions in expressions of HSF1 and 
Hsp47 have not been previously reported. At present it cannot be stated if these are 
features of keratoconus and this would need to be clarified with additional 
experimentation.
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6.3 Vsxl expression in the cornea is most likely temporally 
expressed by activated keratocytes
The issue of whether Vsxl is expressed in the cornea has added to the 
controversy surrounding its involvement in disease, specifically PPCD and 
keratoconus. We have found that Vsxl is expressed within the cornea at P5, PI2 and 
PI 7 of development and it is the temporal expression of Vsxl which is its most 
important aspect. This is the most likely explanation as to why expression in other 
studies has been so variable. This was the first study to show Vsxl expression in the 
mouse cornea over an important period of development (see chapter 3). Recent 
studies have also demonstrated VSX1 expression in human neonatal corneas (Hosseini 
et al. 2008) which is not surprising given the results in chapter three demonstrating 
Vsxl mouse postnatal expression and other studies that have presented mouse 
neonatal expression (Ohtoshi et al. 2001). So far the location of expression of VSX1 
in the cornea has been only been demonstrated in active keratocytes during wound 
healing (Barbaro et al. 2006). Although it is possible that it could be expressed 
elsewhere in the cornea it is likely that VSX1 temporal expression is going to be linked 
to periods of keratocyte activity. This would help to explain why expression occurs at 
these three time points in development as keratocytes are active at this time (Song et 
al. 2003).
6.4 Vsxl is not linked with PPCD
The initial linkage of VSX1 to PPCD and keratoconus (Heon et al. 2002) 
offered researchers opportunities to probe the possible causes of these diseases. 
However these two diseases are quite distinct and present quite different symptoms, 
so it does raise the question as to how the same gene can be involved in two diseases 
that are so distinct. However, there are other examples of genes which appear to be 
involved in two quite specific diseases with very different phenotypes, so this 
situation would not be at all unusual, for example the BIGH3 gene. Over expression 
of a mutant form of BIGH3 in transgenic mice causes retinal degeneration 
(Bustamante et al., 2008), however other mutations are known to cause Avellino 
comeal dystrophy (El-Ashry et al., 2003; Huerva et al., 2008; Igarashi et al., 2003). 
Keratoconus is a multifactorial complex disorder that leads to the cornea developing a 
cone shape through progressive degradation of its ultrastructure. Posterior
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polymorphous comeal dystrophy {PPCD) is an autosomal dominant endothelial 
comeal dystrophy characterized by vesicular lesions and epithelial-like changes of the 
comeal endothelium The association between VSXJ and PPCD has not been verified 
by sequencing of the VSX1 gene in other studies (Aldave et al. 2005, Krafchak et al. 
2005, Gwilliam et al 2005, Liskova et al. 2007, Hosseini et al. 2008). PPCD is a 
posterior comeal disorder and is most likely due in part to disruptions of the Tcf8 
gene and its actions on Col4a3 (Krafchak et al 2005). It is likely that PPCD is 
caused by multiple genes such as TcfB and Zebl (Krafchak et al., 2005; Liskova et al., 
2007b; Liu et al., 2008).
6.5 Possible functions of the Vsxl gene
6.5.1 Is the action ofVSXl to enhance or is it to repress?
VSX1 is a gene that contains at least one crucial binding domain. It contains 
the homeodomain and the CVC domain, which are of unknown fimctioa It is 
suggested that the homeodomain is involved in binding to target genes and then 
mediating repression. The R166W mutation of VSXJ has been used in conjunction 
with binding assays to show that this mutation reduces repression of activated reporter 
genes (Heon et al. 2002, Dorval et al. 2005). Currently it in unknown what 
downstream genes are the target of VSX1, however expression studies conducted here 
(chapter 3 & 4) demonstrate that Col8a2 and HSF1 may be two possible targets. 
During postnatal development at the time of eye opening Col8a2 expression increases 
significantly at a time point after Vsxl expression also increases (see chapter 3). This 
may be due to eye opening itself. However as Vsxl is expressed in keratocytes, which 
is the point of collagen synthesis, it is possible that Col8a2 may be a direct 
downstream target. If this were the case, then the action of Vsxl would be to act as an 
enhancer of transcription rather then a repressor. Similarly in Vsxl KO mice, 
expression of HSF1 is decreased, which possibly indicates its expression is not being 
enhanced and further supporting the case for a role as an enhancer. Direct functional 
studies would be required in order to test these genes as possible downstream targets 
and would help to elucidate whether VSX1 has dud functionality.
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6.5.21s Vsxl involved in collagen synthesis and reorganisation in the cornea?
An appealing prospect is that VSX1 aids in the synthesis of collagen fibrils in 
the cornea, or at least helps to organise collagen fibrils in the comeal stroma. X-ray 
diffraction studies (see chapter 4) have demonstrated that the fibril organisation in the 
comeal stroma in Vsxl -/- mice is altered from that of the WT. This may occur in two 
ways: either the production of fibrils themselves is downgraded due to a shortfall in 
fibril constituents, or the proteoglycans that aid organisation of fibrils are disrupted. 
The reduced expression of HSF1 and Hsp47 (chapter 4) is an indication that the fibrils 
themselves are being disrupted through downgraded fibril production. Hsp47 is 
involved in chaperoning collagen type I during non-stress situations (Koide, 2004; 
Koide et al., 1999; Koide et al., 2000; Koide et al., 2006; Koide et al., 2002; 
Makareeva and Leikin, 2007; Tasab et al., 2000) and if the chaperoning of these 
constituents is down regulated then this can lead to incorrect helix formation. It has 
been proposed that folding of the triple helix requires stabilization by preferential 
binding of chaperones to its folded, native conformation, which is achieved largely by 
Hsp47. It has also been proposed that it takes over 20 Hsp47 molecules to stabilize a 
single triple helix at body temperature. The required 50-200 pM concentration of free 
Hsp47 is not unusual for heat-shock chaperones in the ER, but it is 100 times higher 
than used in reported in vitro experiments, which did not reveal such stabilization 
(Makareeva and Leikin 2007). In this case if the expression of Hsp47 is reduced, 
through a lack of up-regulation by HSF1 and in turn by VSX1, and then there would 
be a shortage of correctly formed helices. The energetically preferred conformation 
of type I collagen at body temperature is a random coil, which would need to be 
degraded. This would in turn account for the increase in degradation seen in 
keratoconus. Functional studies on Hsp47 in keratoconic corneas would need to be 
examined and compared with similar experiments in the Vsxl KO mouse. Although 
this helps to explain how incorrect synthesis of collagen helices may occur, the direct 
targeting of Vsxl to either HSF1 or Hsp47 must be established before the interaction 
of these 3 genes and their role in keratoconus can be confirmed (see fig 6.1).
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Fig 6.1. A schematic proposed for the actions of VSX1, HSF1 and Hsp47 in the 
correct folding of collagen helices.
The second possibility is that the proteoglycans are altered as a result of VSX1 
disruption. The Vsxl KO model would provide an excellent tool to examine the 
proteoglycans to see if this is the case. Proteoglycans help organise and maintain 
collagen fibrils in the cornea. In keratoconus at least three proteoglycans, decorin, 
biglycan (Funderburgh et al., 1998) and keratocan (Wentz-Hunter et al., 2001) are 
known to be increased in keratoconic corneas. The disruption of collagen fibril 
orientations in the VSX1 KO may possibly indicate a functional pathway. Given the 
proposed repressive functions of VSXJ increased proteoglycan content in Vsxl -/- 
mice would offer a good starting point for further study.
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6.6 The possible mechanisms and causes of keratoconus
Keratoconus is a complex disorder that is progressive up until a point where it 
normally arrests. The time period that keratoconus progresses over can vary 
depending on the severity and is unique to each patient. The findings presented in this 
thesis do offer possible explanations as to how certain mechanisms can lead to the 
reported changes associated with keratoconus, and combined with previous research, 
can help to provide a theory as to its possible cause.
6.6.1 VSXJ is a susceptibility gene for keratoconus
Previous mutation studies indicate a role for VSXJ in keratoconus. The 
mutations that have been discovered all lead to missense mutations within the gene 
that can lead to alterations in binding properties or to protein conformations (see 
chapter 5). When Vsxl expression is removed in the mouse there is a clear and 
statistically altered comeal defect that results (see chapter 4) in a keratoconus 
phenotype. Collagen fibril alignment becomes disrupted and there is a possibility that 
the mass distribution is altered as well. Combined with these alterations, key genes 
also have a reduced expression; Aqp5 expression is reduced as well as HSF1 and 
Hsp47. These findings indicate that VSXJ missense mutations alone may not be 
enough to cause keratoconus, but are enough to trigger a series of events in the cornea 
that will lead to keratoconus depending on other susceptibility factors.
When Vsxl expression is ablated it leads to a keratoconic-like phenotype. The 
mice that were analysed were all young adults so this could explain the degree of 
disruption that was seen in our X-ray experiments. Combined with the inherent 
properties of mouse corneas (the thickness and the size), this would offer an 
explanation as to why no gross changes have been witnessed under histological 
examination (Chow et al. 2004). The electron microscopy was performed in the 
centre of the cornea at a young age (Dr R. Chow personnel communication) and this 
may have missed other changes that were occurring in the periphery of the cornea, 
which is usually the first place for any signs of keratoconus to occur. Mutations in the 
VSXJ gene are being associated with keratoconus; however individual mutations are 
not enough to fully cause keratoconus by themselves as most of these mutations have
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been found in normal controls. The severity and likelihood of a mutation being 
associated with keratoconus depends on the location of the mutation and the nature of 
the mutation. Changes in residue in the crucial binding domains appear more frequent 
than mutations that lie outside these domains (see chapter 5). If the mutation is likely 
to strengthen or weaken binding, such as an introduction of an Arginine residue, then 
the likelihood of keratoconus is increased. It is therefore logical to assume that only 
complete disruption of VSXJ will trigger the start of the disorder but missense 
mutations that do not completely eliminate function require other factors to allow the 
initial disruption to progress (see fig 6.2).
Vsxl Keratoconus
Fig 6.2. Proposed initiation of keratoconus by VSXl. The blue arrow indicated 
missense mutations of VSX1 that does not completely destroy the function. The 
green arrow indicates no expression of VSX1 at all.
If the premise that VSXJ is involved in the synthesis/organisation of collagen 
in the cornea is correct then it is most likely that the initial injury caused by VSXJ 
inactivation would occur during development, as so far this is the only time in the 
cornea when VsxJexpression has been recorded (see chapter 3). This would also fit in 
with the slow progressive characteristics of keratoconus. Human keratoconus 
presents in the teen years and this presentation may be due to an acceleration of the 
growth the entire body undergoes during this time acting on the initial impairment. 
Cases of keratoconus from birth are rare if not non-existent and the presentation of 
keratoconus makes it difficult to screen potential keratoconus candidates for changes 
in VSXJ before clinical presentation.
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6.6.2 Super oxide Dismutase 1 (SOD1) is a susceptibility gene for keratoconus
In similar fashion to VSX1, SOD1 has also been proposed as a candidate gene 
for keratoconus (Udar et al. 2006). A unique genomic deletion within intron 2 close 
to the 5’ splice junction of the SOD1 gene was identified in three patients with KC. 
Moreover, mRNA from one affected individual also had two transcript splice variants 
(LE2 and LE2E3) that others have shown to code for proteins lacking the active site 
of the SOD1 enzyme (Udar et al. 2006). Superoxide dismutase isoenzymes are 
altered in keratoconus (Behndig et al., 2001; Behndig et al., 1998) and there is a long 
established connection between oxidative stress and keratoconus (Atilano et al., 2005; 
Behndig et al., 2001; Brown et al., 2004; Buddi et al., 2002; Chwa et al., 2006a; 
Kenney et al., 2000; Kenney et al., 2005). Since establishing this connection there has 
been a lack of follow up within the scientific community to pursue this link. It is 
likely that, whereas VsxJ disruption would trigger the onset of keratoconus, the 
disruption of SOD1 would act to prevent the acceleration of the disease. Currently 
there are no reports that have examined die cornea in SOD1 KO mice. It may be the 
case that detailed investigation of a SOD1-/- cornea may reveal deficiencies consistent 
with keratoconus but at the moment it is best to class this association as being 
susceptibility rather than causative. SOD1 null mice do have associations with 
cataract formation (Olofsson et al., 2007a; Olofsson et al., 2007b), so it may be the 
case that further eye-related abnormalities are yet to be found. The association made 
thus far is valid and important in understanding the mechanisms of keratoconus but 
further investigations are needed.
6.6.3 Keratoconus is susceptibility dependent and accelerated by oxidative stress to 
the point o f  arresting
The theories presented in the wider scientific literature for keratoconus often 
rely on a single causative factor to explain the initial onset of the disease. However 
with a complex disorder surely this cannot be the case. It is more likely that 
keratoconus has multiple susceptibility factors, which combine together and allow an 
initial trigger to start the degradation. This degradation is then accelerated by an 
incremental build up of oxidative stress that eventually leads to the degradation 
arresting through oxidative stress mediated crosslinks (see fig 6.3).
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Fig 6.3. A flow diagram for keratoconus over time. Green area indicates a time for 
susceptibility factors to become unbalanced. The red arrow indicates the transition 
into keratoconus. The yellow flash denotes the trigger that starts the degradation. 
The red area shows the amount of time where the condition is accelerated by 
oxidative stress. The blue arrow indicates the passage of time. The dashed line 
indicates the normal meridian for comeal rigidity and degradation.
Figure 6.3 is a proposed theory for keratoconus that tries to explain the 
different mechanisms that occur during the progression of the disease. In order for 
keratoconus to develop one or more susceptibility factors must be present in order to 
create an environment that allows the normal cellular mechanisms to become 
unbalanced. When this occurs keratoconus is triggered, which leads to increasing 
levels of oxidative stress over time. Over time as the amount of oxidative stress 
increases the cornea degrades and loses rigidity due to stress related mechanisms, 
either mechanical or cellular accelerated by the increased oxidative stress 
environment. This continues to increase until the formation of glycation end products 
starts to reduce the degradation by increasing rigidity through artificial crosslinks.
This eventually leads to arrest but not quick enough to prevent long term structural 
changes to the cornea as a whole. The severity and degree of keratoconus progression 
would be dependent on the number of susceptibility factors and nature of mutations 
within them.
The susceptibility factors that have been associated with keratoconus have 
traditionally been associated with mechanical stressors, such as the tendency to eye 
rub and eye lid pressures on a weakened cornea (Donnenfeld et al., 1991;
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McMonnies, 2008; Nash et al., 1982; Ozcan and Ersoz, 2007; Weed et al., 2008). 
However all factors eventually require a genetic defect. It is helpful to think about the 
causative factors of cancer when considering keratoconus, as similar principles apply. 
Cancer relies on many mechanisms failing before a tumour develops; cancer 
promoting oncogenes are activated in tumour cells; protection is gained from 
programmed cell death and mechanisms that exist to terminate cells, such as P5 3 are 
inactivated. Keratoconus may shares the same trait, in that multiple mechanisms must 
be weakened or defective in order for the keratoconic phenotype to develop. It may 
be enough in certain rare occasions for a mutation to occur that is so significant in its 
altered function that it could lead to disease on its own, but the mutation screening 
evidence in both SOD1 and VSXJ is showing that, in the most common case, a single 
gene defect is not enough. Once this susceptibility alters the balance in the tissue then 
degradative mechanisms overcome maintenance and development. The trigger of 
keratoconus is a subject of great debate, being a complex disease it is unlikely that 
there is a single causative trigger. In accordance with figure 6.3 the trigger would be 
created when there is an imbalance in the processes necessary for normal comeal 
growth and repair, which is brought about by an accumulation of susceptibility 
factors.
The increased degradative processes generate free radicals and reactive 
oxygen/nitrogen species (Chwa et al., 2006b) that act to further increase their 
production. This also propagates (Brown et al., 2004) the additional characteristics 
seen in keratoconus such as increased mitochondrial damage (Atilano et al., 2005), 
increased proteinase activity (Collier, 2001; Collier et al., 2000; Sawaguchi et al., 
1994; Sawaguchi et al., 1989; Smith et al., 1998), decreased proteinase inhibitors 
(Opbroek et al., 1993; Sawaguchi et al., 1990) and loss of transcripts of alpha-enolase 
and beta actin (Srivastava et al., 2006). The progression of keratoconus normally 
arrests on its own and this is also likely due to the actions of increased oxidative 
stress. This would happen by a similar mechanism to the new treatments that are 
trying to form artificial crosslinks by promoting increased reactive oxygen to cause 
advanced glycation end products to accumulate in the corneas of patients with 
keratoconus (Dawczynski et al., 2002). These have the potential to form crosslinks 
that lock the cornea in place preventing further degradation arresting the condition.
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6.7 Future Experiments
Based on the work carried out in this thesis a number of avenues of research 
should be investigated to see whether the theories presented here can be justified with 
supporting biological evidence. The majority of keratoconus research is directed at 
discovering new genes using mutational studies in order to establish a single causative 
gene, which is probably not the case. However, additional research is needed to 
clarify the existing gene connections that have been established in order to determine 
whether there are any polymorphisms present that may affect their function. Existing 
linkage studies have identified candidate genes (see chapter 1, table 1) which may 
prove to be additional susceptibility factors for keratoconus; each represent 
opportunities to further elucidate functional pathways that can lead to keratoconus if 
unbalanced.
To further clarify the role of VSXJ in keratoconus, the proposed Vsxl KO 
model should be used to investigate the levels of degradative enzymes and inhibitors 
of degradation to see if similar results to human keratoconus corneas can be found. 
Additional EM should also be undertaken in order to clarify the changes that are 
happening in the periphery of the cornea where initial changes start to occur. 
Additional EM should also be undertaken on older mice in the centre of the cornea in 
order to see whether there is any collagen degradation or evidence of fibril slippage. 
The location of Vsxl in mouse development should be investigated in order to see 
whether the expression of Vsxl does indeed occur in stromal keratocytes or if it is 
present elsewhere. If Vsxl is expressed in activated keratocytes then this would 
demonstrate that similar mechanisms are at work in development and wound healing. 
This would also offer support to the role of Vsxl in collagen synthesis. Additionally 
if Vsxl is involved with collagen organisation, which may be apparent due to the 
altered fibril patterning (see chapter 4), then there is a good chance that proteoglycans 
such as decorin, are in some way altered. These glycoproteins should be characterised 
in the Vsxl KO. The model can also be used to examine the development of the 
cornea without Vsxl expression, similar to the developmental X-ray studies conducted 
here in wild type mice (see chapter 3). This would provide the opportunity to see 
whether there is a potential trigger effect that allows an initial defect to manifest and 
then progress to a keratoconic level of alteration. This may determine whether there
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are developmental cues that act as an additional accelerator to keratoconus which 
would provide insights as to why most keratoconus cases present in their teens.
The development of the circum-comeal annulus in the mouse was seen at 
postnatal day 10, a time point which also saw significant changes in the expression of 
Vsxl and Col8a2. However day 10 precedes the crucial period of eye opening. To 
investigate whether the changes presented here are due to eye opening it is necessary 
to repeat the same expression studies and X-ray experiments on mice that do not open 
their eyes. An approach would be to artificially prevent the eyelids from opening and 
carry out the same developmental studies that were performed here. Cell culture 
studies using comeal keratocytes from postnatal mice would provide opportunities to 
see whether Ksx7is expressed while comeal keratocytes are active. If this is the case 
then it would strengthen the argument for Vsxl’s role both in development and wound 
healing and that the pathways involved in both processes are similar.
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ABSTRACT
This study is a comparative study of the relationship between corneal 
structure, morphology, and function in a range of mammalian species. X- 
ray scattering patterns were gathered at regular spatial intervals over 
the excised cornea (and in most cases also the scleral rim) of humans, 
marmosets, horses, cows, pigs, rabbits, and mice. All patterns were ana­
lyzed to produce quantitative information regarding the predominant ori­
entation of fibrillar collagen throughout the tissue. The predominant 
direction of corneal collagen varies between mammals. This variation is 
not related to the size, shape, or thickness of the cornea or the frequency 
with which the animal blinks. A relationship does, however, appear to 
exist between corneal collagen arrangement and visual acuity. An excess 
of collagen directed toward one or both sets of opposing rectus muscles is 
a feature of animals that have an intermediate to high level of visual acu­
ity. There is a significant variation in the arrangement of corneal collagen 
between different mammalian species. This finding may be related to dif­
ferences in the frequency of action and the forces generated by the vari­
ous extraocular muscles during eye movement and image fixation. Anat 
Rec, 290:1542-1550, 2007. © 2007 Wiley-Liss, Inc.
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The cornea, often referred to as “the transparent win­
dow at the front of the eye,” provides a tough external 
barrier to protect the contents of the eye from injury 
while also maintaining a precise curvature to enable 
light to be focussed onto the retina. The mammalian cor­
nea is composed mainly of water and type I collagen 
fibrils, and it is the unique arrangement of this collagen 
that governs the strength, shape, and transparency of 
the tissue. The long, cylindrical collagen fibrils have a 
uniform diameter, a regular separation distance, and lie 
parallel to each other within layers (lamellae), which are 
themselves stacked parallel to the surface of the cornea. 
The diameter and separation distance of the fibrils dif­
fers between species but the proportion of the comeal 
stroma occupied by hydrated collagen fibrils remains 
constant (Meek and Leonard, 1993).
As initially proposed by Kokott (1938) and more 
recently confirmed using x-ray scattering (Meek et al., 
1987; Aghamohammadzadeh et al., 2004; Boote et al., 
2006), most lamellae in the central region of the human
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SPECIES STUDY OF THE CORNEAL STROMA 
TABLE 1. Sam ple details
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Species Sample details Source Storage
Human
Homo sapiens sapiens 
Human
Homo sapiens sapiens 
Human
Homo sapiens sapiens 
Common marmoset 
Callithrix jaccus
Horse
Equus caballus 
Cow
Bos indicus 
Pig
Sus scrofa domesticus 
New Zealand White Rabbit 
Oractolagus cunieulus 
Laboratory mouse 
Mus musculus
Right cornea with 3-mm scleral 
rim. Tagged at superior, (n = 2) 
Paired left and right cornea with 
3mm scleral rim. (n = 2)
Left corneas with 3-mm scleral rim.
Tagged at superior, (n = 2) 
Paired left and right cornea with 
0.5-mm scleral rim. Tagged at 
superior, (n = 20)
Cornea with a 2-mm scleral rim. 
Vertical meridian marked, (n =
3)
Cornea with a 2-mm scleral rim. 
Vertical meridian marked, (n :
5)
Cornea with a 2-mm scleral rim.
Tagged at superior, (n = 3) 
Cornea with a 2-mm scleral rim.
Tagged at superior, (n = 3) 
Cornea with a 0.25-mm scleral rim. 
Tagged at superior, (n = 13)
Great Wall Hospital, 
Bejing, China 
Manchester Eye Hospital, 
UK
Bristol Eyebank, UK 
Oxford University, UK
Abattoir, Bristol, UK
Abattoir, Bristol, UK
Abattoir, Bristol, UK
Heath Hospital, Cardiff, 
UK
Cardiff University, UK
Fixed 10% formalin 
Frozen 80°C 
Frozen -80°C 
Frozen -80°C
Frozen 80°C
Frozen -80°C
Frozen 80° C 
Frozen -80°C 
Frozen 80°C
cornea, particularly in the deeper layers of the stroma, 
lie in the superior-inferior and nasal-temporal direc­
tions. As the tensile strength of connective tissue is 
determined in part by the orientation of collagen fibrils 
in relation to the direction of stress (Jeronimidis and 
Vincent, 1984; Hukins and Aspden, 1985), this has 
prompted suggestions that the preferred orthogonal ori­
entation of fibrils in the central human cornea may be 
necessary to resist the mechanical forces of the four rec­
tus muscles that insert behind the limbus at opposing 
positions along each meridian (Kokott, 1938; Daxer and 
Fratzl, 1997; Newton and Meek, 1998). A limbal annul us 
of collagen surrounds the human cornea and is believed 
to provide additional reinforcement at the point where it 
meets the lesser curved sclera (Maurice, 1984; Newton 
and Meek, 1998; Aghamohammadzadeh et al., 2004).
Based on the birefringence properties of the bovine 
cornea, it was suggested that a nonrandom distribution 
of lamellae was also present in the bovine cornea 
(Kaplan and Bettleheim, 1972). Small-angle light scat­
tering of bovine and rabbit cornea confirmed this to be 
the case in both species (McCally and Farrell, 1982), but 
the authors were unable to determine the precise orien­
tation of the stromal lamellae. Of interest, analysis of 
single x-ray scatter patterns obtained from the central 
cornea of over 50 vertebrate species (which included pri­
mates), revealed the human cornea to be unique in pos­
sessing an arrangement of stromal collagen that is pref­
erentially orientated along both the superior-inferior 
and nasal-temporal meridians (Meek et al., 1987).
X-ray scattering is a powerful technique for studying 
the gross orientation of collagen fibrils in the cornea. As 
comeal collagen molecules lie near axially within the 
fibrils, the high-angle equatorial x-ray scattering pattern 
arising from the lateral packing of the molecules in the 
stroma can be used to determine the preferred direction 
of the fibrils at that position in the cornea. In recent 
years, this method has been used successfully to map 
the predominant orientation of collagen at fine spatial 
intervals throughout the entire human and marmoset
cornea and limbus (Aghamohammadzadeh et al., 2004; 
Boote et al., 2004, 2006).
Given the frequent use of nonhuman species in stud­
ies of corneal biomechanics and that the size and orien­
tation of collagen fibrils largely contributes to biome­
chanical calculations (Jeronimidis and Vincent, 1984; 
Hukins and Aspden, 1985), it is clear that a greater 
knowledge of the precise arrangement of corneal colla­
gen in species other than human is needed. Here, we 
have addressed this issue by using x-ray scattering to 
map the predominant orientation of comeal and limbal 
collagen in the human, marmoset, horse, cow, pig, rab­
bit, and mouse.
MATERIALS AND METHODS 
Tissue Samples
All tissue samples used in this study (Table 1) were 
obtained in accordance with the tenets of the Declara­
tion of Helsinki for the use of human tissue and the 
Association for Research in Vision and Ophthalmology 
(ARVO) statement for the use of animals in ophthalmic 
research.
In the majority of cases, the in vivo orientation was 
marked on the scleral rim at the 12 o’clock position by 
means of a nylon suture or a surgical skin marker pen. 
In the case of the horse, cow, and pig cornea, where the 
in vivo orientation was not known, the vertical meridian 
was identified by the elliptical shape of the cornea. Tb 
minimize tissue dehydration, frozen samples were 
wrapped in Clingfilm (Superdrug Stores Pic., Croy­
don, UK) before freezing in liquid nitrogen-cooled iso- 
pentane. Each sample was defrosted at room tempera­
ture immediately before data collection.
X-ray Scattering Data Collection
High-angle x-ray scatter patterns were collected from 
most samples on Station 14.1 at Daresbury Synchrotron 
Radiation Source (Warrington, UK), using a 200 X 200
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Fig. 1. A pig cornea (with sderal rim) enclosed within a sealed 
sample holder. X-ray scattering patterns were recorded at regular 
intervals across the cornea in the directions indicated by the arrows.
micron beam with a wavelength of 0.1488 nm. The 
images were recorded on a Quantum 4R CCD detector 
(ADSC, Poway, CA) placed 150 mm behind the sample. 
The rare opportunity to use the micro-focus x-ray beam 
(measuring 5 microns in diameter and with a wave­
length of 0.984 nm) on Station ID-13 at the European 
Synchrotron Radiation Facility (Grenoble, France) was 
utilized to obtain comparable x-ray scattering data for 
an additional pig cornea.
Each cornea was placed in its correct orientation into 
a sealed sample holder enclosed between two sheets of 
Mylar (Dupont-Teijin, UK; Fig. 1). The sample holder 
was then carefully positioned onto a computer-operated 
translation stage (Newport Spectra-Physics Ltd., New­
bury, UK) so that the most anterior side of the cornea 
faced the x-ray beam. X-ray scatter patterns resulting 
from an exposure time of 75 sec (human), 150 sec (mar­
moset), 30 sec (pig), and 45 sec (rabbit and mouse) were 
collected over the entire cornea and scleral rim of each 
specimen at regular intervals of 0.8 mm (human), 0.5 
mm (marmoset), 1 mm (pig and rabbit), and 0.2 mm 
(mouse). Due to the large size of the horse and cow cor­
nea and the limited capacity of the specimen holder, x- 
ray scatter patterns resulting from a 20-sec x-ray expo­
sure were collected at 1-mm intervals over a 14-mm 
trephined corneal disc taken from the center of each 
cornea.
X-ray Diffraction Data Analysis
A circular x-ray scatter reflection, formed as a result 
of the interference of x-rays scattered by the collagen 
molecules within the fibrils, was present on each x-ray 
scatter pattern. In cases where the collagen was orien­
tated equally in all directions within the plane of the tis­
sue, a uniform ring of x-ray scatter was formed; how­
ever, when there was an excess of fibrils lying in a par­
ticular direction (Fig. 2A) or directions (Fig. 2B), lobes of 
increased scatter intensity were seen at right angles to 
the dominant orientation of the fibrils.
Using image analysis software (Optimas 6.5, Media 
Cybernetics, UK) and Microsoft Excel (UK), a 0-360 
degree intensity distribution profile was produced for 
each x-ray pattern by measuring the intensity of x-ray 
scatter around the intermolecular reflection (Fig. 2C,D). 
Each intensity distribution profile was normalized 
against the exposure time and the average x-ray inten­
sity during exposure (recorded by an ion chamber placed 
between the x-ray beam and the sample). At this point, 
the signal to noise ratio was improved by folding the in­
tensity profile; this was possible without the loss of any 
data, due to the centrosymmetric nature of x-ray scatter 
patterns. The area under the intensity profile, which is 
proportional to the total amount of collagen through 
which the x-ray beam has passed, can be separated into 
two components—the scatter from collagen lying equally 
in all directions within the plane of the cornea (isotropic 
scatter) and the scatter from collagen fibrils that adopt a 
preferred orientation (aligned scatter) (Fig. 2C,D).
Removal of the isotropic scatter from the intensity 
profile leaves only the scatter from aligned fibrillar colla­
gen. To ascertain the preferred orientation of these 
aligned fibrils, it was necessary to first shift the profile 
by 90 degrees to account for the fact that the high-angle 
equatorial reflection occurs at right angles to the fibril 
axis. Using statistical analysis software (Statistica 7, 
StatSoft Ltd., UK), the intensity profile was then con­
verted into a vector plot (Fig. 2E,F), in which the dis­
tance from the center to the edge of the plot at any 
given angle is proportional to the intensity of x-ray scat­
ter from aligned collagen molecules oriented in that 
direction. Individual vector plots were then compiled 
onto a grid relating to comeal position to show the pre­
ferred orientation of aligned collagen in each cornea.
The specific arrangement of comeal collagen in each 
species was examined alongside published values (where 
available) of comeal size, radius of curvature, and thick­
ness as well as the frequency with which the animal 
blinks (shown as the interval between subsequent 
blinks) and its visual acuity (Table 2). Visual acuity, 
which is measured in cycles per degree of visual field, 
may be defined as the spatial resolving capacity of the 
visual system. It provides a measure of the eye’s ability 
to distinguish one object from another in terms of degree 
angles of visual field.
As no values could be found in the literature for the 
blink interval of the pig, this value was measured by 
assessing videographic footage acquired from nine 
healthy Yorkshire/Landrace mix breed sows housed in 
single stalls for birthing. The time between subsequent 
blinks was recorded in several minute episodes using 
the video time counter, and the average blink interval 
was calculated.
RESULTS
Figure 3A shows the predominant direction of colla­
gen in the human cornea. Within the central 5.6 mm, 
most fibrils lie in the superior-inferior and nasal-tem-
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scatter removed) is displayed as a vector plot, taking into account 
that x-rays are scattered at right angles to the fibril axis. The distance 
from the center of a vector plot in any given direction is representative 
of the amount of collagen fibrils preferentially orientated in that partic­
ular direction.
poral directions, giving rise to a characteristic cross­
shaped vector plot (Newton and Meek, 2001; Aghamo- 
hammadzadeh et al., 2004; Boote et al., 2006). With 
increasing distance from the center of the cornea, the 
size of the vector plots increases, indicating that more 
collagen is highly aligned and the principal direction of 
collagen becomes increasingly tangential with respect to 
the edge of the cornea. A distinct annulus of aligned col­
lagen measuring 1.6-2.0 mm spans the comeolimbal 
region.
A predominantly orthogonal orientation of collagen is 
rarely seen in the marmoset cornea (4 of 20 examined). 
In most cases (16 of 20 corneas examined) an excess of 
fibrils are oriented along the superior-inferior meridian 
(Fig. 3B). As with the human cornea, a well-defined lim­
bal annulus measuring 0.5-1.2 mm is a common feature 
of the marmoset.
X-ray scatter patterns recorded from three equine cor­
neas and three bovine corneas revealed that, in the cen­
tral 14 mm, an excess of collagen is orientated along the
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TABLE 2. C orneal collagen  arrangem ent and published values o f corneal dim ensions, v isu al acuity
and b link interval*
Species
Collagen
direction1
Cornea size (horizontal x  
vertical) (mm)
Radius of 
curvature (mm)
Comeal 
thickness (mm)
Visual acuity 
(cycles/deg)
Blink 
interval (sec)
Human + 11.7 x  10.62 7.82 0.559 47.0-86.013 2 .8 1 8
Marmoset 1 (or +) 6.1 x  5.4s 3.53 0.30s 30.0s 1 4 1 9 .2°
Horse 1 35.0 X 28.54 17.27 0.8110 16.4-20.414 2.319
Cow 1 (or O) 29.0 x  24.04 15.87 0.8011 12.415 2.719
Pig O 15.5 x  12.54 9.07 0.859 8 .0 15 3.821
Rabbit O 13.4 x  13.05 7.35 0.3812 4.316 >3019
Mouse O 3.5 horiz.6 1.4® 0.176 0.517 >3019
“The superscript numbers indicate the following:
1 Co meal collagen arrangement is classified as orthogonal ( + ), vertical ( I) or circumferential (O); 2Tripathi and Tripathi, 
1984; sTroilo et al., 1993; 4Smythe, 1956; 5Bozkir et al., 1997; 6Zhang et al., 1996; 7Coile and O’Keefe, 1988; 8Schmucker 
and Schaeflel, 2004; 9Wollensak et al., 2003; 10Svaldeniene et al., 2004; Scott and Bosworth, 1990; “ Li et al., 1997; 
13Hirsch and Curcio, 1989; 14Timney and Keil, 1992; 15Heffner and Heffner, 1992; 16Vaney, 1980; 17Prusky et al., 2000; 
“ Ponder and Kennedy, 1927; 19Blount, 1927; 20The blink interval of the marmoset is not known but is assumed to be simi­
lar to that of published values for the Sudanese monkey; 21Personal observation.
vertical meridian (Fig. 4AJ3)- Collagen orientation 
appears to be tangential at the edge of the 14 mm tre­
phined disks, but this effect may be an artefact caused 
by trephination. Of interest, examination of a further 
two bovine corneas that were prepared in the same man­
ner revealed the presence of collagen lying parallel to 
the edge of the cornea throughout the central 14-mm 
region and this arrangement of collagen will be referred 
to as “circumferential.” A predominantly circumferential 
arrangement of fibrillar collagen was observed in all pig 
(Fig. 4C), rabbit (Fig. 4D), and mouse (Fig. 4E) corneas, 
and as seen in the human and marmoset, the amount of 
aligned collagen increases at the limbus to form an 
annulus of collagen surrounding the cornea.
As shown in Table 2 and Figure 5, the variation in 
corneal collagen arrangement between species does not 
appear to be correlated with the size (Fig. 5A), radius of 
curvature (Fig. 5B), or thickness (Fig. 5C) of the cornea. 
The average blink interval for the pig was calculated to 
be 3.76 (± 2.0) sec, and when these new data were 
included with those taken from the literature, no rela­
tionship seemed to exist between collagen arrangement 
and blink interval (Fig. 5E). However, a relationship 
does appear to exist between the arrangement of corneal 
collagen and the visual acuity of the animal (Fig. 5D).
DISCUSSION
In this study, we have shown that major differences in 
corneal collagen arrangement exist between mammals 
and, as highlighted in the common marmoset and the 
cow, further structural differences may also exist 
between individuals of the same species. The observed 
variation in collagen arrangement does not, however, 
appear to be related to the size, radius of curvature or 
thickness of the cornea.
It has been suggested elsewhere that the presence of 
an annulus of aligned collagen at the limbus may play a 
role in maintaining the curvature of the cornea at the 
point where it meets the lesser curved sclera (Maurice, 
1984; Aghamohammadzadeh et al., 2004; Boote et al., 
2004). Of interest, a limbal annulus of circumferentially 
aligned collagen appears to be a common feature of all 
animals examined within this study group, despite the
existence of large species differences in the amount of 
curvature change between the cornea and sclera. For 
example in the human, a considerable change in radius 
of curvature occurs between the cornea (7.8 mm) and 
the sclera (11.5 mm; Tripathi and Tripathi, 1984), 
whereas in the rabbit a far less notable change in curva­
ture occurs between the two regions (7.5 and 9.8 mm; 
Hughes, 1972).
Because it is a typical property of most connective tis­
sues that an increased level of stress produces an 
increased level of stress resistance (Reichel et al., 1989), 
it has been suggested in the human cornea that the pre­
dominantly orthogonal alignment of collagen, directed 
toward the insertion points of opposing rectus muscles, 
may provide the tissue with additional strength to resist 
distortion during eye movement (Daxer and Fratzl, 
1997). Electrical activity studies of the human extraocu­
lar muscles have shown that, even when the eye is in 
the primary position, there is considerable activity in all 
of the rectus muscles (Bjork and Kugelberg, 1953). Fur­
thermore, the retraction of the eye during blinking has 
been attributed to the co-contraction of the extraocular 
rectus muscles in the case of the human and the com­
bined action of the rectus and retractor bulbi muscles in 
the rabbit (Evinger et al., 1984). The retractor bulbi 
muscle, which forms an inner muscle cone around the 
optic nerve and assists in retracting the globe, is present 
in the horse, cow, pig, rabbit, and mouse but exists only 
as a rudimentary structure in the monkey and is 
entirely absent in the human (Prangen, 1928). The pres­
ence of four extraocular rectus muscles are, however, 
common to all mammalian species, although the length, 
width, and position of insertion varies between animals 
(Prangen, 1928; Prince et al., 1960). For example, the 
rectus muscles of the monkey and human insert at loca­
tions much closer to the limbus than those of the rabbit 
and pig (Prangen, 1928). Despite all mammalian species 
possessing the same four extraocular rectus muscles, a 
predominantly orthogonal arrangement of corneal colla­
gen is not a common feature of vertebrates and has only 
been observed in the human, a minority of marmosets 
(Boote et al., 2004), and the chicken (personal observa­
tion). It must be remembered at this point that x-ray 
scattering patterns provide an average measurement of
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Fig. 3. A,B: Vector plot maps showing the predominant direction 
of stromal collagen in the human (A) and marmoset (B) cornea and 
scleral rim, sampled at 0.8-mm and 0.5-m m  intervals, respectively. 
Vector plots are scaled down by the factors shown in the key. The 
position of the limbus is highlighted by a  broken blue line.
collagen fibril orientation throughout the entire thick­
ness of the cornea. It is possible therefore that other 
nonhuman species also possess an orthogonal arrange­
ment of lamellae but as suggested by Gyi and colleagues 
(1987), they may be fewer in number or of a reduced 
thickness to those present in the human cornea and 
therefore contribute less to the overall x-ray scatter pat­
tern. Indeed electron microscopy, a technique that can 
be used to provide detailed structural information at 
specific sites in a tissue, has provided evidence of some 
fibrils crossing at right angles to each other in the poste­
rior stroma of the developing mouse cornea (Haustein, 
1983), but x-ray scattering has revealed that, on aver­
age, most stromal collagen in the adult mouse cornea lie 
in a circumferential arrangement with respect to the 
edge of the cornea.
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Here, we have shown that a relationship may exist 
between comeal collagen orientation and visual acuity 
(Fig. 5; Table 2). This apparent relationship may be due 
to animals with a higher level of visual acuity having an 
increased frequency of rectus muscle contraction as a 
result of finer eye movements (Prince et al., 1960). Pri­
mates are exclusive among mammals in their possession 
of a fovea—a small circular region of the retina that has 
a high cone photoreceptor density and affords the ani­
mal with a high level of visual acuity. The alignment of 
collagen in the human cornea toward the insertion 
points of the rectus muscles may play a role in main­
taining a stable eye position during image fixation on 
the fovea and/or resisting comeal distortion caused by 
the co-contraction of antagonistic pairs of rectus muscles 
during blinking. It is worth noting here that, although 
marmosets possess a fovea, have a relatively high level 
of visual acuity (30 cycles/degree; Troilo et al., 1993) and 
likely (based on published values of the blink interval in 
the Sudanese monkey; Blount, 1927) blink at a similar 
frequency to humans, they rarely exhibit an orthogonal 
arrangement of comeal collagen. However, in contrast to 
the human retina, which shows a sharp decrease in cone 
density with distance from the fovea, the marmoset ret­
ina exhibits a much more gradual decline of cone density 
along the horizontal meridian (Troilo et al., 1993). The 
need for such precise horizontal eye movements during 
image fixation may therefore be reduced and the pres­
ence of a predominantly vertical arrangement of colla­
gen may help to preferentially counteract the forces gen­
erated by the superior and inferior rectus muscles. It 
must also be considered that, if comeal collagen 
arrangement is indeed influenced by the stresses exerted 
on the cornea by the action of the extraocular muscles, 
then one might expect the corneas of animals bom and 
raised in captivity to differ from their wild counterparts 
as a result of differences in their visual environment 
and, hence, the frequency and direction of eye move­
ments. As suggested by Barmack (1976), deprivation of 
binocular vision in an animal that normally has excel­
lent binocular vision may reduce the stiffness of the ex­
traocular muscles and cause misalignments.
The need for accurate control of eye position is greatly 
reduced in animals that possess a retina with a visual 
streak (a broad strip of increased cone density), because 
the lateral position of their eyes affords a large field of 
view without the need for extensive eye movement 
(Prince et al., 1960; Barmack, 1976). The horse and cow 
possess an intermediate level of visual acuity (relative to 
the other species studied here), and in the majority of 
cases examined in this study have an excess of vertically 
orientated collagen within the central region of the cor­
nea. A predominantly vertical arrangement of collagen 
in these species may help to counteract the forces of 
the superior and inferior rectus muscles, which act 
antagonistically to help maintain a stable retinal 
image on a horizontal visual streak. In lower visual 
acuity animals such as the pig, rabbit, and mouse, the 
predominantly circumferential direction of comeal col­
lagen does not correspond to the insertion points of 
any of the rectus muscles. In these species, the fre­
quency of rectus muscle contraction may be lower as a 
result of limited eye movement and the possession of a 
retractor bulbi muscle, which helps to retract the eye 
during blinking. Such a relationship between collagen
1548 HAYES ETAL.
(A) COW (B) HORSE
— — —
/  /  - H  % H H s ** -  % -X.
/ / % % H N S S V \ /  • • * % % N
✓ % % x \  X \ s \ \ \ / I 1 J t V % %
\ \ % i \  x N % \ \ \ t t  t 1 f  |  1 % N I / \
X \ \ X 5 '  \  V X \ \ \ , X 1 1 1 ♦ I 1 X \ 1 \
\ \ \ \ 5 X X X \ X \ \ \ \ i t 1 « I l i t  1 t I \ \ t
\  \ \ \ \  V % X \ 5 \ \ \ t i i t i • t i i t V I * ♦ I i
\ N \  \ \  X 5 % \ \ : / i 1 I i i t  i t * I 1 1 i 1
\ \ V S \  \ 5 \ i i / \  i 1 l • t X • 4 * * 1 ♦ i t
\ \ s N X N X 5 5 i i 1 1 i « # f # / t t < i
N \ V v S V -V l * i i # 4 • ? 4 i t i ! /
N A V \  * V ■V ♦ s • t \  i v 1 ♦ t t /
1___
■*» ■V -*r -V 
1
+
1 1
V. %
1
-
* *
l1
7 Omni
1
Omm
1
7.0mm 'Omm
T ■ 
Onun
— \
7 Omm
(C) PIG
+ 1.0m+ 1.5
+ 2.0m+ 3 0
+ 4.0
+ 5.0
+ 6 0
/ t V \ \ 1 \ 1 —
\ X \ \ \ A J .mi $ 1 / ✓
•• +% •• — «• ✓
\ — — — -• — •• — ••> - / /
% •• •• — s •% V >** t / /  * •0 — «• — •• K s %\ t ✓
t * + < - -» •• N N s
V f
t —
i It - - > %S \ \ l »  ..
1 11 i - H V \ \ \ \ \ —  .
i
!
\ \ % V * %\ \ \ X « I — N
— \ \ %\ % •B - \ X
! j
I
\  VN \ \ \ %\ ■w - I \ »»
✓ \ \ \ % •w N % % t i ^ X \
t \ \ % %%- ✓ t ' * X
* X % •w — - *» •• / / /  / \
✓ t V •• - — sf  /  \ \
/ / / N S '* if x \ /
* / / / 1 \ \ \ \
I
/ 1 t 1
1 ■ 1
Omm
(D) RABBIT (E) MOUSE
I
/I
I,
;«
< / 
/  t  
«» ✓
: i 
* i
» \  ••
»i*v
'I - 
?/=
/
\  N N -  '  - /
\ \ \  S  S  N  -  — ^  /  / / -
N  s  s  ~  ^  /  / • •
'/!  '
i f  t i
i i  t *i !i i 1 •/ i • i \ *
\  \  S V '
W  N S  S
\
** ** \ N
: : ; v\ \ N
a
/
V
1
J'1 'I ^
5 5m Onun 5.5m Onun
Fig. 4. A-E: Vector plot maps showing the predominant direction of stromal collagen in the central 14 mm 
of the cow (rotated anticlockwise 30 degrees off axis; A) and horse cornea (B) and in the cornea and scleral 
rim of a pig (C), rabbit (D), and mouse (E). Vector plots are scaled down by the factors shown in the key.
arrangement and eye movement is supported by the 
fact that the stiffness of both the cornea (Jue and Mau­
rice, 1986) and the extraocular rectus muscles (Bar­
mack, 1976) of the rabbit are far lower than that of the 
human.
This study has highlighted that major differences in 
corneal structure exist between mammalian species. 
These differences may be related to variations in the 
direction, frequency, and precision of eye movements, 
however, a functional study of comeal collagen arrange-
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ment and ocular muscle activity is needed to confirm 
this. As a consequence of such interspecies structural 
variation, one should be cautious in interpreting the 
clinical relevance of nonhuman corneal biomechanical 
studies.
ACKNOWLEDGMENTS
The authors thank Dr. Mike MacDonald, Dr. Manfred 
Burghammer, Clarke Maxwell, and Jon Ulmer for their 
help with data collection and Dr. Yifei Huang, Tom
1550 HAYES ETAL.
Kelly, and Dr. Stuart Judge for the provision of speci­
mens. Prof. Keith Meek is a Royal Society-Wolfson 
Research Merit Award Holder.
LITERATURE CITED
Aghamohammadzadeh H, Newton RH, Meek KM. 2004. X-ray scat­
tering used to map the preferred collagen orientation in the 
human cornea and limbus. Structure 12:249-256.
Barmack NH. 1976. Measurements of stiffness of extraocular 
muscles of the rabbit. J Neurophysiol 39:1009-1019.
Bjork A, Kugelberg E. 1953. The electrical activity of the muscles of  
the eye and eyelids in various positions during eye movement. 
Electroencephalogr Clin Neurophysiol 5:595-602.
Blount WP. 1927. Studies of the movements of the eyelids of ani­
mals: blinking. Q J Exp Physiol 18:111-125.
Boote C, Dennis S, Meek KM. 2004. Spatial mapping of collagen 
fibril organisation in primate cornea- an X-ray diffraction investi­
gation. J Struct Biol 146:359-367.
Boote C, Hayes S, Abahussin M, Meek KM. 2006. Mapping collagen 
organisation in the human cornea: left and right eyes are struc­
turally distinct Invest Ophthalmol Vis Sci 47:901—908.
Bozkir G, Bozkir M, Dogan H, Ay can K, Guler B. 1997. Measure­
ments of axial length and radius of corneal curvature in the rab­
bit eye. Acta Med Okayama 51:9-11.
Coile D, O’Keefe LP. 1988. Schematic eyes for domestic animals. 
Ophthalmic Physiol Optics 8:215-220.
Daxer A, Fratzl P. 1997. Collagen fibril orientation in the human 
corneal stroma and its implications in keratoconus. Invest Oph­
thalmol Vis Sci 38:121-129.
Evinger C, Shaw MD, Peck CK, Manning MA, Baker R. 1984. 
Blinking and associated eye movements in humans, guinea pigs 
and rabbits. J Neurophysiol 52:323-339.
Gyi TJ, Elliott GF, Meek KM, Wall RS. 1987. Comparative struc­
tural studies of corneal stromas from a range of different species 
using synchro ton x-ray-diffraction and electron-microscopy. Oph­
thalmic Res 19:32-32.
Haustein J. 1983. On the ultrastructure of the developing and adult 
mouse corneal stroma. An at Embryol (Berl) 168:291-305.
Heffner RS, Heffner HE. 1992. Visual factors in sound localisation 
in mammals. J Comp Neurol 317:219-232.
Hirsch J, Curcio CA 1989. The spatial resolution capacity of human 
foveal retina. Vision Res 29:1095-1101.
Hughes A. 1972. A schematic eye for the rabbit. Vision Res 12:123- 
128.
Hukins DWL, Aspden RM. 1985. Composition and properties of con­
nective tissues. Trends Biochem Sci 10:260-264.
Jeronimidis G, Vincent JFV. 1964. Composite materials. In: Huy- 
kins DWL, editor. Connective tissue matrix. London: Macmillan, 
p 187-210.
Jue B, Maurice DM. 1986. The mechanical properties of the rabbit 
and human cornea. J Biomech 10:847-853.
Kaplan D, Bettleheim FA  1972. On the birefringence of the bovine 
cornea. Exp Eye Res 13:219-226.
Kokott W. 1938. Ubermechanisch-funktionelle strikturen des auges. 
Albrecht von Graefes. Arch Ophthalmol 138:424-485.
Li HF, Petroll WM, Mpller-Pedersen T, Maurer JK, Cavanagh HD, 
Jester JV. 1997. Epithelial and corneal thickness measurements 
by in vivo confocal microscopy through focusing (CMTF). Curr 
Eye Res 16:214-221.
Maurice DM. 1984. The cornea and sclera. In: Davson H, editor. 
The eye. London: Academic Press, p 30.
McCally RL, Farrell RA 1982. Structural implications of small- 
angle light scattering from cornea. Exp Eye Res 34:99-113.
Meek KM, Leonard DW. 1993. Ultrastructure of the corneal stroma -  
a comparative study. Biophys J  64:273-280.
Meek KM, Blamires T, Elliot G, Gyi TJ, Nave C. 1987. The organi­
sation of collagen fibrils in the human comeal stroma: a synchro­
tron x-ray diffraction study. Curr Eye Res 6:841-846.
Newton RH, Meek KM. 1998. Circumcomeal annulus of collagen fibrils 
in the human limbus. Invest Ophthalmol Vis Sci 39:1125-1134.
Newton RH, Meek KM. 2001. Mapping the orientations of the colla­
gen fibrils in human cornea and sclera. Invest Ophthalmol Vis Sci 
42:1517.
Ponder E, Kennedy WP. 1927. On the act of blinking. Q J Exp Phys­
iol 18:89-110.
Prangen A  1928. A study of the comparative anatomy of the extra­
ocular muscles. Trans Am Ophthalmol Soc 26:353-380.
Prince JH, Diesem CD, Eglitis I, Ruskell GL. 1960. Anatomy and 
histology of the eye and orbit in domestic animals. Springfield, 
IL: Charles C Thomas.
Prusky GT, West PWR, Douglas RM. 2000. Behavioural assessment 
of visual acuity in mice and rats. Vision Res 40:2201-2209.
Reichel E, Miller D, Blanco E, Mastanduno R. 1989. The elastic 
modulus of central and perilimbal bovine cornea. Ann Ophthal­
mol 21:205-208.
Schmucker C, Schaeffel F. 2004. A paraxial schematic eye model for 
the growing C57BIV6 mouse. Vision Res 44:1857-1867.
Scott J, Bosworth T. 1990. A comparative biochemical and ultra- 
structural study of proteoglycan-collagen interactions in comeal 
stroma. Functional and metabolic implications. Biochem J 
270:491-497.
Smythe RH. 1966. Veterinary ophthalmology. London: Bailliere, 
Tindall and Cox Ltd.
Svaldeniene E, Paunksniene M, Babrauskiene V. 2004. Ultrasonog­
raphy study of equine eyes. Ultragarsas 4:49-51.
Timney B, Keil K. 1992. Visual acuity in the horse. Vision Res 
32:2289-2293.
Tripathi RC, Tripathi BJ. 1984. The cornea and sclera. In: Davson 
H, editor. The eye. London: Academic Press, p 12.
Troilo D, Howland HC, Judge SJ. 1993. Visual optics and retinal 
cone topography in the common marmoset (callitrix jacchus). 
Vision Res 33:1301-1310.
Vaney DL 1980. A quantitative comparison between the ganglion 
cell populations and axonal outflows of the visual streak and pe­
riphery of the rabbit retina. J  Comp Neurol 189:215-233.
Wollensak G, Spoerl E, Seiler T. 2003. Stress-strain measurements 
of human and porcine corneas after riboflavin-ultra violet-A- 
induced cross-linking. J Cataract Refract Sur 29:1780-1785.
Zhang EP, Schrunder S, Hoffmann F. 1996. Orthotopic corneal 
transplantation in the mouse-a new surgical technique with mini­
mal endothelial cell loss. Graefes Arch Clin Exp Ophthalmol 
234:714-719.
Appendix B
Jack Sheppard
Expression o f Col8a2 between the WT and Vsxl KO
166
Jack Sheppard
110
100
80
WT
70
60
KO
so
40
30
20
10
10 25 30
Cycte
Fig X. Raw expression curves of Col8a2. Samples are indicated by corresponding
arrows. NTC- no template control
Figure X shows that expression was gained for the NTCs along with expression of the 
samples of interest indicating that an incorrect product was being amplified which 
was not the Col8a2 transcript. This was confirmed by melt curve analysis that heated 
the samples until the two strands o f synthesised cDNA became disassociated. From 
the curves gained we could see that there was an incorrect product being formed and 
therefore no expression o f Col8a2 was gained (see fig Y).
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Fig Y. Melt curve for Col8a2. Samples are indicated by corresponding arrows. NTC-
no template control
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KC Study Information Leaflet 11/02/05.
School of Optometry & Vision Sciences, Cardiff University
Tel: 020 2087 6163
Ca r d if f
U N I V E R S I T Y
PRIFYSGOL
Ca'RDW
Dear Sir/Madam
My name is Jack Sheppard and I am a research student at Cardiff University in the 
Ocular Genetics Research Group in the School o f Optometry and Vision Sciences. 
Together with Dr Marcela Votruba, who is my Supervisor, we are investigating 
potential genes that can cause keratoconus and relating any possible mutations with 
structural changes using x ray diffraction.
Our School also has an Optometry Clinic that is open to the public, offering a range 
of services.
We are mainly investigating a gene called VSXJ that is known to be linked to 
keratoconus and posterior polymorphous comeal dystrophy (PPCD). Other potential 
candidate genes that may be involved in keratoconus will also be investigated. As 
part of this study we are planning to screen the DNA of people with keratoconus to 
see if we can find any changes in the sequence or mutations that lead to keratoconus 
or PPCD. This will lead to a greater understanding of how keratoconus can begin and 
what factors can cause mutations within the gene. Novel mutations will lead us in 
new directions o f research and may provide us with ways to identify patients with 
suspected keratoconus quicker and earlier. This research may discover new genes for 
keratoconus that will provide new alleys of research to be explored
Why do we need volunteers?
We are planning to conduct a study on keratoconus and are very keen to recruit as 
many people as we can from the community to make sure it’s a success and help us to 
better understand the condition. This study will run concurrently with another study 
investigating the causes of keratoconus in subjects with Down's syndrome.
We are looking for people who have keratoconus to participate in this study.
What will the study involve?
When you come to the clinic, we will ask you for a sample for DNA analysis. This 
sample may be a mouth wash, buccal scrape (from the inside of your cheek) or a 
blood sample (up to 20 ml max). You can choose which you prefer. Samples will be 
collected by Jack Sheppard and blood will be taken by Dr Marcela Votruba in the 
optometry clinic. If  you are unable to attend the clinic and have been approached
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through a local optician, we can arrange for you to send us a mouth wash sample by 
post.
Where will the study be carried out?
The study will take place in the School of Optometry and Vision in Cardiff 
University. The clinic is situated in the Redwood Building, King Edward VIIth 
Avenue, which is in the centre of Cardiff.
What you should do if you’d like to participate.
If you would like to participate in this study please fill in and return the consent form 
enclosed. Once you have returned it we will contact you to arrange an appropriate 
time for you to come to our clinic, if you are not all ready visiting us. We would like 
to thank you in advance for your cooperation
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Consent Form
Investigating the genes that cause keratoconus
Research to be carried out by Jack Sheppard, Dr Marcela Votruba
Declaration
I have read and understood the above information and have had the opportunity to ask 
questions before proceeding:
I agree to participate in the project.
I am aware that:-
a) My participation is voluntary.
b) I can withdraw from this experiment at any time. My withdrawal will not affect 
the standard of clinical care that I receive.
Name of person participating in the study ___________________________________
Contact Details:
Full name____________________________________________
Address
Telephone number
Signed...................
Witness’ Signature
Date.
Date.
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DEPARTMENT OF OPTOMETRY AND VISION SCIENCES 
HUMAN SCIENCE RESEARCH ETHICS COMMITTEE
Please complete form for consideration by assessors appointed by the Human Science 
Research Ethics Committee. Please submit the completed form, with any related 
correspondence, to the Departmental Office. A subject information leaflet and consent 
form must be included.
PROJECT TITLE:
Investigating genes that may cause keratoconus.
LEAD INVESTIGATOR(S): DEPARTMENT/ADDRESS
1. Dr Macela Votruba, OPTOM
2. Dr Maggie Woodhouse, OPTOM
3.
4.
5.
SPONSORING/COLLABORATING ORGANISATION: Cardiff University
DOES THE SPONSORING/COLLABORATING ORGANISATION PROVIDE 
INSURANCE:
YES/NO*
IF DRUGS ARE USED DO ANY REQUIRE A CLINICAL TRIALS CERTIFICATE OR 
CLINICAL TRIALS EXEMPTION CERTIFICATE?
YES/NO*
* If YES please provide a copy of the certificate.
PHONE:
70134
76522
Jack Sheppard
Ca r d iff
U N I V E R S I T Y
P R I F Y S G O L
CaERPyi9
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SUMMARY OF PROJECT:
1. Starting date 1 April 2005
2. Duration 3 years
3. Location School of Optometry & Vision Sciences
4. Physical procedures mouth wash or buccal scrape or phlebotomy
5. Dmgs or substances to be administered* NONE
* A substance is anything other than normal food. Chemical constituents of food stuffs, 
ethanol and variation of die diet are included as substances.
SUBJECTS:
1. Number of subjects to be used 
As many as possible, above 10.
2. Age and gender of subjects
Subjects to be above 16 years of age, male and female
3. How will subjects be recruited?
By invitation from OPTOM Eye clinics, current Down’s cohort, community
4. Will payments be made to the subjects (if so how much)? NO
5. Will any subjects be excluded and if so on what grounds?
Lack of co-operation
6. Is the activity of the subjects to be restricted in any way either before or after the procedure 
(e.g. diet, driving etc.) NO
HAZARDS:
1. Please give full details o f any hazards which could affect the health safety or welfare of 
any subject:
None other than phlebotomy, which occasionally leads to bruising
2. How do you propose to minimise these hazards?:
Routine measures for careful phlebotomy wil be taken by an experienced practitioner ie Dr 
M Votruba
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3. Is there any precedent for these experiments? If so, please give details with references if 
possible:
Yes: ...
4. Has this project been considered, or is it being considered by any other Ethics Committee? 
If so, please give details and decision made. NO
STATEMENT BY NAMES INVESTIGATORS, HEAD OF DEPARTMENT AND 
RESEARCH SUPERVISOR (if necessary).
I consider that the details given constitute a true summary of the project, and the hazards and 
potential risks to any subject are accurately described.
(Signed)................................................................ (Date)
(Signed)................................................................ (Date)
(Signed)................................................................ (Date)
(Signed)................................................................ (Date)
(Signed)................................................................ (Date)
(Signed) (Date)
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Research protocol 
Investigating candidate genes that cause keratoconus
Aims
The aim of our project is to investigate the role of genes that cause keratoconus in 
human subjects. The gene, VSX1 will be the first gene to be screened for mutation in 
panels from subjects, but this will be followed by other candidate genes that become 
available during the course of the study. We plan to investigate two main groups of 
individuals:
1. Subjects with keratoconus
2. Subjects with Down's syndrome.
Study 1
To investigate the role of genes that are either known to cause keratoconus, or which 
are candidate genes for keratoconus, in a panel of subjects from the UK population 
affected by keratoconus, with or without a positive family history of disease.
Study 2
To investigate the genes that are either known to cause keratoconus or are candidate 
genes for keratoconus in a panel of subjects with Downs’s syndrome and keratoconus 
and compare them to subjects with Downs’s syndrome only.
Hypotheses
Studyl
Keratoconus is a disease in which single gene defects may cause disease 
Study 2
Subjects with Down's Syndrome have a higher incidence of keratoconus because 
they carry mutations in genes that may predispose them to develop keratoconus.
Background
Keratoconus
Keratoconus is a major ocular disease in the western world and the main candidate for 
comeal surgery. It is a non inflammatory progressive comeal thinning disease where 
the shape of the cornea is altered thus changing its optic properties and this leads to 
myopia and irregular astigmatism. The disease progresses until the third or fourth 
decade of life, when it arrests and does not continue to deteriorate or improve. 
However there is a possibility that it may commence again at a later 
stage(Rabinowitz, 1998). Keratoconus has been associated with a vast number of 
other systemic disorders, including Down’s syndrome(Schmitt-Bemard et al., 2000). 
As yet there is no known cure to this disease; however numerous studies are being 
carried out into the structure of keratoconic corneas and its developmental 
mechanisms. Not much is known about the cause of the disease but there is evidence 
that some forms of keratoconus could be hereditary and that the cause in all patients 
could have a genetic contribution.
Current research suggests a number of possible aetiologies for keratoconus; on the 
one hand keratoconus appears to be a multifactorial ectasia, caused by the interplay of 
environmental factors and many genes. On the other hand mutational studies have 
shown that mutations in a single gene, VSX1, can result in keratoconus(Bisceglia et 
al., 2005; Heon et al., 2002; Mintz-Hittner et al., 2004). There are an increasing
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number of genetic loci and mapped genes being associated with keratoconus, although 
this number is still currently low. There are also currently several positional and 
functional candidate genes, including COL4. It is very likely that with the advent of 
linkage and population studies this number will increase.
Visual system homeobox gene 1 (VSXJ) is a gene that codes for a homeodomain 
transcription factor. VSXJ has been shown to be essential for late differentiation and 
function of OFF-cone bipolar cells by regulating, either directly or indirectly 4 
proteins expressed by OFF-cone bipolar cells, recoverin, NK3R, Netol and 
CaB5(Chow et al., 2004). Linkage analysis has been performed in several studies on 
patients with posterior polymorphous comeal dystrophy (PPCD), keratoconus or both 
and the results of these studies have resulted in a number of loci and candidate genes. 
However a positive link was made between keratoconus, PPCD and VSXJ when H6on 
et al (2002) identified the first mutations in patients with PPCD/keratoconus by 
screening the coding sequences of VSX1 in these patients (4 Canadian families and 2 
unrelated individuals). They identified at least 4 mutations that were considered to be 
directly disease causing. Further mutational studies have identified more mutations. 
There are currently 8 mutations that have been found within this gene that give rise to 
keratoconus and FPCD(Bisceglia et al., 2005; Heon et al., 2002; Mintz-Hittner et al., 
2004). Of great interest for our study is that mutations in VSX1 were also shown to 
lead to craniofacial anomalies as well as keratoconus in one family(Mintz-Hittner et 
al., 2004).
Keratoconus and Down's Syndrome
It is well known from the literature that the prevalence of keratoconus in people with 
Down’s syndrome (DS) is much higher than in the normal population. The incidence 
of Down’s syndrome patients presenting with keratoconus is reported to be 
15%(Stoiber et al., 2003). The onset of keratoconus is about the age of 16 years, 
although it is reported to be at a younger age in patients with DS. The progressive 
thinning of the cornea is particularly visible in individuals with DS who are known to 
have thinner corneas in general. The tendency to eye mb has been thought as a 
possible cause of keratoconus and could be significant in people with DS who have a 
higher tendency for eye rubbing(van Splunder et al., 2004). This could aggravate the 
keratoconic progression or possibly start it in the first place.
However, there is clearly a genetic component to KC in DS, just as in subjects with 
KC only. A striking example of an association is given by a study carried out by Lang 
et al (1989), who investigated a small family in Germany. The authors found that the 
mother had autosomal dominant posterior polymorphous comeal dystrophy (PPCD), 
the daughter had bullous keratopathy and showed signs of PPCD and the son had 
Down’s syndrome with acute keratoconus(Lang et al., 1989). This suggests a link 
between DS and KC that is as yet unexplained. Whilst DS is due to trisomy 21, no KC 
genes have to date been located on chromosome 21; however a candidate locus is 
known to exist on the most telomeric region of chromosome 21(Rabinowitz et al., 
1992).
As people with Down’s syndrome have a higher prevalence for keratoconus overall, 
we propose to screen the candidate keratoconus genes, including, VSXJ, in these 
individuals. We wish to explore if patients with KC and DS have mutations in the 
same genes as people with KC only.
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Study Organisation 
Location and Researchers
This research is being carried out in The School of Optometry and Vision Sciences by 
the Ocular Genetics Research Group, in collaboration with the Down's Syndrome 
Study Group.
Genetics:
Dr Marcela Votruba MA PhD FRCOphth 
Mr Jack Sheppard BSc(Hons).
Down's Syndrome:
Dr Maggie Woodhouse 
Ms Ping Ji
Samples will be collected at the Eye Clinic within the School of Optometry and 
Vision Sciences and in local optometric practises and analysis will be carried out in 
laboratories of die School.
Subjects:
Study 1: We shall study individuals with keratoconus, with or without a family history. In 
the presence of a family history we shall recruit the participation of other family members, 
both affected and unaffected. In the absence of a family history we shall recruit the 
participation of a spouse or friend without keratoconus.
Study 2: We shall study subjects in two groups: individuals with Down's syndrome with 
keratoconus and individuals with Down's syndrome without keratoconus. In the presence of a 
known family history of keratoconus we shall recruit the participation of other family 
members, both affected and unaffected.
Recruitment
Study 1: Subjects with keratoconus will be recruited from The Optometry Clinic and 
from the local community through local optometrists. This will be done by personal 
approach, letter, posters and local advertising.
Study 2: Individuals with Down’s syndrome will be recruited from the existing 
cohort at the School of Optometry & Vision Sciences (participating in Ping Ji’s 
study), and additional subjects with the help of local community support nurses.
Study Numbers
We hope to get at least 50 (up to 100) subjects with KC only. We have predicted that 
we may get 20 individuals with KC and DS and 30 individuals with DS only.
Procedures and equipment
DNA will be collected from patients via mouthwash, buccal scrape or blood 
depending on the choice of the patient. This will be done in the optometry clinic or 
mouthwash or buccal scrape samples can be sent by post. Blood samples and buccal 
scrape and mouth wash samples will be stored at -20C.
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Samples will then be analysed using molecular genetic techniques. DNA from blood 
will be extracted using standard protocols and DNA from buccal cells will be 
extracted using the proteinase K protocol. DNA samples will be frozen until they are 
needed. Initially primers that have been designed for the gene VSX1 will be used to 
amplify the DNA using polymerase chain reaction (PCR). Later, as other candidate 
genes become available, primers can be designed for them using the Primer 3 program 
and the DNA can be amplified in the same way. Once the DNA is amplified it can be 
sequenced using the BIG DYE sequencing protocol. This will allow us to search for 
mutations by comparing patient DNA will normal control sequences. Sequences will 
be analysed using the EMBOSS software suite. Mutations can be identified by 
comparing the frequency of the sequence change in the affected group to the control 
population using standard parametric statistics. A mutation would be identified if it 
did not appear significantly in the control group. Segregated within a family would be 
powerful evidence in favour of a sequence change being disease causing, as would the 
results of protein prediction algorithms and conserved amino acid homology searches.
Substances to be administered 
NONE
Expected Outcomes
If our hypotheses are correct then the study would show that keratoconus in 
individuals with DS develops as a result of mutation in genes that also cause KC in 
individuals without DS, and not just due to those genes found on chromosome 21. 
The frequency of these mutations in the two populations will be of considerable 
interest.
We expect to present our scientific results both internally within the University, 
externally, and publish in peer-reviewed journals.
We shall also disseminate our results to the DS Cohort and patient support groups 
involved and interested in DS and / or KC.
Confidentiality and sample storage
All samples will be treated in a confidential manner and analysed in an anonymised 
fashion.
At the end of the Study and Ethical Approval the samples will be destroyed.
Timetable 
Year 1:
First 6 months- recruitment, collection of all subject material for Study 1 and Study 2, 
primer design, optimisation, DNA extraction, storage
Next 6 months- analysis of first candidate gene (VSXJ) in subjects with keratoconus 
and / or DS and keratoconus only 
Year 2 and 3:
Completion of above analysis, including normal controls, segregation etc. Studies of 
additional candidate or known genes that cause keratoconus in die study populations. 
Family studies as made possible by material collected.
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CLINICAL TRIALS CHECK LIST
Under certain conditions it is possible to reduce the time taken to refer clinical trials to our 
insurers. The attached check list has been compiled using the criteria stipulated by our 
insurers. Please complete it and return it to Mr Ken Howells Estates.
A Definitions (from our insurers)
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“Clinical Trials” an investigation or series of investigations conducted on any person for a 
Medicinal Purpose.
“Medicinal product” A substance or article for administration to human beings or animals for 
a medicinal purpose.
“Medicinal purpose”
(a) treating or preventing disease
(b) diagnosing disease or ascertaining the existence degree or extent of a physiological 
condition
(c) assisting with or altering in any way the process of conception or investigating or 
participating in methods of contraception
(d) inducing anaesthesia
(e) otherwise preventing or interfering with the normal operation of a physiological function.
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B Questions Please answer Yes or No in the space provided.
1 Does the Clinical Trial involve volunteers outside Great Britain,
Northern Ireland, The Channel Islands or the Isle of Man?
2. Does the Clinical Trial involve administration of a medical product 
without a Product Licence (as defined in the Medicine Act 1968) or 
outside the terms of a Product licence.
(If the answer to 2 is Yes please answer the following question.
If the answer to 2 is No please continue at question 4)
3. Has the manufacturer of the Medicinal Product provided a “hold 
harmless agreement” in favour of the involved?
4. Does the Clinical Trial involve the use of any procedure other than 
questionnaires and/or venopuncture?
(If the answer to 4 is Yes please answer the following questions.)
5. Does the Clinical Trial involve any consent procedure other than the 
provision of written informed consent by the volunteer.
6. Does the Clinical Trial involve the provision of informed consent by 
any party other than the volunteer?
7. Does the Clinical Trial involve the use of volunteers who are pregnant?
8. Does the Clinical Trial involve the use of volunteers who are under 18 
years old?
9. Does the Clinical Trial involve the use of volunteers who have a 
neoplastic condition?
10. Does the Clinical Trial involve the use of volunteers who have 
diseases of the cardovascular system?
11. Does the Clinical Trial involve the use of volunteers who have a 
neurological disorder?
12. Does the Clinical Trial investigate the AIDS or HIV related condition 
of volunteers who have such a condition?
13. Does the Clinical Trial involve the process of conception or contraception?
14. Does the Clinical Trial involve the undertaking of surgery?
Title of Trial
Signed.......................................................................... Date.
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Project Registration Number:
(For R&D Office use only)
Cardiff & Vale NHS Trust 
Research & Development Office
Project Registration Form (Version 2)
Completion o f this form is required as part o f an application for Trust scientific and risk assessment of any research 
jroposal. The form must be completed by the Principal Investigator or their delegate for all projects, both 
;ommercial and non-commercial, that use any Trust resources. This includes projects led by individuals outside 
Cardiff and Vale NHS Trust. Trust resources include additional staff time, the use o f  a Trust location (including 
ecruitment or consent in Trust clinics/wards), patient samples or patient data (including studies where medical 
ecords only are used).
Investigators must not apply to an ethics committee for ethical approval before receiving written approval 
from the Trust R&D Office. Research Ethics Committees require evidence of prior scientific review as part 
of the ethics application.
Please note that both a fully signed hard copy and an e-mail/disk version o f the Project Registration together with 
all other relevant documentation, as specified in the list at the end o f this form, must be received by the Trust R&D 
Office before a project can be reviewed and approved by the Trust.
You are strongly advised to refer to the R&D Project Registration Procedures and Guidelines document 
before sending your application to the Trust R&D Office.
Research using Cardiff and Vale NHS Trust resources must not proceed until a written letter of approval has 
been received from the Trust R&D Office. Failure to comply with this requirement could result in 
disciplinary action in accordance with the Trust Research Misconduct Policy.
This form has been protected. 
Please use the tab key to take you through the form.
1.0 Details of the Principal Investigator
The person wilh overall responsibility fo r  this project at this site. This person will be used as contact name in lht\ 
National Research Register. This individual should not be a student undertaking an undergraduate or postgraduate 
course. In these cases it must be the student's academic or clinical supervisor.
Surname:
Votruba
Title:
First Name(s):    *
Marcela
Address:
School of Optometry and Vision Sciences, Redwood Building, King Edward VII Avenue, Cardiff CF10 3NB
Phone: Bleep Fax: Email:
2.0 Additional information required for projects which are part of an undergraduate or 
postgraduate course
2.1 Details of Student (N.B. A student cannot be named as the principal investigator)
Surname:
Sheppdi d
Title:
Mi-
First Name(s): 
jack
Address:
School o f Optometry and Vision Sciences, Redwood Building, King Edward VHAvenue, Cardiff CF10 3NB
I
Phone: Bleep Fax: Email:
$920 876471 NA N A  sheppardj@cf.ac.uk
2.2 Details of academic supervisor (indicate if  same as section 1.0) 
Surname:
Same as 1.0
Title:
First Name(s):
‘ i
l
Address:
].
Phone: Bleep Fax: Email:
Students must have a clinical supervisor when the project involves contact with patients recruited via the Trust.
Surname: , I
Same as 1.0
! !j
Title:  .
First Name(s):
2
Address:
Phone: Bleep Fax: Email:
2,4 Title of course/qualification that the research relates to 
PhD, Cardiff University (Genetic and structural pathogenesis of keratoconu
3.0 Permission for inclusion on the National Research Register (NRR)
Can details o f this project be listed on the NRR? Yes ^  No f~~l
SB. Details o f  all projects using NHS R&D resources shall be entered on the NRR unless this breaks confidentiality 
igreements with commercial sponsors, or jeopardises intellectual property rights. It is the responsibility o f  the principal 
mstigator to check that the commercial sponsor agrees to inclusion on the NRR.
4.0 Project Details: (Inform ation fro m  this section will be included on the NRR)
Title Use the same title as on any G rant application or Ethics Committee applications. 
Investigating genes that may cause keratoconus
Shortened Name /Acronym (if appropriate) *
Genes and keratoconus
Lay Summary
Keratoconus (KC) is a condition in which the cornea becomes conical in shape because of the thinning of tht 
cornea. This impairs the vision at both near and distance. It usually starts in late childhood. It can b< 
corrected up to a point with contact lenses, although when KC is more advanced only a surgery will restore 
sight. The genetic causes of KC are being investigated, but so far only a small number of genes have beer 
directly implicated. One of these genes is called VSX1, but it may only be responsible for KC in some 
patients. We intend to screen genes that may cause KC to establish their contribution to the development ol 
KC in a UK population. In the long term, this information may enable us to identify people who will develop 
KC in later life at an earlier stage than is now possible, and thus provide more targeted follow-up anc 
appropriate treatment.
This section m u s t  be comprehensible to a  general audience without any specific knowledge o f  the topic. It i: 
essential to provide a  lay sum m ary in order fo r  the project to undergo peer and risk review (250 words maximum).
Principal Research Question
What is the role and significance o f  mutations in single genes in the development o f keratoconus in a UB 
population.
The principal question or hypothesis addressed by the piece o f  research. Information should be as specific as the researci 
design permits. When a hypothesis is being tested, enter the hypothesis. I f  possible, this should be a single sentence
Methodology
* Use either  the p ick  list o r  the f r e e  text option:
Other
3
Genetic screening and mutational analysis: genetic studies involving the recruitement of subjects, obtaining DNA 
(by buccal swab, mouthwash and venepuncture), screening of patient DNA using PCR, Big Dye sequencing, 
restriction enzyme digest and other mutation detection methods.
,{brief description o f  the methodology to be used
Sample G roup(s)
Patients and their families with clinically diagnosed keratoconus (aged 16+ years).
,{description o f  the notional population(s) from which a sample(s) is drawn for the purposes o f  the study
Outcome Measure
Identification of disease causing mutations in candidate genes that may cause keratoconus in both sporadic and 
familial cases of keratoconus.
Endpoints or factors used to evaluate health status, such as symptoms, physiological/behavioural data, survival discharge 
mtus or quality o f  life.
Project start date, (dd/mm/yy) 01/05/05 Project end date: (dd/mm/yy) 01/05/08 
li is essential to provide an estimate i f  exact dates are not known.
5.0 NHS Ethics Committee Approval
Will ethical approval be sought? Yes [3  No H] Already Obtained I~1 
LREC/MREC Ref:
If you will not be seeking ethical approval please state why you consider this is not required:
6.0 Multicentre Studies
Is this a multicentre trial requiring MREC approval?
For multicentre studies, state the Lead Centre.
School of Optometry and Vision Sciences, Cardiff University
Yes £21 No □
Who is the Chief Investigator for the whole study? i
The C hief Investigator is the authorised healthcare professional or other researcher, whether or not he/she is at 
investigator at any particular site , who lakes prim ary responsibility fo r  the conduct o f  the research including co 
ordinaling the principal investigators who take the lead at each site 
Dr Marcela Votruba
If Cardiff and Vale is the Lead Centre list all other participating organisations
7.0 Funding Details
* Use pick lists: these will appear when you  lab into the relevant box and click on the arrow.
* Category Specific name of funder *Funding Funding Funding *Recipient
Status Requested Received
£ £
4
Research Council Medical Research 
Council
Awarded Other
I
.In most cases commercial fund ing  status will be pending.
:8.0 Staff time associated with the project
* It is essential that the approximate number o f  hours devoted to the project by each investigator be specified 
mincluding the principal investigator).
! Post
; (e.g. Research Nurse.
| Consultant)
1
Name
Title Forename Surname
Department / 
Directorate
* Hours 
devoted 
to project
(Per week)
Employer
(Trust, UWCM, 
Other -  p lease  
specify)
Honorary Consultant
11
1
Dr Marcela Votraba Ophthalmology 
and School of 
Optometry and 
Vision Sciences
5 Other: Cardiff 
University
I Other
1
I
I
Mr Jack Sheppard Ophthalmology 
and School of 
Optometry and 
Vision Sciences
40 Other: Cardiff 
University
1
1
1
!
ii !
j
9.0 Anticipated impact on patient care services
How many patients/ 
volunteers will be 
affected by this research?
What will be the effect o f your research on each 
patient/volunteer?
Study location e.g. clinic, ward 
(state if Trust or UWCM)
Out-patients
i
J-
100 No of additional visits per patient/volunteer none to
Trust/ 
UWCM 
(in 
some 
cases up 
to 1 
visit to 
Cardiff 
Univ.)
Length of each additional visit 30 mins 
No of extended routine visits 0 
Extra time per routine visit (min) 0
Neither: Cardiff School 
of Optometry and Vision 
Sciences
i
j In-patients 0 No of additional day stays per patient 0 0
Day cases 0 No of extra procedures performed per patient 0 0
Operating 
theatre time
0 No of additional hours per patient Q
5
If there is an anticipated reduction in outpatient visits/inpatient day stays/procedures give details:
Specify if outpatients’ visits are in ‘split’ locations (e.g. cardiology outpatient clinic and WHRI) and give details o f 
procedures occurring at each location.
N'A ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ '
10.0 Pharmacy Support
Does the study involve the use o f  medicinal products in addition to those used for the participants normal routine 
patient care? Y e s D  N o 0  I
A signature from  the Pharmacy Clinical Trials Department is required below fo r  all studies involving medicinal 
products. Before this signature can be obtained\ the principal investigator must complete a Pharmacy R&D 
Application Form and send this, together with a copy o f  the protocol, to the Pharmacy Clinical Trials Department.
A minimum o f two weeks is required fo r  Pharmacy to process these applications.
Signature o f Clinical Trials Pharm acist...............................................................  D ate.................................................
I’
11.0 Estimated demand for other support services [
NB For commercial clinical trials that involve a contract with the Trust, this section will be completed by the 
Commercial Trials Office. 3
It is important to include tests/procedures being carried out in the investigator’s own department.
Support
Department
Type of Test Extra tests/ 
therapy 
sessions per 
patient
Estimated 
Total Cost 
£
Department Signatory
(Please sign and print name)
UHW Llandough Dental
RES No.
where
appropriate
(*)
Biochemistry/
Immunology
NA *
Cardiology NA
Dental
Orthodontics
Laboratory
NA
Dental Prosthetics 
Laboratory
NA
Dental
Conservation
Laboratory
NA
Haematology NA *
Histopathology/
Cytology
NA
Medical
Genetics
NA
6
Medical
Photography
NA
Medical Physics NA
Microbiology NA
Radiology NA
Other (please 
specify e.g. 
phlebotomy)
NA
Therapy Sessions
(Please specify)
NA
IB. Indicate if any of the above support is being met by an external funder including commercial sponsors
f ti p *
12.0 Estimated costs of additional NHS purchased consumables
Provide information in terms o f  costs or approximate number o f  items to be used
13.0 Additional drug/treatment costs (Excess Treatment Costs)
Are there any additional drug/treatment costs (Excess Treatment Costs) compared to routine patient care? !
YesQ No E l I
If yes, specify who will be responsible for applying to the Wales Office of Research & Development for., 
reimbursement of these costs.
ii. * "iffi
14.0 Primary care involvement i
Does this project have any resource implications for primary care? I
YesQ No El #
If yes, have these been discussed with the Local Medical Committee (LMC)?
Yes n  No I 1
For Bro Taf LMC, contact Dr Gareth Hayes, M edical Secretary, Tel: 029 2046 5261:
E-mail brotaflmc(dfbrealhemail.nel i
15.0 Confidentiality/Data Protection i
Do all members of the research team who deal with research participants recruited through Cardiff and Vale NHJ, 
Trust hold either substantive contracts or honorary contracts with this Trust?
Yes E  No 1 I
Does the research involve the use of personal data?
Yes E  No ["I
Is the Trust’s Data Protection Officer aware of this research proposal?
YesE N oD
If yes, enter the Reference Number provided to you by the Trust’s Data Protection Officer.
RD05207
It is the Principal Investigator ’s responsibility to ensure that the research complies with the Data Protection Ac\ 
1998 and that the advice o f  the Trust's Data Protection Officer has been sought where appropriate prior tc 
submission o f  this fo rm
Trust Data Protection Officer -  M r Nic Drew, Tel: C ardiff029 20336175
E-mail: Nic.Drew@cardijfandvale. wales.nhs. uk I
Honorary contract request fo rm s shotdd be obtained from  the Trust Human Resources Department. Enquiries 
should be directed to:
Assistant Recruitment M anager -  M s Andrea Page, Tel: Cardiff029 20742917 
E-mail: Andrea.Page@cardiffandvale.wales.nhs.uk
16.0 Consumer Involvement
Indicate how consumers have been or will be involved in the development and execution o f this project:
Subjects and their families with keratoconus will be recruited by direct invitation from Eye Clinics, advertisement* 
in The School o f Optometry & Vision Sciences and through local optometry practises. Currently no UK patien 
support group for keratoconus exists, but publicity for recruitment will also be highligted to potential subjects 
through contact with RNIB, Cardiff Institute for the Blind, Guide Dogs UK and so forth. The scientific 
requirements of the actual mutation screening and study design do not lend themselves to consumer involvement I 
However, consumer issues, such as a need for large print leaflets and forms, general information and feedback, wil p 
be addressed if needed It is very unusual for patients with keratoconus to need large print material \
17.0 Duty of Care »I
Is the Principal Investigator the clinician who has overall responsibility for the care as well as the conduct of the 
research for all local participants in the study?
Yes O  No £3 N ot applicable Q
Give the name(s) and contact details o f  all person(s) who will be responsible for the care of local participants in the 
study, and indicate if the participant’s involvement will be recorded in the relevant notes.
Those subjects recruited from UHW  will be under the care of Mr Vinod Kumar. When a subject is recruited a note 
will be made in the notes and a copy o f  the Consent form filed, although patient care will not be affected at all.
Will this/these person(s) be informed that their patient/client has been invited to participate in this project?
Yes £3 No □  N ot applicable f l
If no, explain why not?
18.0 Indemnity Arrangements
The guidelines document may be o f  assistance to those experiencing difficulties with this section
What arrangements have been made to provide indemnification and/or compensation in the event of a claim by, or 
on behalf of, participants for negligent harm?
Cardiff University
What arrangements have been made to provide indemnification and/or compensation in the event of a claim by, 01 
on behalf of, participants for non-negligent harm?
Cardiff University
19.0 Intellectual Property
Could the research lead to the development of a new product/process or the generation of significant intellectual 
property for the Trust?
Yes □  No ^  Not applicable □
If yes, has this been discussed with the Trust Procurement Department Commercial Manager?
(Mr Colin McMillan Tel: 029 2074 6388, E-mail Colin.McMillan@cardiffandvale.wales.nhs.uk)
Yes [U No I I
Could the research lead to the development of a new product/process or the generation of significant intellectua 
property for any other non-commercial organisation?
Yes □  No ^  Not applicable □
20.0 Plan of dissemination and implementation ]
j
Give a brief description of how the research findings will be disseminated both to those participating in the research 
and to all those who could benefit from them, through publication or other appropriate means. Describe how th<; 
findings will inform the progress of service development and practice. ,
Communication with patient support groups (such as RNIB, Guide Dogs UK) will be established, to include item: 
in newsletters etc. Local sources of publicity will be sought out. The membership the Principal Investigator (D | 
Votruba) of The Cardiff Institute of Tissue Engineering and Repair (CITER) will facilitate dissemination within « 
wider scientific community and publication in peer review journals, presentation at scientific meetings as paper: 
and posters. Service develoment and practice will be little affected by this basic research in the short term, althougl 
in the very long term there is a possibility that screening for mutations in commonly identified genes associate! 
with keartoconus could be offered to patients.
21.0 Benefits to NHS
Give a brief description of the anticipated benefits of the research to the NHS. This may include issues such as staf 
and skills development as well as the potential use of the research findings by the NHS
The findings will inform the progress of service development and practice, in the very long term, by casting light oi 
die fundamental mechanisms of keratoconus. This understanding may eventually allow earlier diagnosis, testing o 
at risk subjects and more rational tailored therapies to be evolved, thus potentially leading to an avoidance o 
surgery in some of these patients.
22.0 Risk Assessment
Use the section below to identify hazards and indicate if adequate safety control measures are in place:-
9
NO The hazard does not apply to this project
Normal Clinical The hazard is present and risk is controlled through the procedures of normal clinical
Practice practice
YES The hazard is present and risk is controlled through the procedures specified below
NO Normal
clinical
practice
YES NO Normal
Clinical
Practice
YES
Drugs/Chemicals h □ □ Genetically 
modified micro­
organisms
X □ □
Ionising radiation M □ □ Solvents and
flammable
materials
□ □
Non-ionising 
radiation (e.g. UV, 
IR etc)
□ Medical devices/
electrical
equipment
m □ □
Lasers X □ □ Manual handling X □ □
Display Screen 
Equipment
X □ □ Other hazards 
(please specify 
below)
□ X □
Give details of the risk control measures which you consider to be needed in addition to those expected of normal 
clinical practice. Describe the severity and likelihood of harm arising from manifestation of the hazard(s). Explain1 
who might be at risk (e.g. clinical staff on the project, other clinical staff, visitors to the area, etc) Explain the risk 
control measures you will implement including the provision of information, instruction, training and supervision, i 
No additional risk control measures above the normal clinical practice will be needed. Routine risks of phlebotom) 
will apply and routine measures will be adopted to protect patients and staff.
I
23.0 Commercial Sponsor Details
Complete this section if the study is a commercially sponsored trial.
Company Name 
NA
Name of Study Co-ordinator (CRA)
Tel Number of CRA
10
DECLARATION
Declaration by the Principal Investigator
• The information in this form is accurate to the best of my knowledge and belief and I take full responsibility for
it.
• I undertake to abide by the principles underpinning the Declaration of Helsinki and Good Clinical Practice 
Guidelines on the proper conduct of research.
• I have read the Trust’s guidance document on Research Governance and understand my responsibilities as 
Principal Investigator.
• If the research is approved I undertake to adhere to the study protocol and comply with any conditions set out by 
the Research Ethics Committee.
• I undertake to inform the NHS Research Ethics Committee of any changes in the protocol, and to submit annual 
reports setting out the progress of the research.
• I am aware of my responsibility to be up to date and comply with the requirements of the law and appropriate1 
guidelines relating to security and confidentiality of patient or other personal data, including the need to register 
with, when appropriate, the Data Protection Officer.
• I understand my responsibility to conform with Health & Safety Regulations.
• I have carried out a risk assessment of the project, identified the hazards involved and assessed the risks arising 
from those hazards. The risks arising from these hazards will be controlled through normal clinical procedures 
unless indicated otherwise in Section 22.0.
• I give my consent for information about non-commercial research to be extracted from this application and 
accompanying protocol for inclusion, where appropriate, in the National Research Register.*
• I understand that personal data about me as a researcher in this application will be held by Cardiff and Vale 
NHS Trust and that this will be managed according to the principles established in the Data Protection Act.
• I understand that my research records/data may be subject to inspection for audit purposes if required.
Signature of the Principal Investigator: ................................................................
Name (printed): ................................................................
Date: ............................................................
^Unless you have specified in question 3.0 that information should not be submitted to the NRR
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Declaration by the Directorate R&D Lead
On behalf o f the Directorate, I have considered all service and financial considerations and confirm that the 
Directorate is willing to support this application. Where there are service or financial implications for other 
Directorates, I can confirm that these have been addressed and that all involved parties are willing to support this 
application.
Signature o f Trust D irectorate R & D  L e a d : ...................................................................
Name (p r in ted ):.........................................................................  D a te : ..................................
Documentation required for Full Application 
Non-commercial Trials
• Trust Project Registration Form (electronic and signed hard copy)
• Protocol containing the required elements (electronic copy)
• Local version o f Patient Information Sheet (electronic copy)
• Local version o f the Consent Form (electronic copy)
• Non-standard questionnaires (all ‘in-house’ questionnaires and those for which a reference on content/use
cannot be provided) (electronic copy)
• Copy of successful grant application for externally funded research (electronic or hard copy)
• For non-commercial grant funded trials, a copy o f any study agreements that need to be signed by the Trust and
the drug company or University that is funding the work
• Evidence of a current Clinical Trials Authorisation (CTA) where applicable (This may be submitted to the office 
at a later date)
Applications will not be processed until all relevant documentation has been received.
Commercial Trials
• Trust Project Registration Form (electronic and signed hard copy)
• Study protocol (five hard copies)
• Local version o f Patient Information Sheet (electronic or hard copy)
• Local version o f Consent Form (electronic or hard copy)
• Sponsor indemnity insurance certificate.
• Evidence of a current Clinical Trials Authorisation (CTA)
R&D approval cannot be granted until all relevant and fully completed documentation has been received.
R&D Office
Cardiff & Vale NHS Trust,
Ground Floor Radnor House 
University Flospital o f Wales 
Heath Park 
Cardiff, CF14 4XW
Tel: 029 2074 3742
Fax: 029 2074 5311
E-mail: Research.Development@CardiffandVale.wales.nhs.uk
12
Date: 09/06/2006 Reference: 06/S0501/61 Online Form
All studies except clinical trials of investigational medicinal products
REC Ref: 06/S0501/61
Short Title of Study: G enes and keratoconus version 2
Cl Name: Dr Marcela Votruba
Sponsor: Cardiff University
Please complete this checklist and send it with your application
♦ Send ONE copy of each document (except where stated)
♦ ALL accompanying documents must bear version numbers and dates (except where stated)
♦ When collating please do NOT staple documents as they will need to be photocopied.
Document Enclosed? Date Version Office use
Covering letter on headed paper O Y e s  O N o
NHS REC Application Form, Parts A&B Mandatory
NHS REC Application Form, Part C (SSA) O Y e s  O N o
Research protocol or project proposal (6 copies) Mandatory
Summary C.V. for Chief Investigator (Cl) Mandatory
Summary C.V. for supervisor (student research) O Yes O No
Research participant information sheet (PIS) O Yes O No
Research participant consent form O Y e s  O N o
Letters of invitation to participants O Yes O No
GP/Consultant information sheets or letters O Yes O No
Statement of indemnity arrangements O Y e s  O N o
Letter from sponsor O Yes O No
Letter from statistician O Yes O No
Letter from funder O Yes O No
Referees' or other scientific critique report O Yes O No
Summary, synopsis or diagram (flowchart) of 
protocol in non-technical language O Y e s  O N o
Interview schedules or topic guides for 
participants O Y e s  O N o
Validated questionnaire O Yes O No
Non-validated questionnaire O Yes O No
Copies of advertisement material for research 
participants, e.g. posters, newspaper adverts, 
website. For video or audio cassettes, please also 
provide the printed script.
O Yes O No
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WELCOME TO THE NHS RESEARCH ETHICS COMMITTEE APPLICATION FORM
An application form specific to your project will be created from the answers you give to the following questions. £ $  Please read 
this guidance carefully before selecting your answers.
1. Is your project an audit or service evaluation?
O Yes 0  No
2. Select one research category from the list below:
O  Clinical trials of investigational medicinal products (including phase 1 drug development)
O  Clinical investigations or other studies of medical devices 
O  Other clinical trial or clinical investigation
O  Research administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative 
methodology
O  Research involving qualitative methods only
0  Research limited to working with human tissue sam ples and/or data
If your work does not fit any of these categories, select the option below:
O  Other research
2a. Please answer the following questions:
a) Will you be taking new human tissue sam ples? 0  Yes O N o
b) Will you be using existing human tissue sam ples identifiable to the researcher? O Y e s 0  No
c) Will you be using only existing human tissue sam ples anonymous to the researcher? O Y e s 0  No
d) Will you be using identifiable data? 0  Yes O N o
e) Will you be using only anonymous or pseudonymised data? O Y e s 0  No
3. Is your research confined to one site?
O  Yes 0  No
4. Does your research involve work with prisoners?
O  Yes 0  No
5. Does your research involve adults unable to consent for themselves through physical or mental incapacity?
O  Yes 0  No
6. Is the study, or any part of the study, being undertaken as an educational project?
0  Yes O  No
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NHS Research Ethics C om m ittee^SI
Appiication form for research limited to working with human tissue samples and/or data__________
This form should be completed by the Chief Investigator, after reading the guidance notes. See glossary for clarification 
of different terms in the application form.
Short title and version number: (maximum 70 characters -  this will be inserted as header on all forms)
Genes and keratoconus version 2
Name of NHS Research Ethics Committee to which application for ethical review is being made:
Fife & Forth Valley LREC
Project reference number from above REC: 06/S0501/61 
Submission date: 09/06/2006
PART A: Introduction
A1. Title of the research
Full title: Investigating genes that may cause keratoconus.
Key words: keratoconus, genes, VSX1
A2. Chief Investigator
Title: Dr
Forename/Initials: Marcela
Surname: Votruba
Post: MRC Clinician Scientist, Flon Consultant Senior Lecturer
Qualifications: MA PhD FRCOphth
Organisation: Cardiff University
Address: Cardiff University, Redwood Building
King Edward VII Avenue
Cardiff
Post Code: CF10 3NB
E-mail: votrubam@cardiff.ac.uk
Telephone: 44 (0)29 2087 0134
Fax: 44 (0)29 2087 4859
A copy of a current CV (maximum 2 pages of A4) for the Chief Investigator must be submitted with the appiication
A3. Proposed study dates and duration
Start date: 01/07/2006
End date: 01/07/2008
Duration: Years: 2 ; Months:
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A4. Primary purpose of the research: (Tick as appropriate)
□  Commercial product development and/or licensing 
0  Publicly funded trial or scientific investigation
0  Educational qualification
□  Establishing a database/data storage facility
□  Other
A6. Does this research require site-specific assessment (SSA)? (Advice can be found in the guidance notes on this topic.) 
O  Yes 0  No 
If No, please justify:
The procedures involved are routine and only involve the study patient giving a DNA sample via mouthwash.
If Yes, Part C of the form will need to be completed for each research site and submitted for SSA to the relevant Local 
Research Ethics Committee. Do not submit Part Cs for other sites until the application has been booked for review and 
validated by the main Research Ethics Committee.
Management approval to proceed with the research will be required from the R&D Department tor each NHS care organisation 
in which research procedures are undertaken. This appiies wheiher or noi the research is exempt from SSA.
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PART A: Section 1
A7. What is the principal research question/objective? (Must be in language comprehensible to a lay person.)
What is the role and significance of mutations in single genes in the development of keratoconus in a UK population. This 
question aims to address the ongoing debate whether a gene called Vsx1 is responsible in causing keratoconus by 
screening a UK population of patients. This is the first study to screen this gene in Wales.
A8. What are the secondary research questions/objectives? (If applicable, must be in language comprehensible to a lay 
person.)
A9. What is the scientific justification for the research? What is the background? Why is this an area of 
importance?(M/sf be in language comprehensible to a lay person.)
Keratoconus is a major eye disease in the western world and the main candidate for corneal surgery. It is a disease in which 
the shape of the cornea is altered, thus changing its optical properties, and leading to blurred vision. The disease 
progresses until the third or fourth decade of life, when it usually stops. However there is a possibility that it may commence 
again at a later stage. Keratoconus has been associated with a vast number of other conditions, including Down's 
syndrome. At the moment early stages of keratoconus can be treated with hard contact lenses but as sight worsens only a 
surgery can fully restore sight. As yet there is no known cure for keratoconus other than corneal grafting; however 
numerous studies are being carried out into the structure of affected corneas and its developmental mechanisms.
There is evidence that keratoconus is inherited in som e patients and families and that the cause in all patients could have a 
genetic contribution. There is an increasing amount of evidence that this is the case and a number of potential locations 
within a persons DNA have been found that might have a mutation leading to keratoconus. Current research suggests a 
number of possible genetic causes for keratoconus; on the one hand keratoconus may have multiple mutations causing it 
or on the other hand it may be primarily a single gene defect in some families and individuals. To date one candidate 
gene, VSX1, has been associated with keratoconus and mutations in this gene have been determined to be disease 
causing. A total of eight different mutations have been found so far. Mutation in VSX1 has also shown to lead to 
craniofacial anomalies in addition to keratoconus in one family. Mutations in VSX1 have also been linked with another 
corneal disorder, posterior polymorphous corneal dystrophy (PPCD).
There are a number of other candidate genes that may, by virtue of their position on a persons DNA or by their proposed 
function, be implicated in the genetic cause of keratoconus. We plan to screen for mutations firstly in the VSX1 gene as this 
gene is the foremost linked with keratoconus. We then will screen the other genes dependent on availability of primer 
sequences and reported functions in the literature.
The principle hypothesis that we are investigating is that keratoconus is a disease in which mutations in single genes may 
cause disease. Our rationale for this is that in the gene, VSX1, eight mutations have been found segregating in families and 
have been shown to cause keratoconus or posterior polymorphous comeal dystrophy in individuals in these families. The 
• mutations were also shown to be inherited within these families. We believe that there may be other genes like VSX1. By 
gathering a cohort of keratoconus patients we hope to find novel mutations as well as confirm existing mutations in a 
population within the UK. This research is necessary and important because in the long term, this information may enable 
us to identify people who will develop KC in later life at an earlier stage than is now possible, and thus provide more targeted 
follow-up and appropriate treatment.
A10. Give a full summary of the purpose, design and methodology of the planned research, including a brief 
explanation of the theoretical framework that informs it. It should be clear exactly what will happen to the research 
participant, how many times and in what order. Describe any involvement of research participants, patient groups or 
communities in the design of the research.
This section must be completed in language comprehensible to the lay person. It must also be self-standing as it will be 
replicated in any applications for site-specific assessment on Part C. Do not simply reproduce or refer to the protocol. Further 
guidance is available in the guidance notes.
The design of the investigation does not lend itself to scrutiny in the public domain as subject involvement is minimal. 
However the methodology of this investigation is very similar to other research studies that have been carried out in the past. 
Once ethical approval has been granted invitation letters will be sent to prospective volunteers who are existing patients 
seeing participating ophthalmologists in the study. If they agree to the study or request more information an information 
leaflet along with a consent form will be sent to them. Upon written consent being obtained a 'sample kit' containing 
instructions and a small tube containing salt water (saline) will be sent to them. This would theoretically be returned as soon
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as possible to Cardiff University Similarly if patients are seeing their ophthalmologist they could be informed of the study 
and give consent followed by the sample at their visit. All samples would go to Cardiff University for testing and analysis. 
That would be the extent of subject contact providing a mutation is not found.
Once sam ples have been delivered they will be analysed using molecular genetic techniques. DNA will be extracted and 
amplified up using a known short sequence of single stranded DNA called primers. Once the DNA has been amplified it will 
be sequenced using the BIG DYE sequencing protocol. The sequences will then be analysed using bioinformatical 
techniques and the EMBOSS software suite. This will provide data on any changes in sequence present within the 
samples. Throughout the process sam ples will be coded and only if something is found within a sequence will the sample 
be traced back to the subject and that subject informed. The subject will be provided with any information they wish and 
counselling should the need arise. The subject will then be asked if they can recruit any of their relatives. This would be 
the only second time that the subject is consulted by us. We will of course provide any additional information at any time 
should the subject request it. The theory behind this investigation is that changes in a subjects DNA can lead to the 
presentation of the corneal d isease keratoconus and that these changes can be inherited and can be seen as localising to 
certain families, though this can only be found provided relatives are also screened.
A12. Give details of any clinical intervention(s) or procedure{s) to be received by research participants over and above 
those which would normally be considered a part of routine clinical care. (These include uses of medicinal products or 
devices, other medical treatments or assessments, mental health interventions, imaging investigations and taking samples of 
human biological material.)
Additional
Intervention Average number per participant
Average time 
taken
(mins/hours/days)
Details of additional intervention or 
procedure, who will undertake it, and 
what training they have received.
Routine Care Research
Other tissue/bodily 
sample 1 1/0/0
A mouthwash of 15mt 0.9% sterile saline 
solution will be given by the subject under 
the supervision of either the PI, 
researcher, consultant or GP. No training 
is necessary.
A13. Give details of any non-clinical research-related  intervention(s) or procedure(s).(These include interviews, 
non-clinical observations and use of questionnaires.)
Additional Intervention
Average 
number per 
participant
Average time 
taken
(mins/hours/days)
Details of additional intervention or procedure, who 
will undertake it, and what training they have 
received.
A15. What is the expected total duration of participation in the study for each participant?
5 minutes
A17. What is the potential for pain, discomfort, d istress, inconvenience or changes to lifestyle for research 
participants?
Very minimal, in the short term a visit to participate in research in a participating centre near the volunteer, or a short 
mouthwash routine for 1 morning. In the long term if the patient has a mutation they will be informed and any extra 
information or counselling will be provided. However there should be minimal distress if any.
If a particular mutation happens to be found in a control subject or subjects then this change would be considered non 
disease causing as it appears in a patient that does not have keratoconus, in which case there is no need to take any 
particular action to do with the affected patient as it has no bearing on the affected individual. The purpose of the study is to 
discover what changes occur in the target patient group compared to the control group.
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A18. What is the potential for benefit to research participants?
Participants will be more informed about their condition if this applies.
A19. What is the potential for adverse effects, risks or hazards, pain, discomfort, distress, or inconvenience to the 
researchers themselves? (if any)
none
A20. How will potential participants in the study be (i) identified, (ii) approached and (iii) recruited?
Give details for cases and controls separately if appropriate:
Patients will be initially recruited if they have clinically diagnosed keratoconus. A letter of invitation of participation will be 
sent to existing patients of ophthalmologists and the Cardiff University Eye Clinic upon ethical approval. The age of onset 
of keratoconus is generally from the mid teens to early twenties. We hope to recruit individuals for this study who are 16 
years or above Patients will be identified from patient records within the Optometry clinic in Cardiff and from consultant 
ophthamlmologists who are participating in the study. We aim to recruit 100+ individuals for the study from a number of 
different centres around the country. If this initial study is successful then additional family members will also be recruited 
and all who give consent will have sam ples taken.
A control population will be recruited initially form spouses and partners of affected individuals. These individuals are 
unrelated and so do not have the sam e genetic background. More control individuals shall be recruited through 
advertisements placed in participating institutions and centres and information will be provided about the study upon contact 
with the principle investigator.
A21. Where research participants will be recruited via advertisement, give specific details.
□  Not Applicable
Posters explaining the nature of the study, patient involvement and contact details will be placed in participating institutions. 
Care will be taken to make sure that the advertisement material is open and clear and able to be read by all.
If applicable, enclose a copy of the advertisemenVradio scnptM'ebsiie/Video for television (with a version number and date).
A22. What are the principal inclusion criteria?(Please justify)
Individuals for the study will be included if they have clinically diagnosed keratoconus. Consenting individuals will also be 
included if they are related to an affected individual.
A23. What are the principal exclusion criteria7(Please justify) 
Exclusion will be based on non-compliance.
A24. Will the participants be from any of the following groups?/77c/c as appropriate)
□  Children under 16
O  Adults with learning disabilities 
(Z3 Adults who are unconscious or very severely ill 
Q  Adults who have a terminal illness 
O  Adults in emergency situations
□  Adults with mental illness (particularly if detained under Mental Health Legislation)
□  Adults with dementia 
f~~l Prisoners
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D  Young Offenders
EH Adults in Scotland who are unable to consent for themselves 
0  Healthy Volunteers
\3  Those who could be considered to have a particularly dependent relationship with the investigator, e.g. those in care 
homes, medical students 
l~] Other vulnerable groups
Justify their inclusion.
Healthy volunteers will be recruited to provide an age and background matched controls.
No other group will be included
A25. Will any research participants be recruited who are involved in existing research or have recently been involved in 
any research prior to recruitment?
O  Yes O  No 0  Not Known
If Yes, give details and justify their inclusion. If Not Known, what steps will you take to find out?
Patients will be asked upon their given consent.
A26. Will informed consent be obtained from the research participants?
0  Yes O  No
If Yes, give details of who will take consent and how it will be done. Give details of any particular steps to provide information 
(in addition to a written information sheet) e.g. videos, interactive material.
If participants are to be recruited from any o f the potentially vulnerable groups listed in A24, give details of extra steps taken 
to assure their protection. Describe any arrangements to be made for obtaining consent from a legal representative.
If consent is not to be obtained, please explain why not.
Consent shall be obtained from a consent form given to the prospective volunteer upon initial interest by the volunteer and 
some form of agreement, i.e. verbal, written agreement and if they ask for more information. Information shall be provided 
in an information leaflet and additional information can be provided by the recruiting ophthalmologists, principle investigator 
or researcher upon request.
The same consent form shall be used for both the study group and control group
Copies of the written information and all other explanatory material should accompany this application.
A27. Will a signed record of consent be obtained?
0  Yes O  No
If Yes, attach a copy of the information sheet to be used, with a version number and date.
A28. How long will the participant have to decide whether to take part in the research?
Subjects will have a period of between 1 week to 3 months to decide if they wish to participate.
A29. What arrangements have been made for participants who might not adequately understand verbal explanations or 
written information given in English, or who have special communication needs? (e.g. translation, use of interpreters etc.)
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Translations will be provided and copies of all information will be made available in a different language upon request. As 
the study will be conducted in Wales, welsh and english forms will be provided.
A31. Does this study have or require approval of the Patient Information Advisory Group (PIAG) or other bodies with a 
similar remit?(see the guidance notes)
O Yes ®  No
A32a. Will the research participants' General Practitioner be informed that they are taking part in the study?
(•) Yes O No
If Yes. enclose a copy of the information sheet/letter for the GP with a version number and date.
A32b. Will permission be sought from the research participants to inform their GP before this is done?
®  Yes O  No
If No to either question, explain why not
It should be made clear in the patient information sheet if  the research participant's GP will be informed.
A33. Will individual research participants receive any payments for taking part in this research?
O Yes ®  No
A34. Will individual research participants receive reimbursement of expenses or any other incentives or benefitslor 
taking part in this research?
O Yes ®  No
A35. What arrangements have been made to provide indemnity and/or compensation in the event of a claim by, or on 
behalf of, participants for negligent harm?
NHS indemnity applies
Please forward copies o f the relevant documents.
A36. What arrangements have been made to provide indemnity and/or compensation in the event of a claim by, or on 
behalf of, participants for non-negligent harm?
No compensation arrangements are available under NHS indemnity
Please forward copies o f the relevant documents.
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A37. How is it intended the results of the study will be reported and disseminated?(T/ck as appropriate)
0  Peer reviewed scientific journals
0  Internal report
S  Conference presentation
1 i Other publication
0 3  Submission to regulatory authorities
□  A ccess to raw data and right to publish freely by all investigators in study or by Independent Steering Committee on 
behalf of all investigators
0  Written feedback to research participants
□  Presentation to participants or relevant community groups
□  Other/none e.g. Cochrane Review, University Library
A38. How will the results of research be made available to research participants and communities from which they are 
drawn?
Peer reviewed journal papers will be made available to participants if they wish.
A short report detailing the findings that are relevant to the subject will be sent to them upon completion of their involvement 
in the study.
A39. Will the research involve any of the following activities at any stage (including identification of potential research
participants)?(T/ck as appropriate)
0  Examination of medical records by those outside the NHS, or within the NHS by those who would not normally have 
access
f~l Electronic transfer by magnetic or optical media, e-m ail or computer networks 
("I Sharing of data with other organisations 
0 ]  Export of data outside the European Union
0  Use of personal addresses, postcodes, faxes, e-m ails or telephone numbers 
0  Publication of direct quotations from respondents 
0 ]  Publication of data that might allow identification of individuals 
0 ]  Use of audio/visual recording devices  
0  Storage of personal data on any of the following:
□  Manual files including X-rays 
0  NHS computers
□  Home or other personal computers 
0  University computers
f~l Private company computers 
n  Laptop computers
Further details:
A40. What measures have been put in place to ensure confidentiality of personal data? Give details of whether any 
encryption or other anonymisation procedures have been used and at what stage:
Samples gathered will be anonymised to ensure confidentiality. Patients will be not be referred to directly and only the 
principle investigator and researcher will have access to the real data.
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A41. Where will the analysis of the data from the study take place and by whom will it be undertaken?
Analysis will take place within the School of Optometry and Vision Sciences at Cardiff University and will be carried out by 
the principle investigators research student.
A42. Who will have control of and act as the custodian for the data generated by the study?
Data will belong to Cardiff University
A43. Who will have access to the data generated by the study?
Data will be available to the pricipie investigator and the researcher.
A44. For how long will data from the study be stored?
10 Years Months
Give details o f where they will b e  stored, who will h ave  a cce ss  and  the custodial arrangements for the data:
Data will be stored on optical media at Cardiff University and data will belong to Cardiff University and be made available to 
the PI and researcher in the School of Optometry and Vision Sciences.
A45-1. How has the scientific quality of the research been assessed?(Tick a s appropriate)
Cl Independent external review
□  Review within a company
□  Review within a multi-centre research group
0  Internal review (e.g. involving colleagues, academic supervisor)
□  None external to the investigator
□  Other, e.g. methodological guidelines (give details below)
Justify and describe the review  p ro cess  and  outcom e. If the review  has b een  undertaken but not seen  by the researcher, 
give details o f the body which has undertaken the review:
Local ethical approval and R&D approval has been granted by Cardiff University and the Cardiff and Vale/ Glamorgan Vale 
NHS Trust
If you are in possession  o f any  referees' com m en ts or other scientific critique reports relevant to the proposed research, these  
m ust be enclosed  with the application.
A45-2. Has the protocol submitted with this application been the subject of review by a statistician independent of the 
research team?(Select one  o f the following)
O Yes -  copy of review enclosed
O  Yes -  details of review available from the following individual or organisation (give contact details below)
<•) No -  justify below
The research being conducted d oes not rely on finding a statistical difference and relies instead on finding actual mutations 
within a gene that g o es  not need statistical analysis
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A48. What is the primary outcome measure for the study?
if our hypothesis is correct then the study would show that keratoconus in some individuals develops as a result of single 
mutation in a candidate gene. The frequency of these mutations in the study population will be a measurable outcome 
however the primary outcome will be the actual changes found within the gene.
A49. What are the secondary outcome measures?/// any)
A5Q. How many participants will be recruited?
If there is m ore than one  group, sta te  how  m any participants will be  recruited in each group. For international studies, sa y  how  
m any participants will be  recruited in the UK a n d  in total.
We will aim to recruit 100+ affected individuals with a control group to be consisting of several hundred individuals. Age and 
background matched controls shall be sought from the local population through advertisement.
A51. How was the number of participants decided upon?
A snowballing approach to recruitment will be used to gather research participants. As we intend to look for mutations the 
chance of finding them is increased with a larger population size. Participants are being recruited through local 
opthalomogists and corneal specialists at the local hospital. Once ethical approval has been gained contact shall be made 
with willing collaborators who have existing contact with affected individuals.
If a formal sam ple s ize  calculation w as used, indicate how  this was done, giving sufficient information to justify and  
reproduce the calculation.
A52. Will participants be allocated to groups at random?
O  Yes 0  No
A53. Describe the methods of analysis (statistical or other appropriate methods, e.g. for qualitative research) by which 
the data will be evaluated to meet the study objectives.
Mutation frequency will be analysed using T Test, Chi-square, and simple parametric statistics comparing frequency of 
mutation or DNA change detected in affected subjects versus unaffected subjects.
A54. Where will the research take place?/77ck a s  appropriate) 
0  UK
i~l Other states in European Union
FI Other countries in European Economic Area
□  Other
If Other, give details:
A55. Has this or a similar application been previously rejected by a Research Ethics Committee in the UK, the European 
Union or the European Economic Area?
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A56. In how many and what type of host organisations (NHS or other) in the UK is it intended the proposed study will 
take place?
Indicate the type o f organisation by  ticking the box and give approximate numbers if known:
Number of 
organisations
0  Acute teaching NHS Trusts 4
CD Acute NHS Trusts
CU NHS Primary Care Trusts or Local Health Boards in Wales
□  NHS Trusts providing mental healthcare
□  NHS Health Boards in Scotland
□  HPSS Trusts in Northern Ireland 
D  GP Practices
D  NHS Care Trusts
I"] Social care organisations
FI Prisons
CU Independent hospitals 
[J Educational establishments 
i~l Independent research units
□  Other (give details)
Other:
A57. What arrangements are in place for monitoring and auditing the conduct of the research?
The audit of the research and the monitoring of how it is performed is under the control of the Chief investigator, who will 
adhere to all clinidal governance guidlines and research governance guidelines.
Will a data monitoring committee be convened?
O  Yes <•> No
If Yes, details o f m em bership  o f the data monitoring com m ittee (DMC), its standard operating procedures and summaries o f 
reports o f interim analyses to the DMC m u st b e  forwarded to the NH S Research Ethics Committee which g ives a favourable 
opinion o f the study.
What are the criteria for electively stopping the trial or other research prematurely?
The research would be stopped once enough patients have been gathered.
A58. Has external funding for the research been secured?
O Yes ®  No
If No, what arrangements are being made to cover any costs of the research? If no external funding is being sought, 
please say so:
Funding is available from within the School of Optmetry & Vision Sciences, Cardiff University and within the Investigators 
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research funds.
A59. Has the funder of the research agreed to act as sponsor as set out in the Research Governance Framework?
O Ves ®  No
Has the employer of the Chief Investigator agreed to act as sponsor of the research?
®  Yes O  No
Sponsor (must be completed in all cases)
Name of organisation which will act a s sponsor for the research:
Cardiff University 
Status:
O NHS or HPSS care organisation (•> Academic O Pharmaceutical industry O Medical device industry O Other 
If Other, please specify:
Address:
Post Code: 
Telephone: 
E-mail:
Cardiff University, Redwood Building 
King Edward VII Avenue 
Cardiff 
CF10 3NB 
Fax:
The responsibilities o f the sponsor m a y  b e  shared  betw een  co-sponsors. If this applies, nam e the lead sponsor for the REC  
application in this box  a nd  enc lo se  a letter giving further details of co-sponsors and their responsibilities.
Sponsor's UK contact point for correspondence with the main REC
Title: Mr
Address:
Post Code: 
Telephone: 
E-mail:
Forename/Initials: Chris
Cardiff University, Redwood Building
King Edward VII Avenue
Cardiff
CF10 3NB
02920 879130
ShawC3@cardiff.ac.uk
Surname: Shaw
Fax:
A60. Has any responsibility for the research been delegated to a subcontractor?
O Yes ®  No
A61. Will individual researchers receive any personal payment over and above normal salary for undertaking this 
research?
O  Yes 0  No
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A62. Will individual researchers receive any other benefits or incentives for taking part in this research?
O  Yes 0  No
A63. Will the host organisation or the researcher's department(s) or institution(s) receive any payment or benefits in 
excess of the costs of undertaking the research?
O  Yes 0  No
A64. Does the Chief Investigator or any other investigator/collaborator have any direct personal involvement (e.g. 
financial, share-holding, personal relationship etc.) in the organisation sponsoring or funding the research that may 
give rise to a possible conflict of interest?
O  Yes 0  No
A65. Other relevant reference numbers if known (give details and version num bers a s  appropriate):
Applicant's/organisation’s  own reference number, e.g. R&D (if available): 05/IBD/3361 
Sponsor's/protocol number: SPON CU 128
Funder's reference number: NA
International Standard Randomised Controlled Trial Number (ISRCTN): NA
European Clinical Trials Database (EudraCT) number: NA
Project website: NA
A66. Other key investigators/collaborators/a// grant co-applicants should be  listed)
Title: Mr
Forename/Initials: Jack Surname: Sheppard
Post: PhD Student
Qualifications: BSc (Hons)
Organisation:
Address: Cardiff University
Redwood Building Telephone: 02920 876471
King Ecward VII Avenue Fax:
Postcode: CF24 3NB
E-mail: sheppardj@cf.ac.uk
PART A: Summary of Ethical Issues
A68. What do you consider to be the main ethical issues which may arise with the proposed study and what steps will 
be taken to address these?
The main ethical issu es involved are storage of sam ples and subject confidentiality. This will be dealt with by an 
annonymisation process to be carried out during the investigation where the samples will be coded by a number system so 
that at no time can a sam ple be linked back to a subject. The only time a sample would need to be identified is when there
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is a finding and the subject will be informed. In this case the sample code will be decoded and the subject information
obtained.
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PART A: Student Page
A70. Give details of the educational course or degree for which this research is being undertaken:
Name and level of course/degree:
The Genetic and Structural Pathogenesis of Keratoconus. Doctorate of Philosohpy (PhD).
Name of educational establishment:
Cardiff University
Name and contact details of educational supervisor:
Dr M Votruba MA PhD FRCOphth 
MRC Clinician Scientist 
Hon Consultant Senior Lecturer 
School of Optometry & Vision Sciences  
Cardiff University, Redwood Building 
King Edward VII Avenue 
Cardiff CF10 3NB
A71. Declaration of supervisor
I have read and approved both the research proposal and this application for the ethical review. I undertake to fulfil the 
responsibilities of a supervisor as set out in the Research Governance Framework for Health and Social Care.
Signature: ..........................
Print Name:
Date: (dd/mm/yyyy)
A one-page sum m ary o f the supervisor's C V  should  b e  subm itted  with the application
A72. Declaration by academic sponsor
To be completed by an  authorised person  on  behalf o f the academ ic institution acting a s  sponsor for student research.
I can confirm on behalf of my academ ic institution that any necessary indemnity or insurance arrangements will be in place 
before this research starts, as required by the Research Governance Framework for Health and Social Care.
Signature: ...........................
Print Name:
Post:
Institution:
Date: (dd/mm/yyyy)
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PART B: Section 1 -  Conduct of the research at local sites
From the answer given to question A6, it is assumed that:
• Local Principal Investigators will not be appointed at each research site participating in this study.
• Applications for site-specific assessment by local Research Ethics Committees on Part C of the form will not be 
required.
• There will be no requirement for individual research sites to be approved by the main REC as part of the ethical review. 
The following general information should be provided to the main REC about the local conduct of the study.
1. What research procedures will be carried out at individual research sites?
A mouthwash sample will be given. Sam ples will then be collected and transported to the main research site.
2. Are any ethical issues likely to arise at individual sites that are not covered in the protocol for the study and if so 
how will these be addressed?
For example, a need  for particular facilities, or to notify local clinicians or departments about the research, or to arrange 
additional local support for participants.
All ehtical issues are the sam e as the main site. All concerns and queries at local sites will be directed to the main principal 
investigator at the main research site.
3. How will the Chief Investigator and his/her team supervise the conduct of the research at individual sites? What 
responsibilities will be delegated to local collaborators?
Local collaborators will only supervise the collection of mouthwash samples. All analysis and investigation of samples shall 
be conducted by the chief investigator and her team.
Management approval to proceed with the research will be required from the R D Department for each NHS care organisation in 
which research procedures are undertaken.
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PART B: Section 5 -  Use of newly obtained human biological materials
1. What samples will be collected and/or analysed and by whom will they be collected?
Samples will be collected by post by the principle investigtor's research student. All samples collected at participating 
institutions will be collected by their respective participating consultants in clinics then posted to Cardiff. Samples sent via 
post comply with laws regulating shipping and packaging of biological materials.
2. Are the samples taken solely for research purposes (or are they a by-product of those taken primarily for clinical 
purposes, i.e. surplus to clinical requirements)?
Samples taken are solely for research purposes.
3. How will samples be labelled/identified?
Indicate if sam ples can b e  considered to b e  ”identified", "coded”, “de-identified”, ”anonymised" or "anonymous" and at what 
stage identifiers are removed.
Samples will be anonymised during the course of the study except when the results indicate that there is a finding in which 
case  they will be identified and the relevant individual will be consulted.
4. Give details of where the sample(s) will be stored, for how long, who will have access and the custodial 
arrangements.
Samples will be stored at -8 0  degrees celcius at the School of Optometry and Vision Sciences. Samples will be stored for 
the duration of the study and then transferred to another freezer for long term storage for no more than 5 years. Cardiff 
University will have all custodial rights.
5. Will the research participant retain any rights to the sample(s)?
<•> Yes O No
If Yes, give details. If the sam ple  is a  gift, this m u st b e  clear in the information sheet. What will happen to sam ples if a 
participant withdraws from the study?
If the participant withdraws from the study then their sample will be destroyed
6. Is it known how the samples will be used in the future?
®  Yes O No
If Yes, give details an d  indicate if co nsen t will b e  obtained for the future u se  o f sam ples: 
There wil be no oher use other than in this study.
7. Does the research involve the analysis or use of genetic material from human biological materials?
®  Yes O  No
8. Would it be possible to link the results of any genetic analysis back to individuals?
<•) Yes O  No
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9. Is it intended to link the results of any genetic analysis back to individuals?
0  Yes O  No
If Yes, give details o f w hat support or counselling service will b e  available to individuals:
If a finding presents itself from any of the sam ples then the subject concerned will be contacted and asked if they wish to 
know, and then informed about the finding, what it m eans and what implications there are for the future. Since all subject all 
ready know they have a d is e a se -  ie keratoconus- the knowledge that a specific mutation in a specific gene has been  
identified will not impact on their routine management or prognosis. Routine genetic counselling will be made available to 
the subject.
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PART B: Section 7 -  Declaration
-  The information in this form is accurate to the best of my knowledge and belief and I take full responsibility for it.
-  I undertake to abide by the ethical principles underlying the Declaration of Helsinki and good practice guidelines on the 
proper conduct of research.
-  If the research is approved I undertake to adhere to the study protocol, the terms of the full application of which the main 
REC has given a favourable opinion and any conditions set out by the main REC in giving its favourable opinion.
-  I undertake to seek  an ethical opinion from the main REC before implementing substantial amendments to the protocol or 
to the terms of the full application of which the main REC has given a favourable opinion.
-  I undertake to submit annual progress reports setting out the progress of the research.
-  I am aware of my responsibility to be up to date and comply with the requirements of the law and relevant guidelines 
relating to security and confidentiality of patient or other personal data, including the need to register when necessary with 
the appropriate Data Protection Officer.
-  I understand that research records/data may be subject to inspection for audit purposes if required in future.
-  I understand that personal data about me as a researcher in this application will be held by the relevant RECs and their 
operational managers and that this will be managed according to the principles established in the Data Protection Act.
-  I understand that the information contained in this application, any supporting documentation and all correspondence with 
NHS Research Ethics Committees or their operational managers relating to the application, will be subject to the provisions
of the Freedom of Information Acts. The information may be disclosed in response to requests made under the Acts except
where statutory exemptions apply.
Signature: .............................................
Date: 05/05/2006 (dd/mm/yyyy)
Print Name: Marcela Votruba
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Patient Invitation. Version 1. 22/05/2006
P R I F Y S C O L
CaeRDY|§>
Dear Sir/ Madam,
Research Study: Investigating genes that may cause keratoconus.
We are carrying out a research project to try and discover more about the genes that 
may cause the eye condition, keratoconus. In order to do this we are collecting DNA 
via a simple mouthwash from affected and unaffected members of families. The 
genetic material, called DNA, will be extracted and analysed in order to try and 
determine the faulty gene. This is important in helping us to understand the exact 
nature of the condition and will be a starting point in finding future forms of 
treatment. We would be very grateful if you would be willing to have a mouth wash 
sample taken for this research
If you are interested in taking part, or getting more information, we include an 
Information Leaflet and Consent Form. If you decide to take part in the study you 
can sign and return the Consent Form.
If you have any questions please contact Dr Votruba on tel: 029 2087 0134. You 
should be aware that you are under no obligation to take part in this research. Your 
decision to participate in this study does not affect any treatment you may or may not 
have. Your GP will be notified of your participation in this study unless you would 
not like this.
Yours sincerely,
Dr Marcela Votruba PhD FRCOphth
MRC Clinician Scientist, Honorary Consultant Ophthalmologist and Senior Lecturer
Ca r d if f
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Version 2 Information Leaflet 30/05/2006 
Direct dial: 029 2087 0134
P R I F Y S G O L
CAERDYg)
Dear Sir/Madam,
Re: Investigating genes that may cause keratoconus
My name is Jack Sheppard and I am a research student at Cardiff University in the 
Ocular Genetics Research Group in the School of Optometry and Vision Sciences. 
Together with Dr Marcela Votruba, who is my Supervisor, we are investigating 
potential genes that can cause the eye condition, keratoconus. Keratoconus is a 
disorder of the cornea, which is the clear window at the front of the eye. This window 
is normally smoothly curved but it becomes gradually more cone shape as time 
progresses in people with keratoconus, resulting in visual problems.
Part 1 on this information sheet will tell you about the purpose of the study and what 
you will have to do if you decide to take part.
Part 2 will give you more information on the conduct of the study
Part 1
Purpose of the study
We are planning to investigate the role of some genes that may be involved in 
keratoconus. One o f the genes we will look at is a gene called VSX1. It is known to 
be linked to keratoconus and another comeal problem, posterior polymorphous 
comeal dystrophy (.PPCD), in some patients. Other genes will also be investigated as 
they become known. As part of this study we are planning to screen the DNA of 
people with keratoconus to see if we can find any changes in the genes, known as 
mutations. This will improve our understanding of how keratoconus can begin and 
what genetic factors can cause keratoconus. This work may also provide us with 
ways to identify patients with suspected keratoconus quicker and earlier in the future 
and thus provide a better service and for keratoconus sufferers. The work being 
carried out is part o f a doctorate into the genetics of keratoconus.
Why do we need volunteers?
We are very keen to recruit as many people as we can to make sure that our study is a 
scientific success and help us to better understand the condition.
We need to collect DNA from subjects with keratoconus and from people who do not 
have the condition to act as a control group. If there is a family history of keratoconus 
we will ask you to speak to your relatives. If they then wish to get more information 
about taking part we will contact them as well with your permission.
Ca r d if f
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Do I have to take part?
If you wish to take part we ask that you complete the consent form attached. Your 
participation is completely voluntary and you can withdraw from the study at any time 
for any reason. A decision to withdraw at any time will not affect the standard of care 
you receive.
What will the study involve?
• The study involves 5 minutes of your time.
• We will ask you to take a mouthwash of very mild salty water, which will 
allow us to extract your DNA.
• You will be given clear instructions how to do this.
• The main location for this research is the Cardiff University Eye Clinic, which
is part of the School of Optometry and Vision Sciences. If you are unable to
attend the clinic, or have been approached through a local optician or
consultant, we can arrange for you to send us a mouth wash sample by post.
Expenses and payments
All postage costs and packaging will be provided should you choose to send a sample 
by post. No payments or expenses will be covered for visits or participation.
What happens when the research stops?
When the study has finished the genetic sequence of the gene being studied will be 
compared to that of control subjects to see if there are any changes that occur, if we 
find that there is a change in your sequence that does not appear in the control 
population you will be informed with a short report explaining what this means. 
Unfortunately the finding will not provide any short term benefit to you just a greater 
understanding to your condition that could be used to improve the level of care you 
receive.
Further Information
If you wish further information of the study you can contact us via the details 
provided
Part 2
Do we have Ethical Approval?
We have Ethical Approval for this Study from the Central Office of Research and 
Ethics Committees and approval from the Cardiff & Vale NHS Trust Research and 
Development Office.
Where will the study be carried out?
The laboratory part of the study will take place in the School of Optometry and Vision 
in Cardiff University. The clinic is situated in the Redwood Building, King Edward 
VIIth Avenue, which is in the centre of Cardiff. This study is also taking place in 
centres around the UK and recruitment will be carried out locally to each centre.
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What if new information becomes available?
During the course of this study it is possible that new genes of interest connected to 
keratoconus would be brought to light and will be investigated. This would not 
require any further action on your part.
What If I don’t want to carry on with the study?
If you no longer wish to participate then your sample will be destroyed but any data 
collected from your sample will be included in the research.
Will my participation in this study be kept confidential?
Your sample and any data collected will be assigned a number which only the 
researchers will know. Any information you give will be kept confidential and 
secure. This may be looked at by other authorised people to check that the study is 
being carried out correctly. All will have a duty of confidentiality as you as a research 
participant and nothing tat could reveal your identity will be disclosed outside the 
research site.
Will my GP be notified?
If you wish your general practitioner to be notified about your participation in the 
study then we will inform him with your permission.
What will happen to any samples I give?
Samples will be stored at the research facility and only the researchers will have 
access. Samples will be numbered and anonymised so that only the researchers will 
be able to identify which sample belongs to which patient. After the study has 
finished samples will be stored for 5 years after which they will be destroyed.
What will happen to the data collected?
The data collected will be analysed to see if there are any sequence changes between 
control clinically normal patient samples and those affected with keratoconus. This 
data will be used to further the understanding into what causes keratoconus and will 
be eventually published in peer reviewed journals.
Who is organising and funding die research?
The study is being organised by the School of Optometry and Vision Sciences at 
Cardiff University and is being funded by the Medical Research Council (MRC).
What you should do if you’d like to participate.
If you would like to participate in this study please fill in and return the consent form 
enclosed. If you have any questions please do not hesitate to contact us at the above 
address.
Once you have returned it we will either take the mouth wash sample there and then 
or contact you to arrange to send you a small stamped and addressed tube for the 
mouth wash, which you will return by post.
We would like to thank you in advance for your interest and co-operation.
Yours Sincerely,
Dr Marcela Votruba PhD FRCOphth, Honorary Consultant Senior Lecturer 
and Mr Jack Sheppard, PhD Student.
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CONSENT FORM
Investigating genes that may cause keratoconus
Declaration
1. I agree to take part in the above study and have a DNA sample taken by mouth 
wash.
2. I confirm that I have read and understood the information sheet dated 31/03/05 
(version 1) for the above study and have had the opportunity to ask questions.
3 .1 understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being 
affected.
4. I understand that sections of my medical notes may be looked at by Dr Marcela 
Votruba and regulatory authorities, including the Ethics Committee, where it is 
relevant to my taking part in this research. I give permission for these individuals to 
have access to my records.
5 .1 AM/ AM NOT happy for my GP to be informed (delete as required).
6. Name, address and telephone of GP if you are happy for them to be informed:
Full name of person participating in the
study:................................................................
□
□
□
□
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Contact Details:
Address...............
Telephone number..........................................................................
Signed............................................................................................Date............................
Witness’ Signature.......................................................................Date...........................
Print Witness Name......................................................................
Travel expenses will be reimbursed if I attend for an extra appointment necessary for 
this research.
Research to be carried out by Dr Marcela Votruba (Principal Investigator) and Jack 
Sheppard.
Contact details: Dr M Votruba, PhD FRCOphth. Hon. Consultant
Ophthalmologist. Direct dial: 029 2087 0134.
(1 for patient, 1 for researcher, 1 to be kept with hospital notes if subject recruited in a 
hospital setting.)
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SCerat@©@nus Study
We are currently looking for volunteers to take part in our 
study into the genetics of Keratoconus.
We are looking for volunteers of 16 years of age or over, 
who have been diagnosed with keratoconus to take part.
All you have to do is provide a mouthwash sample and we 
will examine your DNA/genetic material.
The study will only take 5 minutes of your time and will offer 
you the opportunity to take part in exciting scientific research!
If you wish to take part or want more information do not 
hesitate to contact Jack on 02920 876471, 
sheppardi@cf.ac.uk or ask at the Eye Clinic for a leaflet.
This research is being conducted by the Ocular Genetics Research Group at Cardiff University and is part of a multicenter study across the 
UK Department of Optometry and Vision sciences, Cardiff University, Redwood Building, King Edward VII avenue, Cardiff CF10 3NB
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School of Optometry and Vision Sciences 
Ysgol Optometreg a Gwyddorau Golygol
Head of School Pennaeth Yr Ysgol Professor YrAthro  Tim Wess
Cardiff University 
Redwood Building
King Edward VII Avenue Cathays Park 
Cardiff CF10 3NB 
Wales UK
Tel Ffdn +44(0)29 2087 4374 
Fax FJacs ‘44(0)29 2087 4859 
http://www.cf.ac.uk/
Mouthwash Instructions 
version 1 22/05/2006
Prifysgol Caerdydd
Adeilad Redwood
Rhodfa Edward VII Parc Cathays
Caerdydd CF10 3NB
Cymru, Y Deyrnas Gvfunol
Thank you for your help with the study on keratoconus so far. We are now in 
the process of collecting mouthwashes and would be grateful if you would 
please follow the instructions below to provide your samples.
M outhwash Instructions
The mouthwash is quick and painless, although it does taste quite salty. If 
you swallow any mouthwash it will not harm you in any way.
You should have received one plastic container with your name written on the 
side, containing sterile mouthwash solution.
We suggest that you do the mouthwash before breakfast and before brushing 
your teeth.
PLEASE FOLLOW THESE INSTRUCTIONS
1. Pour the mouthwash solution from the container into your mouth.
2. Vigorously swish the solution around your mouth for at least 20 seconds.
3. Carefully spit the solution back into the plastic container.
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4. Please post your mouthwash sample to us, as soon as possible, in the 
freepost addressed bubble wrap envelope provided. (Please screw the cap on 
tightly)
Usually one mouthwash sample is sufficient for our analyses. However each 
individual is different, therefore if we find that there is not enough DNA in the 
samples we may contact you again to provide some more.
If you have any questions please contact Jack Sheppard or Marcela Votruba on 
(029) 20 876471
Thank you for your time.
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